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ABSTRACT
USING MARGINAL STRUCTURAL MODELS TO CONTROL FOR TIME-DEPENDENT CONFOUNDING
AND TO DETECT EFFECT MODIFICATION IN A RANDOMIZED CONTROL TRIAL
WITH A TIME-VARYING EXPOSURE, NON-ADHERENCE AND MISSING DATA
By
Elizabeth A. Lancet
Advisor: Luisa N. Borrell, DDS, PhD
Background: Unlike traditional regression used in the Intention to Treat (ITT) approach, Marginal
Structural Models (MSM) can account for joint effects of baseline and subsequent treatments as well as
the presence of time-dependent confounding influenced by prior treatment and selection bias due to
censoring. In addition, MSMs have been theorized to be able to assist investigators in determining the
overall benefit of a drug in the total population as they are able to provide a summary effect size across
all strata of an effect modifier which cannot be done via tradition regression techniques. The overall
goal of this dissertation is to demonstrate the advantages and disadvantages of using MSM to 1) control
for time-dependent confounding and 2) detect effect modification in a randomized controlled trial (RCT)
with a time-varying exposure, non-adherence and missing data.

Methods: The ITT analysis consisted of a logistic regression model linking the annual rate of acute
asthma exacerbations (outcome) to assigned asthma treatment. Weights for the MSM analysis were
derived from a pooled logistic regression assessing the probability of staying on assigned treatment
(adherence) and, in Aim 1 and 3, of remaining uncensored for subjects at each visit by treatment arm.
Poisson regression models using PROC GENMOD were fitted for the annual rate of acute asthma
exacerbations (outcome) as a function of the assigned treatment using the weighted sample and a
generalized estimating equation (GEE) with an independent correlation matrix in Aims 1 and 3. The final
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outcome model in Aim 2 also included a treatment covariate interaction term. In all aims, the final
models were fit to uncensored cases with complete data.

Results: Despite the theoretical advantages of MSMs, my research found that the approach failed to
invalidate previous ITT analyses, regardless of adherence level. In Aim 1, the ITT analysis found a 22%
increased risk of EPACs for theophylline compared with montelukast (RR=1.22, 95% CI: 0.82-1.86,
p=0.35), no increased risk between theophylline and placebo (RR=0.99, 95% CI: 0.67-1.50, p=1.00), and
an 18% decreased risk of EPACs between montelukast and placebo (RR=0.82; 95% CI: 0.55-1.21, p=0.31)
for the ITT approach. This was in comparison to a 24% increased risk of EPACs for theophylline
compared with montelukast (RR=1.24, 95% CI: 0.83-1.84, p=0.28), no increased risk between
theophylline and placebo (RR=1.01, 95% CI: 0.70-1.48, p=0.95), and a 17% decreased risk of EPACs
between montelukast and placebo (RR=0.83; 95% CI: 0.57-1.19, p=0.27). In Aim 3, despite finding a
statistically significant difference in adherence rates between the self-reported group and the blood
assay group over time (p=0.001), adjusted rate ratios and corresponding 95% confidence intervals
obtained were nearly identical and in both cases non-significant. In the self-report group, those on
theophylline were 28% more likely to have an asthma exacerbation than those in the montelukast group
(95% CI: 0.85-1.94, p=0.24) compared with 24% in the blood assay group (95% CI: 0.84-1.84, p=0.28). In
Aim 2, the MSM analysis was able to detect effect modification by race in one of the treatment groups
(montelukast). In the unadjusted analysis, non-whites were twice as likely to have an EPAC on
montelukast as their white counterparts (5.75 vs. 2.66 episodes per person year, p=0.0034). Similar
findings were seen for increased medication use and health care visits. Results of the MSM also
indicated the presence of effect modification for overall EPACs, medication use and unscheduled health
care when treated with montelukast instead of placebo. Compared with whites, non-whites were more
than twice as likely to suffer from an EPAC on montelukast as on placebo (RR=2.13, 95% CI: 1.08-4.46, p=
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0.04) and almost 3 times as likely to increase medication use (RR=2.86, 95% CI: 1.10-7.42, p=0.03). Nonwhites were over 5 times more likely to have unscheduled health care visits than whites while on
montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02).

Conclusions: In theory MSMs hold much potential for further analyses of RCTs as it allows adjustment
for time-varying exposures, time-dependent confounding and selection bias, issues more traditional
regression based methods cannot account for. However, it remains unclear as to whether this is the
case in practice. At the very least, MSMs should be conducted as a sensitivity analysis to the ITT
approach in RCTs where there is preliminary evidence suggesting the presence of time-varying
exposures, time-dependent confounding and/or selection bias and when MSM’s limitations can be
reasonably ignored. Conducting a MSM as a sensitivity analysis of the ITT can only bolster one’s
confidence of the estimated effects of treatment on an outcome. In terms of effect modification, more
research is needed to determine the most appropriate way to calculate inverse probability treatment
weights propensity scores as there is no consensus in the literature on how best to calculate the
propensity scores required for weighting and achieve accurate subgroup results.
Keywords: clinical trials, intention to treat, marginal structure models, inverse probability weighting,
causal inference
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Chapter 1. Introduction to Marginal Structural Models
Marginal structural models (MSM) are a class of statistical models commonly used to estimate causal
effects in observational and non-experimental studies due to their ability to account for time-dependent
confounding as well as selection bias.1–3 In essence, MSMs measure all prognostic factors (confounders
and/or mediators) that may affect either adherence to an exposure or loss to follow up (attrition) in an
attempt to eliminate all back door pathways that may bias the association between the exposure and the
outcome.1–6

Formally, MSMs relates any possible exposure and censoring history, up to time t, to the corresponding
counterfactual outcome at time t.7–11 In other words, these models allow for the estimation of all
potential outcome-exposure combinations for each study visit, despite the fact that only one response for
a given exposure per visit will be observed in the data, with the rest “counter to the facts”. This is possible
because it is assumed that the average causal effect of treatment is dependent on whether the choice of
an exposure at a particular time point is affected by the presence of time-dependent confounding. If all
time-dependent confounders are eliminated then it can be assumed that all subjects had adhered to their
assigned treatment and therefore, the exposure is said to have a causal effect on the outcome, i.e. there is
a difference in the counterfactual outcomes under two or more treatment regimes.2–4,11 As MSMs
describe the marginal causal expectation of a potential outcome as a function of a specified treatment
regimen, the observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) will equal the unknown counterfactual
risk ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).

The parameters of a MSM are estimated using inverse probability weighting (IPW) which
calculates weights based on the inverse of the predicted joint probabilities (i.e. propensity score values) of
an individual’s treatment and censoring history conditional on their observed set of covariates.1–6,12 In
3

other words, instead of modeling the relationship between a covariate and the outcome as is done in
traditional regression, IPW models the relationship between covariates and missingness with that of the
putative cause, i.e. exposure. This ensures that the reweighted population is a representative sample
from the original study population in which each participant completed follow-up, all measured covariates
are balanced across exposure groups and all mediators are removed from the causal pathway. Once
confounding is “eliminated”, a standard repeated measure model can then be fitted for the outcome as a
function of the treatment history using the weights and a robust ‘sandwich’ variance estimator.2,4,6,8,10,13–16

Another potential benefit of marginal structural models is the purported ease in which effect modification
can be detected by the simple addition of a treatment covariate product term to the final logistic model
weighted by the inverse probability weights.2,9,12 Most importantly, unlike traditional regression models,
MSMs can provide a summary effect size across all strata of the effect modifier that assists investigators in
determining the overall benefit of a drug in the total population.

When assessing effect modification using MSMs, it is assumed that the causal effect of treatment on an
outcome is dependent on whether the choice of a treatment option at a particular time point is affected
by the presence of time-dependent confounding (L) for every level of the effect modifier (M). While
technically no longer a true marginal structural model because the causal effect is now conditional on M, it
is generally accepted that as long as all time-dependent confounders are eliminated, stratum-specific
associational risk ratios can be interpreted as a stratum-specific causal effect of treatment, i.e. there is a
difference in the counterfactual outcomes under two or more treatment regimes in each level of M.6,9,12,17
Therefore, there is conditional exchangeability given L and as such, the observed risk difference (Pr[Y =1
│A=1, M=m] - Pr[Y =1 │A=0, M=m]) or risk ratio (Pr[Y =1 │A=1, M=m] / Pr[Y =1 │A=0, M=m]) will equal the
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unknown counterfactual risk difference (Pr[Ya=1 =1 | M=m] – Pr[Ya=0 =1 | M=m]) or risk ratio (Pr[Ya=1 =1 |
M=m] / Pr[Ya=0 =1 | M=m]), respectively.

Summary and gaps in Current Literature
Confounding
Despite the theoretical advantages of MSMs in assessing the average causal effect of a time varying
exposure on a target outcome, the approach has rarely been used in the analysis of randomized clinical
trials (RCTs). This is mainly due to the perceived superiority of the intention to treat (ITT) analysis to
estimate average causal effects. In an ITT, the analysis is focused on estimating the size of the difference
in predefined outcomes between intervention groups. Subjects are analyzed according to their assigned
randomized treatment group, regardless of their adherence to assignment, subsequent withdrawal from
treatment or deviation from the protocol. With complete adherence and no loss to follow, the ITT
analysis not only preserves baseline randomization, i.e. exchangeability, but it maintains an adequate
sample size and addresses the pragmatic hypotheses about the clinical utility of treatment.18–21 In these
ideal RCTs, association is causation i.e. the observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) equals the
unknown counterfactual risk ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).

Unfortunately RCTs are not infallible, with many suffering from the presence of non-adherence and
missing data. As the proportion of subjects who deviate from the trial increases, the more the trial begins
to resemble a prospective observational study with baseline randomization - along with associated biases
not traditionally found in RCTs.3–5,9 For example, non-adherence to treatment can cause confounding if
prognostic factors that affect treatment decisions are unequally distributed across groups, while loss to
follow-up may cause attrition bias if prognostic factors affect decisions to stay in the study.

5

An added complication of longitudinal research is that treatment selection and/or covariates may take on
different values at different points in time. In fact, research has indicated that adherence to assigned
treatments and staying in a trial depends more on a subjects’ evolving covariate histories than on baseline
randomization.18–20,22 If these evolving covariates happen to cause the outcome and/or bring about
changes in treatment selection at points post randomization then time dependent confounding occurs.5,23
Time dependent confounding is a problem as 1) the confounder may also simultaneously become a
mediator between the current exposure and outcome and 2) selection bias may occur if levels of
nonadherence or censorship are dependent on covariates affected by prior treatment selection.

In both situations, traditional linear regression models used in the ITT approach may cause estimates to be
biased towards the null as 1) the analysis included every subject assigned a treatment at baseline despite
their true outcome2,5,18,24 and 2) these models cannot adjust for intermediate variables or the cumulative
effect of treatment on the outcome.2,7,14,25,26 While a conservative effect estimate is always preferred to
an exaggerated result, there is still a possibility that a Type II error will occur, causing investigators to
wrongly claim no difference between treatments.2,6

Of the few studies that have compared ITT to MSM in the estimation of average causal effects in RCTs with
imperfect adherence and follow up, most have found that the latter approach resulted in slightly less
biased estimates, albeit similar interpretation of findings.27,28,29 One notable exception was that of Toh et
al. who reanalyzed the original ITT data analysis from the Women’s Health Initiative trial examining
whether the use of continuous hormone therapy increased the risk of breast cancer.27 While overall
inferences were grossly similar, the risk of breast cancer was more than two-fold higher in women with
continuous hormone use when using MSM (HR: 1.68; 95% CI: 1.24-2.28) compared to ITT (HR: 1.25; 95%
CI: 1.01-1.54). The authors concluded that the change in magnitude was most likely due to an increase in
6

the proportion of women not adhering to the protocol over time, leading to differential loss-to-follow-up.
In fact, the original authors confirmed that 40% of women had stopped taking at least 80% of their
assigned treatment by the 6th year of follow up, a finding that was not taken into account in the ITT
analysis.30 The other studies who compared ITT to MSM were much shorter in duration and had much
lower levels of non-adherence and lost to follow up.28,29

This begs the question as to whether a threshold exists as to the level of non-adherence and/or censorship
most appropriate for the use of MSM compared with ITT. Unfortunately, there are no known studies that
have looked into this - most likely due to the complexities of measuring adherence in RCTs. First, there is
not a standard definition of what constitutes adherence.27,31–34 Adherence can be thought of as an all or
nothing response – always vs. never taking the assigned therapy – or as a continuum in which patients can
be adherent or non-adherent only part of the time, i.e. discontinuing therapy prematurely, deviating from
instructions but still taking the medication. Second, there is no standard method of assessing adherence
in clinical trials and usually only one method is used per trial.31,32,34–36

Effect Modification
There are even fewer instances in the literature where MSMs have been used to detect effect
modification and none have occurred in RCTs. Findings from observational studies have indicated that
MSMs do lead to similar estimates when compared with traditional regression models.2,12,37–41 For
example, Chiba et al analyzed data from the Western Collaborative Group observational cohort study and
found similar incidence in coronary heart disease after examining the interaction of personality behavior
and smoking using MSM and standard log linear regression (IRR: 0.69 vs. 0.66).12

7

Overview of the dissertation
The overall goal of this dissertation is to demonstrate the advantages and disadvantages of using MSMs to
1) control for time-dependent confounding and 2) detect effect modification in a RCT with a time-varying
exposure, non-adherence and missing data.

Specific aims
The following specific aims were addressed:

AIM 1: To demonstrate the advantages and disadvantages of using MSMs to check the validity of an ITT
analysis in a RCT with a time-varying exposure, non-adherence and missing data assessing treatment
effectiveness on asthma control.

AIM 2: To demonstrate the advantages and disadvantages of using MSMs to detect effect modification by race
in a RCT with a time-varying exposure, non-adherence and missing data assessing treatment
effectiveness on asthma control.

AIM 3: To demonstrate whether the use of different adherence metrics has any effect on the direction and
magnitude of the causal effect of asthma treatments on the rate of episodes of poor asthma
control using MSMs in a RCT with a time-varying exposure, non-adherence and missing data
assessing treatment effectiveness on asthma control.

Organization of the dissertation
Following this introduction, the dissertation contains four additional chapters. Chapter 2 assesses
confounder control using MSMs as stated in Aim 1 while Chapter 3 evaluates whether MSMs can detect
8

effect modification (Aim 2). Chapter 4 is similar to that of Aim 1 as it assesses confounder control using
MSMs; however, it goes further by examining whether different metrics of adherence has any effect on
the outcome. Chapter 5 summarizes findings from Aims 1-3, discusses the strengths and limitations of all
the analyses and concludes with policy implications and directions for future research.

Data source
All three aims of this dissertation use data from the Low Dose Theophylline as Add-On Therapy in the
Treatment of Asthma (LODO) trial, conducted by the American Lung Association Asthma Clinical Research
Centers (ACRC).42 The ACRC is a network of clinical centers throughout the country dedicated to
improving asthma outcomes in diverse populations. Between 1999 and 2015, the network completed
over ten trials that had a direct impact on the lives of asthma participants and the cost of their care,
recruiting more than 5,000 participants with asthma.43 All data collected from the clinical sites are
managed and analyzed by a Data Coordinating Center at Johns Hopkins University. An overview of ACRC
studies is reported elsewhere.44 Since 2015, the ACRC was renamed as the Airways Clinical Research
Centers and its mission was expanded to include other obstructive lung disease such as COPD. This
change in focus is not relevant to this paper and when discussing the ACRC, it will refer to the network as
it was between 1999 and 2015.

Study population
LODO was the ACRCs second trial that began in 2002 and ran throughout 2003. It aimed to evaluate
whether low-dose theophylline was as effective as an add-on therapy in treating asthmatics compared
with 1) anti-leukotriene antagonist montelukast and 2) placebo. To be eligible for the study, participants
had to be over the age of 15 years, have physician-diagnosed asthma, have been prescribed daily asthma
medication for at least a year, have an FEV 1 of 50% or more of predicted values and have a score of 1.5 or
9

greater on the Asthma Control Questionnaire. Potential participants who smoked or used oral
corticosteroids, leukotriene antagonists or theophylline with four weeks preceding enrollment or had
other significant illness were ineligible to participate. In total 488 patients were randomized and
participated in the study.

Study design
LODO was a multicenter, randomized, double-blind, parallel design and placebo-controlled trial.
After a one to two week run-in, eligible participants were randomized in a stratified permuted block
method in a 1:1:1 allocation ratio to 300mg/day theophylline (n=160) or 10mg/day montelukast (n=164)
or placebo (n=164) – in addition to their existing asthma therapy. Participants were followed for six
months (24 weeks), attended three follow-up visits (one, three and six months after randomization) and
were contacted by phone periodically in between visits to ensure the participant was not experiencing any
problems associated with study participation. Data collected through diaries included sociodemographic
characteristics, recorded peak expiratory flow rates, medical history and asthma symptoms. Medication
adherence was assessed three ways – by 1) diary cards; 2) visit patient care questionnaires and 3) the
collection of plasma montelukast or theophylline concentrations at one and six months.

Primary Data Analysis Results
LODO achieved a sample size that had 80% power to detect a 15% difference in the proportion of patients
experiencing one or more asthma exacerbations between active treatment groups and placebo, assuming
that 50% of the placebo group had an episode of poor asthma control (EPAC). Poisson regression models
with Huber-White variance estimates were used to calculate event rates of EPACs. Linear and logistic
regression models with generalized estimating equations (GEE) were used to evaluate differences among
treatment groups adjusted for age, sex, race, obesity and lung function.
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Despite initial hypotheses that adding low dose theophylline to the treatment of persistently symptomatic
patients would decrease the rate of asthma exacerbations when compared with placebo add-on
treatment, ACRC investigators found no difference in EPAC rates between the three treatment groups;
theophylline 4.9 (95% CI: 3.6-6.7); montelukast 4.0 (95% CI: 3.0-5.4) and placebo 4.9 (95% CI: 3.8-6.4).42

Follow up throughout the 24 week study remained strong with 95% of patients completing diary cards and
94% completing follow-up spirometry. However, adherence to therapy faltered throughout the study
period. Overall, self-reported adherence to the study drugs was 84% for theophylline and 88% for both
montelukast and placebo yet plasma drug concentrations indicated that actual adherence to the study
drugs was even lower at 79% and 71% at 4-weeks for theophylline and montelukast, respectively, and at
60% in both groups at week 24.

Outcomes
The primary outcome for all dissertation aims mirrored that of the original ITT analysis - the annual rate of
acute asthma exacerbations (events/person/time). This was defined as having at least one of the
following episodes of poor asthma control (EPACs):

•

30% drop in peak flow for 2 consecutive days; or

•

Increase of 2 or more used of rescue medication (4 puffs MDI, 2 nebulizer uses); or

•

New course of oral steroids for asthma; or

•

Unscheduled health care for asthma symptoms
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This composite outcome measure was used to reflect the several dimensions of good asthma control,
including physiology, symptoms and health care use. It should be noted that EPACs is not a standardized
composite measure of asthma control and this definition was created by the ACRC for this and other trials.

Statistical analysis
Inverse Probability Weighting Models
Pooled logistic regression models were fitted separately for the probability of staying on assigned
treatment (adherence) and, in Aim 1 and 3, of remaining uncensored for subjects at each visit by
treatment arm. The dataset for these models was discretized into one observation per subject per visit so
that 1) time could be fit as a class variable to allow a separate intercept for each time and 2) lagged
variables for previous treatment and confounder histories would be comparable between subjects.
Stabilized treatment weights were created by dividing the baseline probability of selecting a treatment
(numerator in equation 1) by the probability of selecting treatment given prior treatment history and
potential confounders up to time t (denominator in equation 1). Calculation of the censored probabilities
mirrored that of treatment weights but had to be offset by one visit as censoring looked forward i.e. ‘did
the subject return for a following visit?’ compared with ‘what was the treatment at the previous visit?’
(equation 2). Each covariate was entered in the pooled logistic models as a main effect only.

Resulting predicted probabilities were then used to construct the final stabilized treatment and censoring
weights for each subject at each visit. For the Inverse Probability Treatment Weights, the pooled logistic
regression models provided the estimated probability of remaining on assigned treatment, so the next
step was to subtract the propensity score by 1 to get the probability of not staying on assigned treatment
for those who were non-adherent. Once all subjects had a stabilized weight for each visit, a final stabilized
weight per participant was obtained by multiplying the estimated probability of their observed treatment
12

at each visit cumulatively over time, i.e. the first score was left as is, and for all others, the scores at the
current visit was multiplied by the score of the previous visit. For the Inverse Probability Censoring
Weights, the estimated probabilities of being uncensored for each visit were multiplied cumulatively over
time. The final Inverse Probability Weight for each subject was the product of the treatment selection
weights and the censoring weights.

Outcome Models
Poisson regression models using PROC GENMOD were fitted for the annual rate of acute asthma
exacerbations (outcome) as a function of the assigned treatment using the weighted sample and a
generalized estimating equation (GEE) with an independent correlation matrix in Aims 1 and 3. The final
outcome model in Aim 2 also included a treatment covariate interaction term. In all aims, the final models
were fit to uncensored cases with complete data.

All data management procedures were conducted with SAS 9.4 (SAS Institute, Cary, NC).45

Applications of findings
Information obtained from ITT analyses can be important information for policy makers and health planners,
but patients and clinicians usually prefer to know what are the benefits and risk of receiving a treatment rather
than being assigned to one. When analyzing clinical trial data that resemble a prospective observational study,
using an approach like MSMs may provide more clinically relevant information due to its ability to
appropriately account for time-varying exposures, non-adherence and loss to follow-up.
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Chapter 2: Using Marginal Structural Models to check the validity of
Intention to Treat analysis in the presence of non-adherence and missing
data
Background: The intention to treat (ITT) analysis is the cornerstone statistical method used to analyze
data from randomized controlled trials (RCT). However, in the presence of non-adherence and missing
data, results of the ITT analysis may be biased as it is measuring the effect of assignment rather than the
effect of treatment. The purpose of this study is to demonstrate the advantages and disadvantages of
using MSMs to check the validity of ITT analyses in the presence of non-adherence and missing data. A
RCT of treatment of asthma is used as working model.

Methods: The ITT analysis consisted of a logistic regression model linking the annual rate of acute asthma
exacerbations (outcome) to assigned asthma treatment. Weights for the MSM analysis were derived from
a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of
remaining uncensored for subjects at each visit by treatment arm. The weighted sample was then pooled
into a MSM analysis using a Poisson generalized estimating equation (GEE) with an independent
correlation matrix.

Results: The adjusted rate ratio, and corresponding 95% confidence intervals, obtained from the MSM
were nearly identical to that of the ITT analysis, indicating that adherence and censoring were not a
significant problem in these data and that the baseline randomization held throughout the trial.

Conclusions: MSMs allow adjustment of the ITT analysis for time-varying confounding and selection bias
due to censoring, issues more traditional regression based methods cannot account for. MSMs should be
conducted as a sensitivity analysis to the ITT approach in RCTs when time-varying non-adherence is
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suspected or data are missing. Concordance between the ITT and the MSM analysis indicates that
adherence and censoring may not invalidate the ITT analysis.

Keywords: clinical trials, intention to treat, marginal structure models, inverse probability weighting,
causal inference
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Introduction
Randomized controlled trials (RCT) commonly use the Intention to Treat (ITT) approach to provide unbiased
comparisons among treatment groups. When there is full compliance and no loss to follow up, this analytical
approach will maintain the prognostic balance generated from the original randomization, allowing for causal
inference.1,2 Unfortunately, most clinical trials will have some levels of non-adherence and missing data,
making them more like longitudinal studies with baseline randomization and causing results from an ITT
analysis to be biased towards the null and to cause a Type II error in which investigators will claim no
difference in treatment when there might actually be an important difference.2–4

Marginal Structured Models (MSM) have been increasingly used to estimate causal effects in
observational studies, replicating measures most commonly reported in RCTs.1,3,5 In essence, MSM
measure all post randomization prognostic factors (confounders and/or mediators) that may affect either
adherence to treatment choices or loss to follow up (attrition) in an attempt to eliminate all back door
pathways that may bias the association between the treatment and the outcome, making the baseline
randomization once again valid.1,3–7 The parameters of a MSM are estimated using inverse probability
weighting (IPW). IPW first calculates the inverse of the predicted joint probabilities (i.e. propensity score
values) of an individual’s treatment and censoring history, conditional on their observed set of covariates.
These propensity scores are then weighted such that the reweighted data are balanced on the exposure of
interest at each point in time during the follow-up. A final weighted model is then fitted using these
weights with only a function of exposure history predicting the outcome of interest, together with a
robust ‘sandwich’ variance estimator.

In this paper, I utilize MSMs to check the validity of ITT analyses in the presence of a time-varying
treatment, non-adherence and missing data. This is a secondary data analysis of the American Lung
20

Association Asthma Clinical Research Centers (ACRC) Low Dose Theophylline as Add-On Therapy in the
Treatment of Asthma (LODO) trial.8 LODO evaluated the effectiveness of low dose theophylline, a drug
known for its narrow therapeutic window and severe interactions with various drugs, in maintaining
asthma control in mild to moderately severe asthmatics compared with the widely used anti-leukotriene
antagonist montelukast (Singulair) and placebo, respectively. The ITT analysis published by the ACRC
found no difference between treatment groups when assessing Episodes of Poor Asthma Control (EPACs),
despite initial hypotheses that adding low dose theophylline to the treatment of persistently symptomatic
participants would decrease the rate of asthma exacerbations when compared with placebo and would be
equally effective as the more popular and expensive drug, montelukast. While study participants were
randomized to treatment initially, noncompliance and censorship occurred in each of the follow up
periods. As the decision to terminate treatments or drop out of the study is a nonrandomized event,
influenced by both subject attributes and previous treatment, it was assumed that time dependent
confounding may have caused the results of the ITT to be biased towards the null.

Intention-To-Treat Approach
In epidemiology, randomized controlled trials (RCT) are considered the most rigorous study design for
assessing the efficacy and/or safety of medicine.9–12 This is due to several important methodological
features such as randomization, blinding and the intention to treat (ITT) analysis, all of which theoretically
exert control over most threats to internal validity.

The act of randomization minimizes the likelihood of prognostic differences between treatment groups
preventing selection bias and confounding on baseline participant characteristics commonly found among
other study designs. Baseline randomization ensures that not only are the treatment groups
exchangeable, i.e. the risk of the outcome in one group would have been the same in the second group if
21

all subjects received the same treatment, but that any differences seen between the groups occurred by
chance.11 Blinding, on the other hand, minimizes the likelihood of differential treatment or assessments of
outcomes preventing performance and ascertainment bias after randomization.9,10 The concealment of
intervention group allocations from both participants and study investigators, in theory, ensures that all
study subjects will be treated equally except for the experimental treatment.

Yet, many believe that the simplicity of the ITT analysis is the real reason behind the RCT's perceived
superiority. Under ideal conditions, the ITT analysis not only preserves baseline randomization but it
maintains an adequate sample size and addresses the pragmatic hypotheses about the clinical utility of
treatment.9,10,12,13 In an ITT, the analysis is focused on estimating the size of the difference in predefined
outcomes between intervention groups. Subjects are analyzed according to their assigned randomized
treatment group, regardless of their adherence to assignment, subsequent withdrawal from treatment or
deviation from the protocol. By including noncompliant participants and dropouts in the final study
population, power is maintained, minimizing the chance of a Type II error – the failure to reject a false null
hypothesis. The ITT also avoids overoptimistic estimates of the efficacy of an intervention resulting from
the removal of non-compliers by accepting that noncompliance and protocol deviations are likely to occur
in actual clinical practice. As such, one can claim that with full compliance and no loss to follow up, the
results of the ITT will be unbiased estimates of the treatment effects, as the analysis will maintain the
prognostic balance generated from the original randomization.1,2,6,13 In these ideal RCTs, association is
causation i.e. the observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) equals the unknown counterfactual
risk ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).

Unfortunately, the presence of non-adherence and missing data are all too common in RCTs and as the
proportion of subjects who deviate from the trial increases, the more the trial begins to resemble a
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prospective observational study - along with all its associated biases not traditionally found in RCTs.4–6,11
For example, non-adherence can cause confounding if prognostic factors that affect treatment decisions
are unequally distributed across groups, while loss to follow-up may cause attrition bias if prognostic
factors affect decisions to stay in the study. Furthermore, research has indicated that subsequent values
of received treatment depend more on evolving covariate histories than on baseline randomization, which
may affect the level of non-adherence and loss to follow up, increasing the likelihood of cross
contamination, confounding and selection bias.9,12–14

By avoiding the issue of post-randomization exchangeability, estimates from the ITT analysis may be
biased towards the null because the analysis included every subject assigned a treatment at baseline
despite their true outcome i.e. “once randomized, always analyzed”.2–4,13 While a conservative effect
estimate is always preferred to an exaggerated result, there is still a possibility that a Type II error will
occur, causing investigators to wrongly claim no difference between treatments.3,7 Furthermore,
traditional regression models used in an ITT analysis may fail to adjust appropriately when there are time
dependent covariates that act simultaneously as confounders and intermediate variables.3,15–18 This
‘circular’ relationship can result in conditional associations or selection bias, where none existed at
baseline, and may lead to an underestimate the impact of the cumulative effect of treatment on
outcome. In any event, association can no longer be considered causation as exchangeability is not met,
i.e. Pr [Y =1 │A=1] / Pr [Y =1 │A=0] ≠ Pr [Ya=1 =1] / Pr [Ya=0 =1], and estimates will be biased.

Marginal Structural Models
Marginal structural models (MSM) can be used to estimate effects of time-varying treatment selection in
the presence of time-dependent confounding and censoring in longitudinal studies.3,6,15,19–21 A concern
with estimating effects that span more than one time point is that it is assumed that a subjects’ behavior
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and subsequently the distribution of risk factors will change with time. For example, if participants who
do not comply with treatment or who are censored differ from those who comply or are still being
followed, then imbalances with respect to the risk factors by treatment group (confounding) can occur
and this imbalance can fluctuate over time. Furthermore, in the presence of time-dependent
confounding, a confounder may be simultaneously a mediator between the current exposure and
outcome. If reasons for nonadherence or censorship are due to covariates that have been affected by
prior treatment, selection bias will occur and estimates from traditional regression models will be biased
as they cannot adjust for intermediate variables. Unlike conditional regression approaches, MSMs
account for both the joint effects of baseline and subsequent treatments and for the presence of timedependent confounding influenced by prior treatment, by modeling exposures at each follow up and the
final outcome.3,6,15,21

Formally, MSM is a regression model for longitudinal data that relates any possible exposure and
censoring history, up to time t, to the corresponding counterfactual outcome at time t.11,17,19,22,23 In other
words, these models allow for the estimation of all potential outcome-treatment combinations for each
study visit, despite the fact that only one response for a given treatment level per visit will be observed in
the data, with the rest “counter to the facts”. This is possible because it is assumed that the average
causal effect of treatment is dependent on whether the choice of a treatment option at a particular time
point is affected by the presence of time-dependent confounding. If all time-dependent confounders are
eliminated then it can be assumed that all subjects had adhered to their assigned treatment and
therefore, the exposure is said to have a causal effect on the outcome, i.e. there is a difference in the
counterfactual outcomes under two or more treatment regimes.3,5,6,23 As MSMs describes the marginal
causal expectation of a potential outcome as a function of a specified treatment regimen, the
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observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) will once again equal the unknown counterfactual risk
ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).

MSM parameters are estimated using inverse probability weighting (IPW). IPW adjusts for postrandomization confounding and selection bias due to 1) non-adherence, 2) mediators and 3) loss to follow
up by creating a pseudo-population where the time-varying treatment is independent of stable and timevarying covariates that preceded it, at every time point allowing for causal treatment comparisons using
standard repeated measure models.3,6,7,18–22,24 Instead of modeling the relationship between a covariate
and the outcome as is done in the ITT approach, IPW models the relationship between covariates and
missingness with that of the exposure.

Conducting an MSM-IPW analysis is a two-step process. The first step is to estimate each subject’s
probability of 1) having their own treatment history and 2) having their own censoring history at each
time-point and then use these to derive Inverse Probability Treatment (IPT-) and Inverse Probability
Censoring (IPC-) weights. The second step is to estimate the treatment-outcome association in
a conventional regression model for repeated measures that is weighted by the product of IPT- and IPCweights.

Weights can be are either non-stabilized or stabilized. The former is estimated by taking the reciprocal of
the probabilities of receiving treatment given the covariates (1/p for those treated and 1-1/p for those
untreated), while the latter adds a numerator representing the overall probability of being treated for
those who were treated and of not being treated for those who were not treated using baseline covariates
only. As the numerator and denominator in stabilized weighting will share common factors, the weights
will be less variable, the sample size will be close to that of the original population and there will be less
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chance of Type 1 errors.3,7,24 Therefore, stabilized weights increase statistical efficiency attains better
coverage of confidence intervals and is recommended when using IPW to fit a marginal structural model.
For the purposes of the following analysis, I will be referring to stabilized inverse probability weights.

Treatment Weights
Confounding due to non-adherence in RCTs is eliminated through the application of an inverseprobability-of-treatment weighting (IPTW).1,4,11 IPTWs adjust for imbalances in the characteristics of the
treated and untreated participants. It is fit by building a predictive model for receiving the treatment of
interest given past treatment and prognostic factor history at each time point and then obtaining a single
weight per subject by multiplying the current treatment weight with that of the treatment weights from
the previous time points. Most researchers do this in one step by fitting pooled logistic regression
treatment models with time as a class variable to allow a separate intercept for each time. The resulting
predicted probabilities (i.e. propensity scores) are used to construct the stabilized weights for each subject
at each time point during follow-up. The treatment weights are defined as:

𝑆𝑆𝑆𝑆(𝑡𝑡) = ∏𝑡𝑡𝑘𝑘=0

𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝑉𝑉]
𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝐿𝐿(𝑘𝑘),𝑉𝑉]

Equation 1

The denominator of the model represents the probability that the subject received their own treatment
history (ƒA k ), given all prior treatments (A k-1 ) and covariate histories (L) until the last visit (k) for all possible
treatments (R). The numerator acts as a stabilizing factor to reduce the variance of the estimates and
represents the overall probability of being treated for those who were treated and of not being treated for
those who were not treated. When analyzing RCTs with baseline randomization, the value of A at time 0
will be each participant’s assigned treatment and since there is no confounding the stabilized weight will
be 1.6,17,22
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Censoring Weights
To account for attrition bias due to loss to follow up, one may also calculate inverse-probability-ofcensoring weights (IPCW) following the same steps above.11,25 The only difference is that each study
subject is assigned a weight that is the inverse probability of remaining in the trial for the entire duration
i.e. uncensored. The censoring weights are defined as:

𝑆𝑆𝑊𝑊(𝑐𝑐) = ∏𝑡𝑡𝑘𝑘=0

𝑓𝑓[𝐶𝐶(𝑘𝑘+1)=0|𝐶𝐶(𝑘𝑘)=0,𝐴𝐴(𝑘𝑘) ]
𝑓𝑓[𝐶𝐶(𝑘𝑘+1)=0|𝐶𝐶(𝑘𝑘)=0,𝐴𝐴(𝑘𝑘),𝐿𝐿(𝑘𝑘)]

Equation 2

where the denominator depicts the probability that the subject remained in the trial given their treatment
(A k ) and covariate histories (L) until the last visit (k) in each treatment group (R) and the numerator, the
overall probablity of remaining uncensored per treatment. The stabilized weights do not eliminate
censoring in the pseudo-population, they make censoring occur at random with respect to the measured
covariates. Complete cases with similar characteristics to those of censored cases are weighted to
represent those who were lost. Just as with treatment, when analyzing RCTs with baseline
randomization, the value of C at time 0 will be 0 as there is no loss to follow up.6,17,22

Treatment-Outcome Model
When both non-adherence and loss to follow-up are present, the weights from both models (treatment
and censoring) are multiplied together to form one stabilized weight per participant. The simulated
pseudo-population now represents a sample from the actual randomized study population in which each
participant completed follow up, all measured covariates are balanced across exposure groups, and all
mediators are removed from the causal pathway. It is the balance across exposure groups, i.e.
exchangeability, which allows for unbiased estimates of treatment effects in RCTs without nonadherence
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and censoring. Once balance is established, the average causal effect of treatment on the outcome can be
unbiasedly estimated in a conventional regression model that does not include the measured confounders
as covariates.

Assumptions
There are several assumptions that must be met when fitting a MSM. First is the assumption of no
unmeasured confounders, i.e. conditional exchangeability or sequential randomization. This assumption
requires that all covariates which are associated with treatment assignment, outcomes or censorship are
adjusted for at each visit, enabling treatment selection to once again be random as it was at baseline.5,6,24
If unobserved confounders are present, then treatment groups will no longer be exchangeable and
residual bias in the treatment-outcome association can remain. Therefore, it is important, although not
empirically verifiable, to ensure that all possible confounders which affect treatment selection and
outcome are added to the models.

The second assumption of positivity assumes that the conditional probability of receiving either treatment
and of remaining under complete follow-up will be greater than zero. Positivity is guaranteed in
randomized control trials because, by design, there will be individuals assigned to each level of the studied
treatment and therefore, there is no possibility of a structural violation of positivity.5,11,24 However,
depending on the sample size and the number of confounders, there can be instances where, at one or
more levels of the confounders, no one happens to be observed at one or more levels of the exposure
(zero cells). These random violations of probability occur by chance and can be corrected by using
parametric models or combining adjacent subgroups with cells greater than zero.11,24
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The third is the unverifiable assumption that one is using the correct weighting and analysis models. Any
parametric model may be mis-specified by the omission of unmeasured confounders, non-linear terms or
interactive relationships. If misspecification occurs, residual bias in the treatment-outcome association
can remain or, in some cases, even increase.5,18 Sensitivity analyses to test the listed structural model
specifications above must be done to determine whether the stabilized weights have a mean of 1.0 and a
minimum and maximum that is not very extreme.

Lastly, it is assumed that all missing data will be missing at random (MAR). The MAR assumption states
that conditional on some set of variables that are fully observed, the probability of missing outcome or
exposure is independent of all variables in the model.20,22,26

Methods
Study population
The American Lung Association Airway Clinical Research Centers (ACRC) is a network of clinical centers
throughout the country dedicated to improving asthma outcomes in diverse populations (figure 2.1).
Between 1999 and 2015, the network completed over ten trials that had a direct impact on the lives of
asthma participants and the cost of their care, recruiting more than 5,000 participants with asthma.27 As a
multicenter network, the ACRC is well poised to conduct comparative effectiveness research due to its
ability to enroll large numbers of participants from diverse populations from different regions of the
United States to ensure that the research findings has external generalizability and are relevant to large
groups of participants.27 All data collected from the clinical sites is managed and analyzed by a Data
Coordinating Center at Johns Hopkins University. An overview of ACRC studies is reported elsewhere.28
Since 2015, the ACRC was renamed as the Airways Clinical Research Centers and its mission was expanded
to include other obstructive lung disease such as COPD. This change in focus is not relevant to this paper
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and when discussing the ACRC, it will refer to the network as it was between 1999 and 2015.

Study Design
The Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial was the ACRCs
second trial that began in 2002 and ran throughout 2003. It was a multicenter, randomized, double-blind,
parallel design, placebo-controlled trial evaluating whether low-dose theophylline was as effective as an
add-on therapy in treating asthmatics compared with 1) montelukast and 2) placebo in 488 participants
with poor asthma control.

To be eligible for the study, participants had to be over the age of 15 years, have physician-diagnosed
asthma, have been prescribed daily asthma medication for at least a year, have an FEV 1 of 50% or more of
predicted values and have a score of 1.5 or greater on the Asthma Control Questionnaire. Potential
participants who smoked or used oral corticosteroids, leukotriene antagonists or theophylline with four
weeks preceding enrollment or had other significant illness were ineligible to participate.

After a one to two week run-in, eligible participants were randomized in a stratified permuted block
method in a 1:1:1 allocation ratio to 300mg/day theophylline (n=160) or 10mg/day montelukast (n=164)
or placebo (n=164) – in addition to their existing asthma therapy. Participants were followed for six
months (24 weeks), attended three follow-up visits (one, three and six months after randomization) and
were contacted by phone periodically in between visits to ensure the participant was not experiencing any
problems associated with study participation (figure 2.2).
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Primary Outcome
The outcome of interest in the LODO trial was the annual rate of acute asthma exacerbations
(events/person/time) defined as having at least one of the following episodes of poor asthma control
(EPACs):

•

30% drop in peak flow for 2 consecutive days; or

•

Increase of 2 or more used of rescue medication (4 puffs MDI, 2 nebulizer uses); or

•

New course of oral steroids for asthma; or

•

Unscheduled health care for asthma symptoms

This composite outcome measure was used to reflect the several dimensions of good asthma control,
including physiology, symptoms and health care use. It should be noted that EPACs is not a standardized
composite measure of asthma control and this definition was created by the ACRC for this and other trials.

Treatment Groups
In the original ITT analyses, participants were randomized in equal allocation ratio to one of three
treatment groups:

•

Theophylline (Theo-Dur®) 300 mg/capsule

•

Montelukast (Singulair®) 10 mg/capsule

•

Placebo capsule

Subjects were instructed to ingest 1 capsule daily following their evening meal. All treatments were
masked by opaque capsules. After randomization, the remainder of the study was observation in the
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sense that participants could discontinue study medication.

As such, for the IPW analysis treatment groups consisted of all those who were compliant with their
respective assigned treatments at each visit compared to those who were not compliant for each arm of
the original randomization. This allowed for a participant’s propensity for adherence to vary as
circumstances changed over the course of the study. Adherence information was obtained from
questionnaires given by study investigators at the 1, 3 and 6 month clinical visits. A person was
considered to be adherent to assigned treatment if they reported, at the time of their clinic visit, being on
study treatment with no interruptions since the last clinic visit or if they were currently on study
treatment but had temporarily discontinued since last visit. All other cases were considered to be nonadherent.

In total, 174 participants did not adhere to their assigned study treatment at 218 visits. Twenty three
participants were non-adherent with assigned medication at 1 month – 11, 8, and 4 in the theophylline,
montelukast and placebo groups, respectively. Twelve were non-adherent at three months – 6, 4 and 2 in
the theophylline, montelukast and placebo groups, respectively. At the six month visit, an additional 139
participants did not adhere to the study medication – 45 in the theophylline group, 49 in the montelukast
group and 45 in the placebo group.

Potential Time-Dependent Confounders
A number of covariates were considered as potential time-dependent confounders. It was assumed that
these variables were measured prior to deciding whether or not to continue with their assigned treatment
or the study in general.
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Variables that were collected only at baseline and remained static throughout the trial included age
(defined as a continuous variable), sex (male, female) and race (white, black or other).

Covariates considered potential time-vary confounders included:

•

Lung function test volumes such as forced expiratory volume (FEV 1 ), forced vital capacity (FVC)
and ambulatory peak flow (PF) which objectively measure airway obstruction or the ability of the
lungs to perform in asthmatic participants.29,30 Volumes were interpreted as percentages of
predicted values based on Hankinson et al. well-established reference equations for healthy
subjects of similar demographic characteristics (height, age, sex, race and weight). A detailed
description on how percent predicted values based on normal lung function are calculated has
been previously published.31,32

•

Average Asthma Symptom Utility Index (ASUI) is a 10-item self-administered questionnaire
assessing asthma symptoms. It was scored from 0 to 1, with 0 indicating severe symptoms for at
least one week to 1 signifying no symptoms in the two week period.33 The items are then
weighted according to participant preferences and scored based on a multi-attribute utility
function of ASUI= 1.200 x (S1 Cough * S2 Wheeze * S3 Shortness of Breath * S4 Awake At Night *
S5 Medical Side Effects) - 0.200. A detailed description of the ASUI has been previously published
elsewhere.33

•

Medication use was defined as a binary measure. Participants were asked if they had used any of
the following medications since their last visit: inhaled corticosteroids, inhaled long-acting beta-
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agonists, inhaled short-acting beta-agonists, inhaled anticholinergic, combination drugs such as
Advair.

•

Adverse effects were also defined as a binary measure. Participants were asked if they had any of
the following adverse effects since their last visit – nausea, vomiting, poor appetite, heartburn,
headache, insomnia, anxiety, tremor, heart palpitations and skin rash.

•

Use of health care services was also defined since their last visit. Starting with the 1 month visit,
participants were asked if they visited with their doctor or were hospitalized since their last study
visit.

All potential time-varying confounders came from participant diary cards except for FEV 1 and FVC
measures which were collected through spirometry at each visit. It was assumed that these covariates
fully encompass the clinician’s and participant’s perspective of asthma and therefore, was considered
good predictors of the outcome (asthma exacerbation), treatment adherence and censorship. For
example, a lower than normal FEV 1 is associated with severity of asthma symptoms, increased asthma
attacks, reduced quality of life and the likelihood of both hospitalizations and respiratory failure all of
which have been shown to affect whether a participant stays on their assigned treatment.30 In addition,
since clinical trials are longitudinal studies, current spirometry measures are in part a result of previous
treatment, mediating the association between treatment and asthma control. A similar case can be made
for all of the other potential time-varying confounders mentioned above.

Figure 2.3 shows a possible directed acyclic graph34 that represents the relationships between the timevarying treatments (generally a time-varying variable as each day you may take it or not take it) and the
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above covariates with the outcome, assuming no unmeasured confounding. L(0) denotes baseline
demographic characteristics along with baseline FEV 1 . It was assumed that there was no effect of L(0) on
A(0), because of randomization and full initial compliance. Therefore, confounding is assumed to occur
only after A(0) (baseline). A(1), A(2) and A(3) represent treatments actually received, irrespective of
randomization, at follow up times 1, 2, and 3. L(1), L(2) and L(3) denote the current levels of the time
varying covariates - pulmonary function measures, asthma symptoms, medications and adverse effects at
follow-up visits 1, 2, and 3. C(1), C(2), and C(3) account for lost to follow-up which occurred due to past
treatment history and confounder levels. Lastly, Y denotes the annual rate of asthma exacerbations
indicating poor asthma control.

Overall, there are 10 possible outcomes (arrows into Y) for each subject, representing all possible
combinations of treatments for the four time periods, of which only one is observed. However, once all
confounding paths are blocked, only the causal paths (green arrows into Y) remain.

Missing Data
Thirty-one participants (6% of participant visits) had missing covariate estimates for one or more
confounders despite attending visits and providing exposure and outcome data. Missing covariate data
were imputed using the mean value for the treatment and time period groups. These cases were retained
for all analyses.

Data were censored at the time of the first missed visit, i.e. exposure, or in cases where the outcome was
missing. Research has indicated that censored at first missed visit is generally the least biased across all
missingness mechanisms.15,20,35 Twenty-eight cases were lost to follow-up after the baseline visit – 13
from the theophylline group, 5 from montelukast and 10 from the placebo group - leaving 460 cases with
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complete data at the six week visit. Another 33 participants had been lost to follow-up after the six-week
visit – 10 from theophylline, 14 from montelukast and 9 from placebo – leaving 427 cases with complete
data at the three month visit. At the six month visit, another 24 were censored – 10 from the
theophylline, 5 from montelukast and 9 from placebo – leaving 403 cases with complete data at the six
month and final visit.

Statistical Analysis
Intention-to-Treat – Outcome Model
The original ITT analyses were replicated using data on 488 participants randomized at baseline. Poisson
regression models with Huber-White variance estimates were used to calculate event rates of EPACs.
Logistic regression models with generalized estimating equations (GEE) to evaluate differences among
treatment groups.

Marginal Structural Models
1) Inverse Probability Weighting
Pooled logistic regression models were fitted separately for the probability of staying on assigned
treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment
arm. The dataset for these models was discretized into one observation per subject per visit so that 1)
time could be fit as a class variable to allow a separate intercept for each time and 2) lagged variables for
previous treatment and confounder histories would be comparable between subjects. Stabilized
treatment weights were created by dividing the baseline probability of selecting a treatment (numerator
in equation 1) by the probability of selecting treatment given prior treatment history and potential
confounders up to time t (denominator in equation 1). The calculation of censored probabilities mimicked
that of treatment adherence weights but was offset by one visit as censoring looked forward i.e. ‘did the
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subject return for a following visit?’ compared to ‘what was the treatment at the previous visit?’ (equation
2). Each covariate was entered in the pooled logistic models as a main effect only.

Resulting predicted probabilities were then used to construct the final stabilized treatment and censoring
weights for each subject at each visit. For the Inverse Probability Treatment Weights, the pooled logistic
regression models provided the estimated probability of remaining on assigned treatment, so the next
step was to subtract the propensity score by 1 to get the probability of not staying on assigned treatment
for those who were non-adherent. Once all subjects had a stabilized weight for each visit, a final stabilized
weight per participant was obtained by multiplying the estimated probability of their observed treatment
at each visit cumulatively over time, i.e. the first score was left as is, and for all others, the scores at the
current visit was multiplied by the score of the previous visit. For the Inverse Probability Censoring
Weights, the estimated probabilities of being uncensored for each visit were multiplied cumulatively over
time. The final Inverse Probability Weight for each subject was the product of the treatment selection
weights and the censoring weights.

To determine whether the final stabilized weights resulted in balanced data, distribution plots were
created to assess central tendency and skewness between the original and weighted data sets.

2) Outcome Model
A poisson regression model using PROC GENMOD were fitted for the annual rate of acute asthma
exacerbations (outcome) as a function of the assigned treatment using the weighted sample and a
generalized estimating equation (GEE) with an independent correlation matrix. The use of GEE accounted
for the correlation within-subjects typically seen when analyzing data from longitudinal data.36–38
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The final model were fit to all uncensored cases with complete data (N=403). Final analyses of treatment
effects on asthma control were conducted for three groups – theophylline vs. montelukast, theophylline
vs. placebo and montelukast vs. placebo.

All data management procedures were conducted with SAS 9.4 (SAS Institute, Cary, NC).39

Results
Participant Characteristics
Baseline characteristics of the 488 subjects randomized to the LODO study is shown in table 2.1. Assigned
treatment groups were balanced with respect to demographics and baseline asthma characteristics.
Participants tended to be middle-aged, predominantly female and white. On average, participants’ prebronchodilator FEV 1 was slightly below that of a normal population indicating mild asthma severity. Postbronchodilator lung function continued to be mildly reduced on average compared to a normal
population. Around 9% of participants were prescribed daily asthma medication, but did not use it. The
majority of subjects either took short acting beta-agonists, inhaled corticosteroids or a combination of
medications.

Table 2.2 shows participant characteristics over the follow-up period. After randomization, study
discontinuation was similar across the treatment groups. At four weeks, the theophylline group tended to
be slightly sicker than the montelukast group (significant findings were found for ASUI score, inhaled
corticosteroids, nausea) and placebo group (significant findings for insomnia). By the 3 month follow up
visit, these differences had disappeared and by time 3 there were no significant differences between
groups.
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Inverse Probability Weights
The model for the denominator of the weights is the most important component for determining the
predicted probabilities. Covariates with negative coefficients predict those individuals who would be
more likely to be non-adherent and be censored.24 For the inverse probability treatment weights,
previous treatment was strongest predictor of present treatment in all treatment groups (-5.70 for
theophylline, -4.96 for montelukast and -18.17 for placebo). None of the other time-varying covariates
were strong predictors of treatment changes – suggesting bias in treatment selection over time may not
be particularly strong in these data (see Appendix 2.A, 2.B, 2.C).

For the inverse probability censoring weights, most of the covariates in the MSM model were not
associated with censoring. The exceptions were pre-bronchodilator percent predicted FEV 1 (-0.64,
p=0.03), ASUI score (1.70, p=0.03), being black (-0.54, p=0.04) and age (0.03, p=0.003). Similarly to the
treatment weights, this indicates that selection bias may not be particularly strong in these data (see
Appendix 2.D).

The mean of the final stabilized weights (treatment x censoring) was 0.995 and ranged from 0.4 to 4.3,
indicating that the model was correctly specified. Furthermore, the sum of the weights in the pseudo
population was 1785 which was identical to the number of visits with complete data in the original
sample. Figure 2.4 shows the distribution overlap of the stabilized weights for all groups over time.
The distribution of treatment groups (theophylline vs. montelukast, theophylline vs. placebo and
montelukast vs. placebo) was examined through plotting the stabilized weights in the treated and
untreated groups over time both in the original and in the weighted data sets. The central tendency of the
covariate values coincided between groups indicating that balance was achieved; however, there was no
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difference in central tendency measures between the original and weighted data sets. The distribution
plots for the weighted data sets are shown in figures 2.5a, b, and c.

Outcome Models
Table 2.3 summarizes the outcome using poisson binominal regression models, looking at asthma control
rates using EPAC composite events as well as each component individually due to treatment effects.

The results of the ITT analysis found no significant treatment effect on overall asthma exacerbation rates
among all three groups: theophylline vs. montelukast (RR=1.22, 95% CI: 0.82-1.86, p=0.35); theophylline
vs. placebo (RR=0.99, 95% CI: 0.67-1.50, p=1.00) and montelukast vs. placebo (RR=0.82; 95% CI: 0.55-1.21,
p=0.31). However, montelukast was significantly less likely to cause drops in peak flow than in the
placebo group (RR = 0.44 p-value= 0.01).

The effect estimates obtained from the MSM, using no further adjustments other than the stabilized
weights, were nearly identical to that of the ITT analysis, indicating that adherence and censoring was not
a significant problem in this data and that the baseline randomization held throughout the trial. This
result was expected as the inverse probability weights were not particularly variable, and therefore, would
not dramatically change the results of the ITT Poisson regression.

Discussion
A marginal structural model for repeated measures was used to estimate the causal effect of treatment on
asthma control in the LODO trial of the ALA-ACRC. This method was used as it was assumed that, due to
non-adherence and censoring over time, there may have been time-dependent confounding and selection
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bias that could not have been appropriately adjusted for by standard statistical methods used in an ITT
analysis.

Although non-adherence and censoring occurred over time in the LODO trial, the results of the MSM did
not change the findings of the original ITT analysis. After adjustment, the theophylline group had a 24%
and a 1% increased risk of having episodes of poor asthma control compared with the montelukast and
placebo groups, respectively, while the montelukast group had 0.57 times the risk of the outcome than
those in the placebo group. None of these findings were significant and were nearly identical to the ITT
estimates.

Concordance between the ITT and the MSM analyses may indicate that non-adherence and censorship will
not invalidate ITT analyses but more research on potential adherence thresholds is warranted. Previously
published studies that have found improved efficiency, albeit similar interpretations, using MSM
compared to ITT did so in RCTs with significantly longer follow up periods and higher rates of censorship
and non-adherence.40,41 For example, Toh et al. reanalyzed data from the Women’s Health Initiative trial
examining whether the use of hormone therapy increased the risk of breast cancer over a 6 year period in
a sample of roughly 600 patients using IPW compared to ITT.41 The MSM approach found the risk of
breast cancer to be more than two-fold higher in women with continuous hormone use(HR: 1.68; 95% CI:
1.24-2.28) compared to the original ITT analysis by Rossouw et al. (HR: 1.25; 95% CI: 1.01-1.54).42
Although these differences led to grossly similar inference, it is apparent that the change in magnitude
was most likely due to an increase in the proportion of women not adhering to the protocol over time,
leading to differential loss-to-follow-up. In fact, the original authors confirmed that about 40% of women
had stopped taking at least 80% of their assigned treatment by the 6th year of follow up, a finding that was
not taken into account in the ITT analysis.42
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In contrast, the LODO study had a follow up time of six months and self-reported adherence was 84% for
theophylline and 88% for both montelukast and placebo while only 6% of study participants were
censored. The length of the LODO trial and the good clinical practices exercised by the ALA-ACRC
prevented the presence of non-adherence and differential loss-to-follow up, which limited the ability to
show a difference between ITT and MSM approaches. Results of this study are comparable to other trials
that had similar proportions of noncompliance and censorship.43,44

These results should be considered in the context of the following limitations. First, MSMs requires the
untestable assumption of no unmeasured confounding; i.e. that subjects are exchangeable, conditional on
the measured variables.5,11,16,40 It is assumed that all the most important confounders were identified
using the expert knowledge of the ALA-ACRC investigators and were then appropriately measured and
included in the analysis. However, it can never be verified that all joint predictors of exposure and
outcome were added to the models.

Second, due to the small sample size and the number of potential confounders added to the MSM models,
finite-sample bias occurred leading to the presence of random zeros in a few of the exposure-covariate
groups. Therefore, one cannot assume that the positivity assumption was met in this study. However,
random zeros are essentially guaranteed because of the infinite number of possible values and a more
valid assessment of positivity includes looking at extreme values, mean of weights and values of exposurecovariate groups adjacent to those with zero.5 Overall, the mean stabilized weight in this study was 0.995
and the sample did not have very extreme values. Also, as seen in figures 2.5a, b, and c, many if not all of
the exposure-covariate groupings with zero were surrounded by non-zero groups.
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Lastly, it is assumed that the models used in this analysis are correctly specified. To explore the robustness
of the models, linear and quadratic terms of continuous variables were tested to restrict the possible
values of the propensity scores such that on a logit scale the conditional relation between the continuous
covariates and the risk of treatment can be represented by a parabolic curve, and each covariate
contributions to the risk is independent of that of the other covariates.22 No significant changes to the
outcome were noted. Additionally models were fitted with different groupings of covariates. For
example, models were fitted for individual side effects and medications alone, for composite measures of
side effects and medications and for both composite and individual grouping. Again, there were no
significant changes to the outcome. Finally, the fact that the mean of the final stabilized weight was close
to 1 and that the MSM and ITT results were near identical, gives strength to the assumption that the MSM
was not mis-specified. Unfortunately, the assumption of a correctly specified model can never be proven.

However, since none of these limitations can be reasonably assumed to be consequential in the current
working model and since time-varying non-adherence was suspected and data were missing, it is
reassuring to see that both the ITT and MSM approaches yielded consistent results. This only bolsters
confidence in the ITTs validity in estimating effects of theophylline vs montelukast or placebo on asthma
control.

Conclusion
In my analysis, fitting MSMs using IPW did not change the ITT analysis outcomes, validating the original
findings of the study. It is possible that these findings could have been due to the relatively low rates of
non-adherence and censorship over the six months LODO was conducted. In a longer RCT with baseline
randomization, it is assumed that there would be higher rates of non-adherence and censorship and that
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MSMs could serve as an alternative, and maybe more efficient, method to ITT in elucidating causal
interpretations.

In any event, it is my recommendation that MSMs be used, at a minimum, as a sensitivity analysis to the
ITT approach in RCTs when time-varying non-adherence is suspected or data are missing and when MSM’s
limitations can be reasonably ignored. Concordance between the ITT and the MSM analysis may indicate
that non adherence and censorship does not invalidate the ITT analysis but more research is warranted.
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Figure 2.1. Asthma Clinical Resarch Centers, 1999-2015

Figure 2.2. Schema of the Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma
(LODO) trial (ACRC, 2002-2003)

V1/Run-In: Potentially eligible patients were followed for a 1-2 week run-in period
V2/M0: Patients who successfully completed the run-in and agreed to be randomized were assigned to
one of the three treatments shown
V3: 1 month follow up visit
V4: 3 month follow up visit
V5: 6 month follow up visit
P1-P4: Telephone calls between visits to assess diary card completion and adverse/side effects
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Figure 2.3. Structural relationships over time between treatments and asthma control in the Low Dose
Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial (ACRC, 2002-2003)1

1

Created through Daggity software: Johannes Testor, Juliane Hardt, and Sven Knuppel. Daggitty: A graphical tool
for analyzing causal diagrams. Epidemiology, 22(5): 745, 2011
-A0, A1, A2, A3 represent observed cumulative treatment exposure to either Theophylline, Montelukast or
Placebo from baseline randomization (A0), 1 month (A1), 3 months (A2) and 6 months (A3).
-L1, L2, L3 denote measured confounders (pulmonary function measures, asthma symptoms, medications and
adverse effects) that may be associated with A(k),respectively. L(0) denotes baseline demographic characteristics
along with baseline FEV 1 . It was assumed that there was no effect of L(0) on A(0), because of randomization and
full initial compliance.
-C1, C2, C3 reflects loss to follow up at 1 month (C1), 3 months (C2) and 6 months (C3).
-Y indicates the outcome of annual rate of asthma exacerbations indicating poor asthma control. If all possible
confounding paths are blocked, the green arrows into Y represent the remaining causal paths.
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Table 2.1. Baseline Characteristics of the 488 LODO Participants by Treatment Assignment
Theophylline
160

Montelukast
164

Placebo
164

p-value 1
---

41.5 ± 14.7
25.0

39.8 ± 15.0
28.1

40.0 ± 14.6
25.6

60.0
31.3
8.8

62.2
25.6
12.2

59.8
30.5
9.8

0.56
0.80
0.88
0.48
0.57

Asthma Symptoms, mean ± SD
ASUI Average Score

0.66 ± 0.15

0.68 ± 0.15

0.70 ± 0.15

0.16

Pulmonary Function, mean ± SD
Pre-BD FEV1, % predicted*
Pre-BD FVC, % predicted*
Post-BD FEV1, % predicted*
Post-BD FVC, % predicted*
Peak Flow, % predicted*
FEV1 Bronchodilator % change
FVC Bronchodilator % change

78.3 ± 16.5
87.2 ± 14.8
84.4 ± 15.6
91.8 ± 15.7
83.4 ± 20.3
9.2 ± 12.6
5.9 ± 10.3

77.5 ± 17.5
87.1 ± 16.9
83.7 ± 17.1
91.6 ± 16.0
83.0 ± 20.3
9.3 ± 11.7
6.6 ± 13.8

80.3 ± 16.2
88.5 ± 14.8
86.8 ± 15.2
91.7 ± 14.1
80.6 ± 19.3
8.9 ± 10.3
3.8 ± 7.2

0.32
0.65
0.18
1.00
0.39
0.94
0.06

90.0
2.5
22.5
58.1
37.5
39.4

92.7
4.9
22.6
60.4
40.2
34.8

93.3
3.7
18.3
56.7
36.6
39.0

0.51
0.52
0.56
0.79
0.78
0.63

Number of patients
Demographics
Age, mean ± SD
Male, %
White, %
Black, %
Other Race, %

Daily Asthma Treatments, %
Using asthma medication daily
Inhaled anticholinergic
Inhaled long-acting -agonist
Inhaled short-acting -agonist
Combination drugs
Inhaled Corticosteroids

*Predicted values of Hankinson and colleagues.
1 P values for categorical variables from Pearson Chi-Square test compared to ANOVA test for continuous variables.
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Table 2.2. Time-Varying Characteristics of LODO Participants by Treatment Assignment over LODO Follow Up Periods 1,2
Time 1 (4 Weeks)
N=460
Number of patients

Pulmonary Function, mean ± SD
Pre-BD FEV 1 , % predicted*
Pre-BD FVC, % predicted*
Post-BD FEV 1 , % predicted*
Post-BD FVC, % predicted*
Peak Flow, % predicted*
FEV 1 Bronchodilator % change
FVC Bronchodilator % change
Daily Asthma Treatments, %
Using asthma medication daily
Inhaled anticholinergic
Inhaled long-acting -agonist
Inhaled short-acting -agonist
Combination drugs
Inhaled Corticosteroids
Adverse Effects %
Nausea
Vomiting
Poor Appetite
Heartburn
Headache
Insomnia
Anxiety
Tremor
Heart Palpitations
Skin Rash
Use of Healthcare Services, %

Time 3 (6 Month)
N=410

T

M

P

p

T

M

P

p

T

M

P

p

147

159

154

--

137

145

145

--

131

141

138

--

0.73 ± 0.17

0.78 ± 0.15

0.74 ± 0.15

0.02

a

0.76 ± 0.15

0.78 ± 0.20

0.79 ± 0.16

0.38

0.74 ± 0.15

0.78 ± 0.15

0.81 ± 0.17

0.66

80.1 ± 16.0
88.7 ± 15.4
86.1 ± 15.6
93.0 ± 16.5
86.1 ± 18.8
8.4 ± 10.3
5.3 ± 8.5

78.8 ± 17.8
88.7 ± 16.4
84.1 ± 17.4
92.4 ± 19.4
84.1 ± 18.7
7.7 ± 11.0
4.6 ± 11.3

79.7 ± 16.4
87.9 ± 15.7
85.6 ± 15.9
91.5 ± 13.9
82.4 ± 18.4
8.9 ± 12.2
5.0 ± 10.6

0.79
0.87
0.54
0.67
0.22
0.63
0.82

79.6 ± 15.8
88.7 ± 16.8
85.5 ± 15.4
92.2 ± 17.4
84.7 ± 17.0
8.7 ± 12.9
4.5 ± 9.70

78.6 ± 18.6
87.8 ± 16.6
83.8 ± 18.2
90.9 ± 16.7
84.5 ± 19.7
7.6 ± 11.2
4.1 ± 9.0

0.86
0.79
0.63
0.78
0.31
0.54
0.83

80.7 ± 18.3
90.2 ± 17.3
85.6 ± 15.8
92.6 ± 16.2
85.4 ± 17.4
7.7 ± 12.7
3.5 ± 9.4

79.8 ± 17.9
89.2 ± 19.3
84.7 ± 17.5
91.6 ± 16.7
85.9 ± 18.0
7.1 ± 10.4
3.6 ± 8.9

78.3 ± 15.7
87.1 ± 14.5
84.6 ± 15.1
90.4 ± 14.5
82.6 ± 19.6
9.0 ± 10.3
4.1 ± 7.9

0.49
0.28
0.85
0.50
0.30
0.29
0.79

88.8
2.5
17.5
51.3
38.8
38.8

88.4
3.7
19.5
48.2
38.4
28.1

88.4
4.9
15.9
50.0
35.4
34.2

0.99
0.52
0.68
0.86
0.79
b
0.12

87.8
2.0
19.7
48.3
37.4
39.5

89.3
3.8
18.2
42.1
40.9
30.2

78.9 ± 15.8
87.5 ± 14.5
85.2 ± 15.2
91.0 ± 13.7
81.5 ± 20.5
9.0 ± 9.3
4.8 ± 9.9
.
88.3
2.6
16.2
46.8
37.0
33.1

0.91
0.64
0.73
0.53
0.74
0.22

85.8
2.1
19.9
43.3
37.6
36.2

85.6
2.7
20.6
36.3
42.5
30.8

89.1
3.4
13.6
45.6
40.8
29.3

0.61
0.80
0.23
0.25
0.69
0.42

14.4
2.5
3.8
8.1

6.1
1.8
2.4
8.5

7.9
4.3
4.3
10.4

0.03
0.39
0.65
0.75

3.4
1.4
6.1
9.5

6.3
2.5
2.5
6.3

5.2
2.6
2.0
5.2

0.51
0.71
0.10
0.31

1.4
1.4
4.3
7.8

5.5
1.4
4.8
11.6

4.8
0.7
4.8
11.6

0.17
0.80
0.97
0.48

21.9
23.8

20.1
18.3

22.6
14.0

0.86
d
0.08

19.7
17.7

20.8
12.6

13.6
15.6

0.21
0.46

17.7
22.7

17.8
16.4

22.5
16.3

0.51
0.28

11.9
2.5
3.1
2.5

6.1
1.2
1.8
1.8

10.4
2.4
3.1
4.3

0.18
0.65
0.72
0.39

8.8
2.7
4.1
3.4

8.2
0.6
3.1
3.1

5.8
2.6
2.6
3.9

0.58
0.33
0.77
0.93

10.6
4.3
3.6
3.6

11.0
1.4
2.7
6.9

10.9
3.4
5.4
4.8

1.00
0.34
0.47
0.43

Asthma Symptoms, mean ± SD
ASUI Average Score

Time 2 (3 Month)
N=427

c

Hospitalization

1.9

1.2

0.0

0.23

2.0

4.4

2.60

0.45

Doctor Visits

15.0

13.4

14.6

0.91

16.3

25.8

18.8

0.10

e

2.8

2.7

3.4

0.94

23.4

28.8

23.8

0.51

*Predicted values of Hankinson and colleagues.
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T=Theophylline, M=Montelukast, P=Placebo
1 P values for continuous variables from ANOVA. Significant results p<=0.05 level were further tested with Bonferroni to determine which group was significantly
different than the others.
2 P values for categorical variables were obtained from Pearson Chi-Square test. As Pearson Chi-Square tests only for interactions among groups, any significance
level less than 0.15 was then reanalyzed in binary groups - Theophylline vs. Montelukast, Montelukast vs. Placebo and Theophylline vs. Placebo - to determine
significant differences between groups.
a) Patients taking Theophylline have significantly lower ASUI scores, indicating poorer asthma control than those taking
Montelukast.
b) Patients taking Theophylline were significantly more likely to be taking inhaled corticosteroids (ICS) than those taking
Montelukast (p=0.04).
c) Patients taking Theophylline were significantly more like to be nauseous than patients in the Montelukast
(p=0.01).
d) Patients taking Theophylline were significantly more like to have insomnia than patients taking placebo
(p=0.03).
e) Patients taking Montelukast were significantly more like to report visiting the doctor than patients in the
Theophylline (p=0.04)

52

Figure 2.4. Distribution Overlap of the Stabilized Inverse Probability Weights for all Treatment Groups By Time Period

-Stabilized Inverse Probability Weights (SW) in each time period showed a mean (◊) and median (─) close to 1 indicating
that the model was correctly specified. Overall, the mean of the SW was 0.995 and ranged from 0.4–4.3.
-Time Period 0: Baseline with 488 participants; Time Period 1: 1 month with 460 participants; Time Period 2: 3 months
with 427 participants; Time Period 3: 6 months with 410 participants
Figure 2.5a. Distribution of Stabilized Inverse Probability Weights in the Treated (Theophylline) and Untreated
(Montelukast) Groups

-Stabilized Inverse Probability Weights (SW) in the theophylline and montelukast groups had means of 1 and followed a
similar distribution indicating balance between both groups.
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Figure 2.5b. Distribution of Stabilized Inverse Probability Weights in the Treated (Theophylline) and Untreated
(Placebo) Groups

-Stabilized Inverse Probability Weights (SW) in the theophylline and placebo groups had means of 1 and followed a
similar distribution indicating balance between both groups.
Figure 2.5c. Distribution of Stabilized Inverse Probability Weights in the Treated (Montelukast) and Untreated
(Placebo) Groups

-Stabilized Inverse Probability Weights (SW) in the montelukast and placebo groups had means of 1 and followed a
similar distribution indicating balance between both groups.

---
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Table 2.3. Estimated Effects of Treatment on Episodes of Poor Asthma Control (EPACs) in the LODO Trial, 200220031

Treatment Groups

Inverse Probability Weights
(SWA*SWC) RR

Intention to Treat RR

T

M

P

T vs. M

T vs. P

M vs. P

T vs. M

T vs. P

M vs. P

150

160

154

Events, n

269

236

293

Rate, events/person-year

4.9

4.0

4.9

1.22

0.99

0.82

1.24

1.01

0.83

95% CI

3.6-6.7

3.0-5.4

3.8-6.4

0.82-1.86

0.67-1.50

0.55-1.21

0.83-1.84

0.70-1.48

0.57-1.19

p-value

--

--

--

0.35

1.00

0.31

0.28

0.95

0.27

Events, n

75

43

100

Rate, events/person-year

1.3

0.7

1.6

1.85

0.81

0.44

1.94

0.78

0.40

95% CI

0.8-2.2

0.5-1.1

1.0-2.5

0.96-3.54

0.42-1.59

0.24-0.81

0.99-3.78

0.40-1.52

0.22-0.73

p-value

--

--

--

0.07

0.55

0.01*

0.05

0.44

0.00 *

Events, n

198

179

200

Rate, events/person-year

3.5

3.0

3.3

1.16

1.07

0.92

1.19

1.15

0.97

2.4-5.0

2.2-4.2

2.4-4.5

0.71-1.90

0.66-1.73

0.58-1.45

0.72-1.95

0.71-1.85

0.61-1.53

--

--

--

0.55

0.79

0.72

0.50

0.60

0.85

30

32

34

Number of patients
Asthma EPACs

Peak flow, 30% drop

Increased medication use

95% CI
p-value
New use of oral
corticosteroids
Events, n
Rate, events/person-year

0.5

0.5

0.5

0.99

0.96

0.97

1.03

1.14

1.10

95% CI

0.4-0.7

0.3-0.8

0.3-0.8

0.56-1.75

0.53-1.73

0.51-1.84

0.58-1.79

0.67-1.94

0.62-2.01

p-value

--

--

--

0.97

0.89

0.93

0.91

0.63

0.74

Events, n

41

34

41

Rate, events/person-year

0.7

0.5

0.6

1.27

1.09

0.85

1.28

1.32

1.03

0.5-1.0

0.4-0.8

0.4-1.2

0.72-2.24

0.54-2.19

0.42-1.75

0.73-2.27

0.72-2.41

0.56-1.89

Unscheduled health care

95% CI

p-value
---0.40
0.81
0.67
0.40
0.37
0.92
p values for treatment effects on rates of episodes of poor asthma control are based on negative binominal regression with robust variance
* Montelukast was significantly less likely to cause drops in peak flow than in the placebo group for both ITT and MSM models.
1
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Chapter 3: Using Marginal Structural Models to Determine Whether Race
is an Effect Modifier in Analyzing Treatment Effects on Asthma Control
Background: Marginal Structural Models (MSMs) have been commonly used to control for confounding in
longitudinal studies with time-varying treatments and time-dependent covariates, yet their use in detecting
effect modification, while plausible, has been limited in practice. The purpose of this paper is to
demonstrate the use of MSMs for detecting effect modification by race in a randomized controlled trial
(RCT) assessing treatment effectiveness on asthma control.

Methods: MSMs using inverse probability treatment weighting (IPTW) on the full cohort were
implemented. Pooled logistic regression models were first fitted to assess the probability of staying on
assigned treatment (adherence) for all subjects at each visit by treatment arm to control for
confounding. A final pooled logistic regression model was fitted for the annual rate of acute asthma
exacerbations (outcome) as a function of the IPTWs, assigned treatment and an interaction term
between treatment and race using a Poisson generalized estimating equation (GEE) with an
independent correlation matrix to assess effect modification by race in the relationship between
treatment and asthma control.

Results: IPTWs were first computed for both the full cohort and by strata; however, when examining
balance between treatment groups by race, it was determined that the non-white group was not of
sufficient size to obtain meaningful estimates. As such weights for the full cohort were used to detect
effect modification. Effect modification by race was seen on the multiplicative scale only when
comparing montelukast to placebo for overall episodes of poor asthma control (EPACs), increased
medication use and unscheduled health care visits. Compared with whites, non-whites were more than
twice as likely to suffer from EPACs on montelukast as on placebo (RR=2.13, 95% CI: 1.08-4.46, p= 0.04)
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and almost 3 times as likely to increase medication use (RR=2.86, 95% CI: 1.10-7.42, p=0.03). Nonwhites were over 5 times more likely to have unscheduled health care visits than whites while on
montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02).

Conclusions: Race modified the relationship between montelukast and most of the asthma control
outcomes. While MSMs can be used in the detection of effect modification, more research is needed to
determine the most appropriate way to calculate inverse probability treatment weights propensity
scores as there is no consensus in the literature on how best to calculate the propensity scores required
for weighting and achieve accurate subgroup results.

Keywords: marginal structure models, effect modification, inverse probability weighting, clinical trials,
causal inference, asthma control
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Introduction
In certain situations, average causal effects may differ within subgroups compared to the entire
population. Understanding whether the effect of a treatment (or exposure) is different in groups of
patients with different characteristics can assist clinically in determining who would benefit most, or
least, from a particular treatment.1,2 Unfortunately, designing a clinical trial to study time-varying
treatment effects in relevant subgroups is a costly and time consuming endeavor and therefore, analytic
methods to assess effect modification are needed.

Marginal Structural Models (MSMs), which have been commonly used to eliminate confounding in
longitudinal studies with time dependent covariates, have been posited to be able to detect whether a
pre-treatment fixed covariate modifies the causal effect of a time varying treatment on an outcome at
the same time as adjusting for post-randomization confounding in a clinical trial.2–4 In essence, MSMs
first estimate inverse probability weights (IPW) to determine joint probabilities, i.e. propensity score
values, of an individual’s treatment and censoring history, conditional on their observed set of
covariates. This theoretically eliminates all back door pathways (post randomization confounding in
clinical trials) that may bias the association between the treatment and the outcome, making the
baseline randomization once again valid.3–9 Once confounding is “eliminated”, a final weighted model is
then fitted for the outcome as a function of the treatment history and a treatment-covariate interaction
term for the computation of a causal effect of treatment within levels of a covariate that may potentially
act as an effect modifier in the association between exposure and outcome.3

While the use of MSMs to adjust for confounding in longitudinal studies is increasing common, there are
only a few instances in the literature that use MSMs to assess for effect modification. To add to the
literature, I utilize MSMs to assess whether race modifies the causal effect of asthma treatments on the
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rate of episodes of poor asthma control (EPACS) in a 6 month randomized control trial that was not
initially designed to do so.

Race was chosen as a potential effect modifier for two reasons. First, research has indicated that certain
racial and ethnic groups fare significantly worse than whites when assessing asthma control.10–17 For
example, one study found that African Americans were three times more likely than whites to visit an
emergency room for an exacerbation (18.3% vs. 6.1%)18while another study found that Hispanics were
60% more likely than non-Hispanic whites to have poorly-controlled asthma.4 Lastly, a few studies have
indicated that certain first-line asthma treatments were not as effective in improving asthma control in
African Americans and Puerto Ricans in comparison with other racial and ethnic subgroups.19–23

Second, this is a secondary data analysis of the American Lung Association Airway Clinical Research
Centers (ACRC) Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial24.
The ACRC has been extremely successful in enrolling large numbers of patients from diverse
populations. 25,26 As such, the opportunity presented itself to examine whether race was an effect
modifier in the estimation of the causal effect of theophylline, montelukast and placebo on the annual
rate of EPACs using a MSM while also accounting for potential time-dependent confounding that could
have occurred due to post randomization confounding. While the original results of the LODO study
found a null average casual effect between asthma treatment and episodes of poor asthma control, I
postulate that these estimates may differ when stratified by race using a MSM.

Effect Modification
Effect modification, i.e. heterogeneity of effect, occurs when the magnitude of the effect of the primary
exposure on an outcome differs within levels of a third variable.1,2,4,27,28 Unlike confounders, effect
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modifiers are not associated with the exposure nor can they be descendants of either exposure or
outcome. They are natural occurrences that can be viewed as another independent cause of the
outcome of interest. Therefore, failure to consider potential effect modification and estimating only the
individual contribution of an exposure to an outcome may result in erroneous conclusions.

The most common way of identifying effect modification is to examine the association between an
exposure and outcome separately for each level of the third variable, i.e. stratification. If the causal
effect happens to be different between the two strata, then there is evidence of effect modification.
The type of effect modification found is dependent on the measure of association (i.e. risk difference,
risk ratio) being used. When the causal risk difference varies across strata (M), then effect modification
is present on the additive scale (equation 1)

Pr[Ya=1=1|M=m] - Pr[Ya=0=1|M=m]

Equation 1.

while the use of the causal risk ratio indicates that effect modification exists on the multiplicative scale
(equation 2).

Pr[Ya=1=1|M=m] / Pr[Ya=0=1|M=m]

Equation 2.

Furthermore, effect modification can be classified as being qualitative or quantitative in nature. The
former is present when the direction of the effect differs across the strata, i.e. when 1) there is an
association in one subgroup but no association in the other or 2) there is an increased risk in one
subgroup but decreased risk in the other. In contrast, quantitative effect modification exists when the
direction is the same across strata but the strength of the association differs. When qualitative effect
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modification occurs it will be present on both the additive and multiplicative scale. However,
quantitative effect modification can occur on both scales or only on one. Regardless of type, if effect
modification exists, the crude effect measure will be between the estimates of the stratum-specific
estimates.

The clinical motivation behind the assessment of effect modification is to identify whether the effect of
a treatment (or exposure) is different in groups of patients with different characteristics to determine
who would benefit most, or least, from a particular treatment.1,2 Ultimately, understanding effect
modification may allow individualized preventive medical advice before diagnosis, in addition to
personalized medical treatment after a disease diagnosis or susceptibility to a particular disease has
been determined.

Marginal Structural Models
A concern with estimating effects from longitudinal data is the assumption that a subjects’ behavior and
subsequently the distribution of risk factors will change with time. Unlike traditional regression models,
Marginal Structural Models (MSMs) can account for both the joint effects of baseline and subsequent
treatments and for the presence of time-dependent confounding which may be influenced by prior
treatment (mediators), by modeling exposures at each follow up and the final outcome.3,6,29,30 Formally,
an MSM relates any possible exposure (A), up to time t, to the corresponding counterfactual outcome
(Y) at time t to measure overall population impact.2,31–34 In other words, these models allow for the
estimation of all potential outcome-treatment combinations for each study visit, despite the fact that
only one response for a given treatment level per visit will be observed in the data, with the rest
“counter to the facts”.
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Less commonly, MSMs have been used to detect whether the causal effect of a time-varying treatment
on an outcome is modified by a pre-treatment fixed covariate (M).3,4,35–39 When assessing effect
modification using MSMs, it is assumed that the causal effect of treatment on an outcome is dependent
on whether the choice of a treatment option at a particular time point is affected by the presence of
time-dependent confounding (L) for every level of M. While technically no longer a true marginal
structural model because the causal effect is now conditional on M, it is generally accepted that as long
as all time-dependent confounders are eliminated, stratum-specific associational risk ratios can be
interpreted as a stratum-specific causal effect of treatment, i.e. there is a difference in the
counterfactual outcomes under two or more treatment regimes in each level of M.2,4,9,27 Therefore,
there is conditional exchangeability given L and as such, the observed risk difference (Pr[Y =1 │A=1,
M=m] - Pr[Y =1 │A=0, M=m]) or risk ratio (Pr[Y =1 │A=1, M=m] / Pr[Y =1 │A=0, M=m]) will equal the
unknown counterfactual risk difference (Pr[Ya=1 =1 | M=m] – Pr[Ya=0 =1 | M=m]) or risk ratio (Pr[Ya=1 =1 |
M=m] / Pr[Ya=0 =1 | M=m]), respectively.

MSM parameters are estimated through the application of an inverse-probability-of-treatment
weighting (IPTW).2,7,8 IPTWs adjusts for post-randomization confounding due to 1) non-adherence and
2) mediators by creating a pseudo-population where the time-varying treatment is independent of
stable and time-varying covariates that preceded it, allowing for causal treatment comparisons using
standard repeated measure models.3,9,30,32,33,40–42 Instead of modeling the relationship between a
covariate and the outcome as is done in traditional regression, IPTW models the probability of receiving
the treatment given past treatment and prognostic factor history at each time point. Most researchers
do this in one step by fitting pooled logistic regression treatment models with time as a class variable to
allow a separate intercept for each time point. The resulting predicted probabilities (i.e. propensity
scores) are used to construct the stabilized weights for the entire study population at each time point
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during follow-up. A single weight per subject is then obtained by multiplying the current treatment
weight with that of the treatment weights from the previous time points.

Weights can be either non-stabilized or stabilized. The former is estimated by taking the reciprocal of
the probabilities of receiving treatment given the covariates (1/p for those treated and 1-1/p for those
untreated), while the latter adds a numerator representing the overall probability of being treated for
those who were treated and of not being treated for those who were not treated. As the numerator
and denominator in stabilized weighting will share common factors, the weights will be less variable, the
sample size will be close to that of the original population and there will be less chance of Type 1
errors.3,9,42 Therefore, stabilized weights increase statistical efficiency attains better coverage of
confidence intervals and is recommended when using IPTW to fit a marginal structural model. For the
purposes of the following analysis, I will be referring to stabilized inverse probability weights.

Stabilized treatment weights are defined as:

𝑆𝑆𝑆𝑆(𝑡𝑡) = ∏𝑡𝑡𝑘𝑘=0

𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝑉𝑉]
𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝐿𝐿(𝑘𝑘)]

Equation 3.

The denominator of the model represents the probability that the subject received their own treatment
history (ƒA k ), given all prior treatments (A k-1 ) and all baseline and time-varying covariate histories (L)
until the last visit (k) for all possible treatments. The numerator acts as a stabilizing factor to reduce the
variance of the estimates and represents the overall probability of being treated for those who were
treated and of not being treated for those who were not treated using baseline covariates only (V)
which includes the potential effect modifier (M). When analyzing RCTs with baseline randomization, the
value of A at time 0 will be each participant’s assigned treatment and since there is no confounding the
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stabilized weight will be 1.6,31,33

Once the IPTWs are calculated and balance between treatment groups is established, both the detection
of effect modification and the average causal effect of treatment on the outcome can be unbiasedly
estimated in a conventional regression model for repeated measures. This is done by fitting the
outcome as a function of the stabilized weights and an interaction term between treatment history and
the potential effect modifier in all complete cases.2–4 If the interaction term is significant at the 0.05
level, multiplicative effect modification exists and stratum specific conditional estimates should be
reported.

Assumptions
There are several assumptions that must be met when fitting a MSM to assess either confounding or
effect modification. First is the assumption of no unmeasured confounders, i.e. conditional
exchangeability or sequential randomization. This assumption requires that all covariates which are
associated with treatment assignment, outcomes or censorship are adjusted for at each visit, causing
treatment selection to once again be random as it was at baseline.5,6,42 If unobserved confounders are
present, then treatment groups will no longer be exchangeable and residual bias in the treatmentoutcome association can remain. Therefore, it is important, although not empirically verifiable, to
ensure that all possible confounders which affect treatment selection and outcome are added to the
models.

The second assumption of positivity assumes that the conditional probability of receiving either
treatment and of remaining under complete follow-up will be greater than zero. Positivity is guaranteed
in randomized control trials because, by design, there will be individuals assigned to each level of the
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studied treatment and therefore, there is no possibility of a structural violation of positivity.2,5,42
However, depending on the sample size and the number of confounders, there can be instances where,
at one or more levels of the confounders, no one happens to be observed at one or more levels of the
exposure (zero cells). These random violations of probability occur by chance and can be corrected by
using parametric models or combining adjacent subgroups with cells greater than zero.2,42

The third is the unverifiable assumption that one is using the correct weighting and analysis models.
Any parametric model may be mis-specified by the omission of unmeasured confounders, non-linear
terms or interactive relationships. If misspecification occurs, residual bias in the treatment-outcome
association can remain or, in some cases, even increase.5,41 Sensitivity analyses to test the listed
structural model specifications above must be done to determine whether the stabilized weights have a
mean of 1.0 and a minimum and maximum that is not very extreme.

Lastly, it is assumed that all missing data will be missing at random (MAR). The MAR assumption states
that conditional on some set of variables that are fully observed, the probability of missing outcome or
exposure is independent of all variables in the model.33,40,43

The Importance of Looking at Race as an Effect Modifier in the LODO trial
In the ACRC LODO trial, the investigators tested the effectiveness of low dose theophylline, a drug
known for its narrow therapeutic window and severe interactions with various drugs, in maintaining
asthma control in mild to moderately severe asthmatics compared to the widely used anti-leukotriene
antagonist montelukast (Singulair) and placebo, respectively. Results of the LODO study found no
difference in EPAC rates between theophylline and montelukast (1.22; 95% CI=0.82-1.86; p=.35) as well
as theophylline and placebo (0.99; 95% CI=0.67-1.50); p=1.00).24
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Maintaining asthma control was defined as the rate of episodes of poor asthma control assessed
by spirometry measures, ambulatory peak flow monitoring, participant-reported symptoms and the use of
rescue or reliever medications or health care services. Not only do these measures predict asthma control,
they have also been shown to predict subsequent treatment adherence and be affected by prior treatment.
For example, a lower than normal FEV 1 is associated with severity of asthma symptoms, increased asthma
attacks, reduced quality of life and the likelihood of both hospitalizations and respiratory failure all of which
have been shown to affect whether a participant stays on their assigned treatment.44 In addition, since
clinical trials are longitudinal studies, current spirometry measures are in part a result of previous treatment,
mediating the association between treatment and asthma control. A similar case can be made for all of the
other potential time-varying confounders mentioned above. As the decision to terminate treatments is a
nonrandomized event, influenced by both subject attributes and previous treatment, it was assumed that
time dependent confounding may have caused the results of the ITT to be biased towards the null.

Similarly, the above measures have been shown to differ within and between racial and ethnic
subgroups. Increasing evidence has supported the notion that racial and ethnic disparities for asthma
outcomes and trial participation come about when biases in the health care system interface with
individual and societal traits10,11,45–48 First, physicians may have unintentional biases and stereotypical
beliefs about minority populations that influence medical decision-making, leading to under treatment,
inadequate levels of self-management education and excess asthma morbidity and mortality.11,46,48–50
For example, Okelo et al. found that physicians frequently underestimate the severity of disease in black
compared with whites (65% vs. 59%, p=0.05).50 Studies have also shown that physicians are more likely
to believe that their African American and Hispanic patients would be less capable of adhering to
doctor’s orders than their white counterparts leading to non-representation in clinical trials and/or the
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potential for information bias.51,52 Unfortunately, the stereotyping of minorities is not a new
phenomenon as anecdotes as far back as the early twentieth century have indicated the medical
community’s prejudice against ‘groups that could not be assimilated into a complex, white civilization’.53

Consequently, poor interactions with physicians have lead patients to distrust their provider and the
health care system in general which affects participation and adherence in clinical trials.17,54–56 A
number of studies have found that minorities, particularly African Americans, distrust healthcare
institutions and providers, in general, due to past experiences of racism within the medical community
such as in the case of Tuskegee, where doctors purposely withheld syphilis treatment from poor black
men for more than 20 years post penicillin.46,53,57 It has been estimated that 25% of African Americans
have a high level of distrust in physicians, but this is most likely an underestimate.58 Furthermore,
adherence to prescribed medications may become sub-optimal when patients do not trust their
clinicians or believe that the medications prescribed are actually ineffective or unneeded. For example,
studies have found that asthma medication use in inner-city minority populations is over reliant on
symptom-driven management rather than daily use of controller medications to treat the underlying
disease.56,59 Riekert et al found that even when providers practiced according to the guidelines, at least
a third of the patients did not take their controller medications, with children managing symptoms of
asthma with short-term beta-agonists instead of controller medications (70% vs. 45%).56

Lastly, racial and ethnic differences have been shown to exist in regards to certain treatment response
and effects.60 Albuterol is the most commonly prescribed short-acting bronchodilator (SABA) asthma
medication in the US and is likely to be the only medication used to treat airflow obstruction due to
asthma regardless of severity among minority populations. However, a number of studies have found
that the drug may not be as effective in Puerto Ricans and African Americans as it is in whites and
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Mexicans.20,61–64 In addition, inhale corticosteroids (ICS), which have been recommended by National
Asthma guidelines as a first-line therapy for the treatment of chronic asthma,65 has been consistently
shown to reduce airway responsiveness, diminish symptoms and prevent exacerbations over time.
However, there is substantial inter-individual variability in response to ICS and there is evidence that
these first-line treatments are not as effective in improving asthma control in African Americans in
comparison with other racial and ethnic subgroups.20,21,66–68 One study found that ICS, improved the
change in FEV1 after albuterol administration in Mexican Americans (21.7%, P=.01) and Puerto Ricans
(18.5%, P=.02) but not in African Americans (3.0%, P=.73).21 Unfortunately, information on the
pharmacokinetics of theophylline or montelukast by race is not known.

Understanding the complex etiologies of asthma as they relate to diverse populations will become
increasingly important from the perspective of public health. Over the next four decades, the U.S. will
experience significant demographic shifts with minority or multiple race populations becoming the
majority. First, having knowledge about beneficial, or non-successful, treatment options in diverse
research participants would improve the generalizability of research findings and provide clinical
guidance in asthma management for minority patients.69 Second, diversity in clinical research is a
prerequisite for equity and elimination of disparities.46,69–71 The inclusion of minority groups in trials will
not only improve patients’ knowledge and sense of empowerment, but over time will lead to better
health advocacy, study participation and health outcomes. In fact, one study found that when patients
are empowered by their physicians, inner city families are highly motivated to comply with medical
regimens and asthma action plans.56

Knowing that the ACRC has been successful in enrolling large numbers, the opportunity presented itself to
examine whether race was an effect modifier in the estimation of the causal effect of theophylline,
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montelukast and placebo on the annual rate of EPACs using a MSM while also accounting for potential timedependent confounding that could have occurred due to post randomization confounding.

Figure 3.1 shows a possible directed acyclic graph72 that represents the relationships between the timevarying treatments (generally a time-varying variable as each day you may take it or not take it) and the
above covariates with the outcome stratified by an effect modifier, assuming no unmeasured confounding.
L(0) denotes baseline demographic characteristics along with baseline FEV 1 . It was assumed that there was
no effect of L(0) on A(0), because of randomization and full initial compliance. Therefore, confounding is
assumed to occur only after A(0) (baseline). A(1), A(2) and A(3) represents treatments actually received,
irrespective of randomization, at follow up times 1, 2, and 3. L(1), L(2) and L(3) denotes the current levels of
the time varying covariates - pulmonary function measures, asthma symptoms, medications and adverse
effects at follow-up visits 1, 2, and 3. C(1), C(2), and C(3) accounts for lost to follow-up which occurred due
to past treatment history and confounder levels. M represents the effect modifier - race. Lastly, Y denotes
the annual rate of asthma exacerbations indicating poor asthma control.

While the DAG implies that both A and M affect Y, it does not indicate whether effect modification exists
or if it does, how M modifies the effect of A on Y.2 Overall, there are 10 possible outcomes (arrows into
Y) for each subject representing all possible combinations of treatments for the four time periods, of
which only one is observed. However, once all confounding paths are blocked, only the causal paths
(green arrows into Y) remain.

Methods
Study population
The American Lung Association Airway Clinical Research Centers (ACRC) is a network of clinical centers
69

throughout the country dedicated to improving asthma outcomes in diverse populations. Between 1999
and 2015, the network completed over ten trials that had a direct impact on the lives of asthma
participants and the cost of their care, recruiting more than 5,000 participants with asthma with
average study populations consisting of 40% non-Hispanic white, 40% African American and 20%
Hispanic.26 As a multicenter network, the ACRC is well poised to conduct comparative effectiveness
research due to its ability to enroll large numbers of participants from diverse populations from
different regions of the USA to ensure that the research findings had external generalizability and were
relevant to large groups of participants.26 All data collected from the clinical sites is managed and
analyzed by a Data Coordinating Center at Johns Hopkins University. An overview of ACRC studies has
been reported elsewhere.25 Since 2015, the ACRC mission was expanded to include other obstructive
lung disease such as COPD. This change in focus is not relevant to this paper and when discussing the
ACRC, it will refer to the network as it was between 1999 and 2015.

Study Design
The Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial was the ACRCs
second trial that began in 2002 and ran throughout 2003. It was a multicenter, randomized, doubleblind, parallel design, placebo-controlled trial evaluating whether low-dose theophylline was as effective
as an add-on therapy in treating asthmatics compared with 1) montelukast and 2) placebo in 488
participants with poor asthma control.

To be eligible for the study, participants had to be over the age of 15 years, had physician-diagnosed
asthma, been prescribed daily asthma medication for at least a year, had an FEV 1 of 50% or more of
predicted values and had a score of 1.5 or greater on the Asthma Control Questionnaire. Participants
who smoked or used oral corticosteroids, leukotriene antagonists or theophylline with four weeks
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preceding enrollment or had other significant illness were ineligible to participate.

After a one to two week run-in, eligible participants were randomized in a stratified permuted block
method in a 1:1:1 allocation ratio to 300mg/day theophylline (n=160) to 10mg/day montelukast (n=164)
to placebo (n=164) – in addition to their existing asthma therapy. Participants were followed for six
months (24 weeks), attended three follow-up visits (one, three and six months after randomization) and
were contacted by phone periodically in between visits to ensure the participant was not experiencing
any problems associated with study participation (figure 3.2).

Primary Outcome
The outcome of interest in the LODO trial was the annual rate of acute asthma exacerbations
(events/person/time) defined as having at least one of the following episodes of poor asthma control
(EPACs):

•

30% drop in peak flow for 2 consecutive days; or

•

Increase of 2 or more used of rescue medication (4 puffs MDI, 2 nebulizer uses); or

•

New course of oral steroids for asthma; or

•

Unscheduled health care for asthma symptoms

This composite outcome measure was used to reflect the several dimensions of good asthma control
including physiology, symptoms and health care use. It should be noted that EPACs is not a standardized
composite measure of asthma control and was created by the ACRC investigators. This measure has
been used as the primary outcome for many of their trials in order to achieve its mission to provided
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evidence to support optimal standards of care into clinical or public health practice for persons with
asthma.

Treatment Groups
In the original ITT analyses, participants were randomized in equal allocation ratio to one of three
treatment groups:

•

Theophylline (Theo-Dur®) 300 mg/capsule

•

Montelukast (Singulair®) 10 mg/capsule

•

Placebo capsule

Subjects were instructed to ingest 1 capsule daily following their evening meal. All treatments were
masked by opaque capsules. After randomization, the remainder of the study was observation in the
sense that participants could discontinue study medication.

As such, for the IPW analysis treatment groups consisted of all those who were compliant with their
respective assigned treatments at each visit compared to those who were not compliant for each arm of
the original randomization. This allowed for a participant’s propensity for adherence to vary as
circumstances changed over the course of the study. Adherence information was obtained from diary
cards participants provided to study investigators at the 1, 3 and 6 month clinical visits. A person was
considered to be adherent to assigned treatment if they reported being on study treatment with no
interruptions since the last clinic visit or if they were currently on study treatment but had temporarily
discontinued since last visit. All other cases were considered to be non-adherent. In total, 174
participants did not adhere to their assigned study treatment in 218 visits. Twenty three participants
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were non-adherent with assigned medication at 1 month – 11, 8, and 4 in the theophylline, montelukast
and placebo groups, respectively. Twelve were non-adherent at three months – 6, 4 and 2 in the
theophylline, montelukast and placebo groups, respectively. At the six month visit, an additional 139
participants did not adhere to the study medication – 45 in the theophylline group, 49 in the
montelukast group and 45 in the placebo group.

Potential Effect Modifier
Racial/ethnic group, a pretreatment covariate, was considered to be a potential effect modifier in the
relationship between treatment and asthma control. In the original LODO study, race/ethnicity
consisted of the following self-reported groups: white (61%), black (29%), Hispanic (7.9%), Asian (0.4%),
American Indian (0.2%) and Other (1.6%).24 For the preservation of positivity in my analysis, race was
restricted to two mutually exclusive subgroups: white (61%) vs. non-white (39%).

Time-Dependent Confounders
A number of covariates were considered as potential time-dependent confounders. It was assumed that
these variables were measured prior to deciding whether or not to continue with their assigned
treatment or the study in general.

Variables that were collected only at baseline and remained static throughout the trial included age
(defined as a continuous variable), sex (male, female) and race (white, non-white).

Covariates considered potential time-vary confounders included:
•

Pulmonary Function Test indices such as forced vital capacity (FVC), forced expiratory volume
(FEV 1 ); bronchodilator reversibility (BD); and ambulatory peak flow (PEF) - interpreted as
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percentages of predicted values based on Hankinson et al. well-established reference equations
for healthy subjects of similar demographic characteristics (height, age, sex, race and weight). A
detailed description on how percent predicted values based on normal lung function are
calculated has been previously published.73,74

•

Average Asthma Symptom Utility Index (ASUI) was scored from 0 to 1, with 0 indicating severe
symptoms for at least one week to 1 signifying no symptoms in the two week period.75 The
items are then weighted according to participant preferences and scored based on a multiattribute utility function of ASUI= 1.200 x (S1 Cough * S2 Wheeze * S3 Shortness of Breath * S4
Awake At Night * S5 Medical Side Effects) - 0.200. A detailed description of the ASUI has been
previously published elsewhere.75

•

Medication use was defined as a binary measure. Participants were asked if they had used any
of the following medications since their last visit: inhaled corticosteroids, inhaled long-acting
beta-agonists, inhaled short-acting beta-agonists, inhaled anticholinergic, combination drugs
such as Advair.

•

Adverse effects were also defined as a binary measure. Participants were asked if they had any
of the following adverse effects since their last visit – nausea, vomiting, poor appetite,
heartburn, headache, insomnia, anxiety, tremor, heart palpitations and skin rash.

•

Use of health care services was also defined since their last visit. Starting with the 1 month visit,
participants were asked if they visited with their doctor or were hospitalized since their last
study visit.
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It was assumed that these covariates fully encompass the loosely associated four domains of asthma, as
well as, both the clinician’s and participant’s perspective and therefore, was considered good predictors
of the outcome (asthma exacerbation), treatment adherence and censorship.

Missing Data
Thirty-one participants (6% of participant visits) had missing covariate estimates for one or more
confounders despite attending visits and providing exposure and outcome data. Missing covariate data
were imputed using the mean value for the treatment and time period groups. These cases were
retained for all analyses.

Data were censored at the time of the first missed visit, i.e. exposure or in cases where the outcome was
missing. Research has indicated that censored at first missed visit is generally the least biased across all
missingness mechanisms.29,40,76 Twenty-eight cases were lost to follow-up after the baseline visit – 13
from the theophylline group, 5 from montelukast and 10 from the placebo group - leaving 460 cases
with complete data at the six week visit. Another 33 participants had been lost to follow-up after the
six-week visit – 10 from theophylline, 14 from montelukast and 9 from placebo – leaving 427 cases with
complete data at the three month visit. At the six month visit, another 24 were censored – 10 from the
theophylline, 5 from montelukast and 9 from placebo – leaving 403 cases with complete data at the six
month and final visit.

Statistical Analysis
Inverse Probability Weighting Models
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There is lack of consensus as to whether the propensity scores used to calculate the IPTWs when
attempting to detect effect modification should be estimated on the full cohort or by strata.35–37,39 In all
of these studies, both methods seem to provide valid subgroup analyses as long as the propensity score
correctly reflects the underlying distribution and that the cohort and subgroups are of sufficient size. To
test these findings, propensity scores were computed for both the full cohort and by stratum.

Pooled logistic regression models were fitted for the probability of staying on assigned treatment
(adherence) for subjects at each visit by treatment arm in the full cohort as well as by stratum. The
dataset for these models was discretized into one observation per subject per visit so that 1) time could
be fit as a class variable to allow a separate intercept for each time and 2) lagged variables for previous
treatment and confounder histories would be comparable between subjects.

Stabilized treatment weights were created by dividing the baseline probability of selecting a treatment
(numerator in equation 1) by the probability of selecting treatment given prior treatment history and
potential confounders up to time t (denominator in equation 1). Each covariate was entered in the
pooled logistic models as a main effect only.

Resulting predicted probabilities were then used to construct the final stabilized treatment weights for
each subject at each visit. Once all subjects had a stabilized weight for each visit, a final stabilized
weight per participant was obtained by multiplying the estimated probability of their observed
treatment at each visit cumulatively over time, i.e. the first score was left as is, and for all others, the
scores at the current visit was multiplied by the score of the previous visit. To determine whether the
final stabilized weights resulted in balanced data, distribution plots were created to assess central
tendency and skewness between the original and weighted data sets.
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Outcome Models
Poisson regression models using PROC GENMOD were ran for the entire population and for each level of
M. The full cohort model fitted the annual rate of episodes of poor asthma control (outcome) as a
function of the assigned treatment using the final weights and an interaction term between the assigned
treatment and potential effect modifier. Stratum specific models were fitted using the same criteria as
the full cohort model with the exception of the interaction term.

Final models were fit to all uncensored cases with complete data (N=403) and were conducted for three
treatment groups – theophylline vs. montelukast, theophylline vs. placebo and montelukast vs. placebo.
Generalized estimating equations (GEE) with an independent correlation matrix were used in all models
to account for the correlation within-subjects when estimating regression parameters to make valid
statistical inferences from longitudinal data.77–79 All data management procedures were conducted with
SAS 9.4 (SAS Institute, Cary, NC).80

Results
Participant Characteristics
Table 3.1 delineates baseline characteristics and treatment assignment rates by race. Out of the 488
subjects randomized to the LODO study, 296 (61%) were white and 192 (39%) were non-white, with the
majority of the latter being African American (29%) and Hispanic (8%). Treatment groups had similar
representation of both white and non-white subjects. No differences between racial groups were seen
for baseline characteristics except for the fact that whites were significantly more likely to be taking
inhaled corticosteroids than their non-white counterparts (p-value= 0.02).
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Table 3.2 shows participant characteristics by race over the follow-up period. Treatment adherence
over time was similar for racial groups. At four weeks, white subjects had significantly lower declines in
their FVC bronchodilator change rate and were significantly more likely to report heartburn than their
non-white counterparts. Non-whites displayed lower pre-bronchodilator FEV 1 than whites throughout
the trial but this difference only became significant after 3 months. Lastly, non-whites were significantly
more likely to report tremors at six months than their white counterparts (p-value=0.02).

Table 3.3 summarizes the number and rates of EPAC composite events as well as each component
individually due to treatment effects by race. Event rates were similar for racial groups in both the
theophylline and placebo groups however, in the montelukast group, nonwhites were found to have
more EPACs overall and by episode components. Significant differences in event rates were found
between whites and non-whites assigned to montelukast for overall EPACs (2.66 vs. 5.75, pvalue=0.0034), increased medication use (2.15 vs. 4.60, p-value=0.0212) and unscheduled health care
(0.33 vs. 0.93, p=0.0007).

Inverse Probability Weighting Models
Propensity scores were initially computed for the full cohort and by racial strata. The mean stabilized
weight in the full cohort was 0.998 and ranged from 0.04 to 4.0, indicating that the model was correctly
specified. Figure 3.2 shows the distribution overlap of the stabilized weights for all groups over time in
the full cohort. In comparison, the stratum-specific mean stabilized weights were similar to the full
cohort for whites but ranged from 0.02 to 10 in the non-white group. Furthermore, the non-white
group had abnormally large standard errors and violated the positivity assumption as many exposurecovariate groupings had zero cases. This led to the conclusion that the non-white group was not of
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sufficient size to obtain meaningful estimates. As such, the full cohort was used for all subsequent
analyses.

The distribution of treatment groups (theophylline vs. montelukast, theophylline vs. placebo and
montelukast vs. placebo) in the full cohort was examined through plotting the stabilized weights in the
treated and untreated groups over time both in the original and in the weighted data sets. The central
tendency of the covariate values coincided between groups in both data sets indicating that balance was
achieved. The distribution plots for the weighted data sets are shown in figures 3.3a, b, and c.

The denominator of the inverse probability treatment weight models for the full cohort were further
examined to find covariates with negative coefficients as these predict which individuals would be more
likely to be non-adherent.42 In these models, previous treatment was strongest predictor of present
treatment in all treatment groups (-5.72 for theophylline, -4.97 for montelukast and -18.43 for placebo).
None of the other time-varying covariates were strong predictors of treatment changes – suggesting
bias in treatment selection over time may not be particularly strong in this data (see Appendix 3.A, 3.B,
3.C).

Outcome Models
The results of the MSM analysis for the full cohort are found in table 3.4. There found no significant
treatment effect on overall asthma exacerbation rates among all three groups: theophylline vs.
montelukast (RR=1.20, 95% CI: 0.81-1.77, p=0.36); theophylline vs. placebo (RR=1.01, 95% CI: 0.69-1.49,
p=0.96) and montelukast vs. placebo (RR=0.84; 95% CI: 0.58-1.22, p=0.36). However, taking
montelukast was associated with significantly reduced drops in peak flow than for the placebo group (RR
= 0.40 p-value= 0.00). No other significant treatment effects were found for any other outcomes.
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Effect modification by race was seen only when comparing montelukast to placebo for overall EPACs,
increased medication use and unscheduled health care visits. Compared with whites, non-whites were
more than twice as likely to suffer from an EPAC on montelukast as on placebo (RR=2.13, 95% CI: 1.084.46, p= 0.04) and almost 3 times as likely to increase medication use (RR=2.86, 95% CI: 1.10-7.42,
p=0.03). Furthermore, non-whites were over 5 times more likely to have unscheduled health care visits
than whites while on montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02). Lastly,
while only borderline significant, it should be noted that compared with whites, non-whites on
theophylline were 66% less likely to have unscheduled health care visits than those on montelukast
(RR=0.34, 95% CI: 0.11-1.01, p=0.05).

Table 3.5 shows the effects of treatment by strata for those outcomes in which effect modification by
race was found. The only significant finding was that whites on montelukast were significantly less likely
to have an EPAC than those on placebo.

Discussion
This study examined the moderating impact of race on the causal effect of treatment on asthma control
in the LODO trial of the ACRC using MSMs. As hypothesized, qualitative effect modification on the
multiplicative scale existed for a number of treatment-outcome associations. However, race differences
only seemed to exist for patients on montelukast. In the unadjusted analysis, non-whites were twice as
likely to have an EPAC on montelukast as their white counterparts (5.75 vs. 2.66 episodes per person
year, p=0.0034). Similar findings were seen for increased medication use and health care visits (table
3.3). Results of the MSM also indicated the presence of effect modification for overall EPACs,
medication use and unscheduled health care when treated with montelukast instead of placebo. For
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example, non-whites were over 5 times more likely to have unscheduled health care than whites on
montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02) (table 3.4).

These finding may be indicative of potential information bias in adherence levels, which was determined
in this study by self-report. Research has shown that minority groups are more likely to be over reliant
on symptom-driven management rather than daily use of controller medications.56,81,82 One study found
that at least a third of black patients claimed to not take their controller medications, with many
managing symptoms of asthma with short-term beta-agonists alone.56 However, since the significant
findings only applied to montelukast and not to theophylline, it may be more plausible that the
difference is due to pharmacogenetics reasons. Prior research has found that African Americans do not
respond as well as whites to inhaled corticosteroids and albuterol.20,21 Unfortunately, there have been
no studies to date that have examined racial differences in pharmacokinetics for montelukast.

These results should be considered in the context of the following limitations. First, MSMs requires the
untestable assumption of no unmeasured confounding; i.e. that subjects are exchangeable, conditional
on the measured variables.2,5,83,84 It is assumed that all the most important confounders were identified
using the expert knowledge of the ALA-ACRC and were then appropriately measured and included in the
analysis. However, it can never be verified that all joint predictors of exposure and outcome were
added to the models.

Second, there is lack of consensus as to whether the propensity scores used to calculate the IPTWs
should be estimated on the full cohort or by strata.35–37,39 It is assumed that strata-propensity scores
would lead to better balance between treatment groups and therefore, less bias in the treatmentoutcome relationship when dealing with studies like this with rare outcome events. However, the same
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research indicates that weighting according to the distribution of effect modifiers observed in the full
cohort is the ideal method when estimating a casual contrast from randomized clinical trials (or any trial
where there is well defined inclusion and exclusion criteria and everyone has the indication under
study). Unfortunately, there is no guideline as to what constitutes a sufficient size for strata-specific
propensity score models.36

Even when using the full-cohort propensity scores model, finite-sample bias occurred due to the small
overall sample size and the number of potential confounders. This led to the presence of random zeros
in a few of the exposure-covariate groups. Therefore, one can assume the positivity assumption was not
met in this study. However, random zeros are essentially guaranteed because of the infinite number of
possible values and a more valid assessment of positivity includes looking at extreme values, mean of
weights and values of exposure-covariate groups adjacent to those with zero.5 Also, as seen in figures
3.5a, b, and c, many if not all of the exposure-covariate groupings with zero were surrounded by nonzero groups.

Third, it is assumed that the models used in this analysis are correctly specified. To explore the
robustness of the models, linear and quadratic terms of continuous variables were tested to restrict the
possible values of the propensity scores such that on a logit scale the conditional relation between the
continuous covariates and the risk of treatment can be represented by a parabolic curve, and each
covariates contributions to the risk is independent of that of the other covariates.33 No significant
changes to the outcome were noted. Additionally models were fitted with different groupings of
covariates. For example, models were fitted for individual side effects and medications alone, for
composite measures of side effects and medications and for both composite and individual grouping.
Again, there were no significant changes to the outcome. Finally, the fact that the mean of the final
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stabilized weight was close to 1 and that the MSM and ITT results were nearly identical, gives strength
to the assumption that the MSM was not mis-specified. Unfortunately, the assumption of a correctly
specified model can never be proven.

Lastly, while there has been plenty of research published regarding racial disparities on asthma
morbidity and burden, it is important to note that race may not be the true causal factor but instead
serves as a proxy or marker for one or more of the complex, multilevel and intertwined environmental
and cultural factors thought to be associated with asthma control disparities.13,16,45,69,85,86 Related to this
last point, the original LODO study results found that the use of inhaled corticosteroids modified the
effect of treatment on asthma control. Comparatively, the only significant difference in baseline
characteristics in this study was the fact that whites were significantly more likely to be taking inhaled
corticosteroids than their non-white counterparts (p-value= 0.02). Adding credence to the argument
that race is an effect modifier by proxy and not a direct effect modifier in this study is the fact that while
there was significance for effect modification in some treatment-outcome relationships, there was no
significant relationship found between race and any of the asthma control outcomes (table 3.2). Having
an association with the outcome is a prerequisite of being an effect modifier.1,2,27,28 Unfortunately,
effect modification by inhaled corticosteroids was not examined in this paper and it is unknown if it
would have impacted the results of the MSM analysis.

In summary, my analysis found that race modified the relationship between montelukast and most of
the asthma control outcomes. Unfortunately, there is little information on the appropriate method to
and sample size for a MSM to accurately assess effect modification despite the obvious need for ways to
combine moderation analysis with advanced causal methods and with the increasing use of MSMs to
adjust for confounding in longitudinal data with time-varying exposures and covariates. While this
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analysis adds to the scarce literature, there are many limitations that may preclude confidence in the
results including the use of race as an effect modifier and a not so large sample size for at least one of
the stratum. However, the fact that all significant findings were found for montelukast indicates that
something unrelated to the MSM process is at play.

Conclusion
While MSMs have been commonly used to adjust for confounding in longitudinal studies with timevarying exposures and time-dependent covariates, they have been rarely used for detecting effect
modification and there is no consensus in the literature on how best to achieve accurate results.
Despite theoretical evidence, more practical research on MSMs ability to assess effect modification is
needed.
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Figure 3.1. Structural relationships over time between treatments and asthma control in the Low Dose
Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial (ACRC, 2002-2003)1

1

Created through Daggity software: Johannes Testor, Juliane Hardt, and Sven Knuppel. Daggitty: A
graphical tool for analyzing causal diagrams. Epidemiology, 22(5): 745, 2011
-A0, A1, A2, A3 represent observed cumulative treatment exposure to either Theophylline, Montelukast
or Placebo from baseline randomization (A0), 1 month (A1), 3 months (A2) and 6 months (A3).
-L1, L2, L3 denote measured confounders (pulmonary function measures, asthma symptoms,
medications and adverse effects) that may be associated with A(k),respectively. L(0) denotes baseline
demographic characteristics along with baseline FEV 1 . It was assumed that there was no effect of L(0)
on A(0), because of randomization and full initial compliance.
-C1, C2, C3 reflects loss to follow up at 1 month (C1), 3 months (C2) and 6 months (C3).
-M represents the potential effect modifier, race.
-Y indicates the outcome of annual rate of asthma exacerbations indicating poor asthma control. If all
possible confounding paths are blocked, the green arrows into Y represent the remaining causal paths.
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Table 3.1. Baseline Characteristics of the 488 LODO Participants by Race/Ethnicity
White
296

Non-White
192

p-value1
--

32.4
34.5
33.1

33.3
32.3
34.4

0.84
0.62
0.77

Demographics
Age, mean ± SD
Male, %

41.3 ± 15.3
26.7

39.1 ± 13.8
25.5

0.10
0.77

Asthma Symptoms, mean ± SD
ASUI Average Score, mean ± SD

0.68 ± 0.14

0.68 ± 0.17

0.93

79.6 ± 16.0
87.3 ± 14.9
85.8 ± 15.1
90.9 ± 13.4
83.1 ± 18.1
8.9 ± 9.9
5.1 ± 9.8

77.3 ± 17.7
88.0 ± 16.4
83.6 ± 17.1
92.8 ± 17.5
81.1 ± 22.4
9.5 ± 13.6
6.0 ± 12.1

0.14
0.62
0.13
0.21
0.30
0.58
0.34

Number of patients (N=488)
Treatment Assignment, %
Theophylline
Montelukast
Placebo

Pulmonary Function, mean ± SD
Pre-BD FEV 1, % predicted*
Pre-BD FVC, % predicted*
Post-BD FEV 1, % predicted*
Post-BD FVC, % predicted*
Peak Flow, % predicted*
FEV 1 Bronchodilator, % change
FVC Bronchodilator, % change

Daily Asthma Treatments, %
93.6
89.6
0.11
Using asthma medication daily
3.0
4.7
0.35
Inhaled anticholinergic
21.0
21.4
0.91
Inhaled long-acting b-agonist
57.4
59.9
0.59
Inhaled short-acting b-agonist
Combination drugs
37.8
38.5
0.88
Inhaled Corticosteroids
41.9
31.3
0.02a
*Predicted values of Hankinson and colleagues.
1 P values for categorical variables from Pearson Chi-Square test or Fisher Exact test compared to
ANOVA test for continuous categories.
a) Whites were significantly more likely to be taking inhaled corticosteroids (ICS) than non-whites
(p=0.02).

91

Table 3.2. Time-Varying Characteristics of LODO Participants by Race over LODO Follow Up Periods
Time 1 (4 Weeks)
White
Non-White
Number of patients

1

p

Time 2 (3 Months)
White
Non-White

Time 3 (6 Months)
White
Non-White

1

p

1

p

296

192

--

279

181

--

270

164

--

------

------

------

------

------

------

3.78 ± 0.38
1.02 ± 0.19
2.98 ± 0.38
0.47 ± 0.08
0.61 ± 0.12

4.99 ± 0.62
1.35 ± 0.30
3.61 ± 0.59
0.58 ± 0.10
0.64 ± 0.13

0.08
0.34
0.35
0.41
0.85

29.4
33.1
32.1

32.3
30.2
33.9

0.50
0.50
0.69

28.0
33.0
31.5

29.3
30.9
33.2

0.76
0.65
0.72

17.0
20.0
20.4

21.3
20.1
25.0

0.26
0.98
0.26

0.75 ± 0.15

0.75 ± 0.17

0.90

0.78 ± 0.16

0.76 ± 0.18

0.38

0.80 ± 0.15

0.79 ± 0.17

0.73

Pre-BD FEV 1 , % predicted*

80.6 ± 15.5

77.9 ± 18.4

0.11

80.4 ± 15.9

76.8 ± 17.9

0.03

c

81.1 ± 16.6

76.8 ± 18.3

0.02

Pre-BD FVC, % predicted*

88.4 ± 14.9

88.4 ± 17.5

0.98

88.2 ± 14.1

87.5 ± 18.2

0.66

88.6 ± 15.5

89.3 ± 19.7

0.72

Post-BD FEV 1 , % predicted*
Post-BD FVC, % predicted*
Peak Flow, % predicted*

86.1 ± 15.0
91.3 ± 13.5
85.0 ± 17.3

84.0 ± 17.8
93.8 ± 20.8
82.9 ± 20.5

0.19
0.15
0.25

85.9 ± 15.2
91.1 ± 13.8
84.5 ± 17.5

83.0 ± 17.9
91.8 ± 18.9
82.0 ± 21.6

0.08
0.67
0.21

86.1 ± 15.1
91.1 ± 14.3
85.8 ± 18.0

82.9 ± 17.8
92.3 ± 18.3
82.6 ± 19.0

0.07
0.48
0.09

FEV 1 Bronchodilator % change
FVC Bronchodilator % change

7.8 ± 10.6
3.9 ± 8.4

9.15 ± 11.9
6.5 ± 12.3

0.19
a
0.01

7.9 ± 10.2
3.8 ± 9.3

9.2 ± 12.6
5.5 ± 9.9

0.25
0.08

7.1 ± 9.3
3.4 ± 7.3

9.4 ± 13.8
4.4 ± 10.8

0.06
0.30

Using asthma medication daily

89.9

86.5

0.25

89.3

87.3

0.52

86.7

87.2

0.87

Inhaled anticholinergic
Inhaled long-acting b-agonist
Inhaled short-acting b-agonist
Combination drugs
Inhaled Corticosteroids

3.0
17.9
49.7
37.8
35.1

4.7
17.2
50.0
37.0
31.3

0.35
0.84
0.94
0.85
0.37

3.2
18.6
44.8
38.7
35.5

2.2
17.1
47.0
38.1
32.0

0.52
0.68
0.65
0.90
0.45

3.0
17.8
39.3
40.7
33.7

2.4
18.3
45.7
39.6
29.3

0.75
0.89
0.18
0.82
0.34

Nausea

8.8

10.4

0.55

6.1

3.3

0.18

4.1

3.7

0.83

Vomiting
Poor Appetite
Heartburn
Headache
Insomnia
Anxiety

3.4
3.0
11.8
19.9
18.9
8.8

2.1
4.2
4.7
24.0
18.2
10.4

0.40
0.51
b
0.01
0.29
0.85
0.55

3.2
3.9
7.2
17.6
16.1
8.2

0.6
2.8
6.6
18.8
13.8
6.6

0.05
0.50
0.82
0.74
0.50
0.52

1.5
4.1
11.9
18.5
17.0
9.6

0.6
5.5
8.0
20.7
20.7
12.8

0.41
0.50
0.19
0.57
0.34
0.30

Tremor
Heart Palpitations

1.4
3.0

3.1
2.1

0.18
0.52

1.8
2.5

2.2
4.4

0.75
0.26

1.5
2.6

5.5
6.1

0.02
0.07

Skin Rash

3.4

2.1

0.40

3.9

2.8

0.50

5.2

4.9

0.89

Outcomes, mean ± SD
Any EPAC
Peak flow, 30% drop
Increased medication use
New use of oral corticosteroids
Unscheduled health care
On Treatment, %
Theophylline
Montelukast
Placebo
Asthma Symptoms, mean ± SD
ASUI Average Score
Pulmonary Function, mean ± SD

c

Daily Asthma Treatments, %

Adverse Effects %
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Table 3.2. Time-Varying Characteristics of LODO Participants by Race over LODO Follow Up Periods
Time 1 (4 Weeks)
White
Non-White
Use of Healthcare Services, %
Hospitalization
Doctor Visits

0.68
13.9

1.6
15.1

1

p

0.34
0.70

Time 2 (3 Months)
White
Non-White

2.9
19.4

3.3
22.1

1

p

0.78
0.48

Time 3 (6 Months)
White
Non-White

2.6
23.7

3.7
28.1

*Predicted values of Hankinson and colleagues.
1 P values for categorical variables from Pearson Chi-Square test compared to t-tests for continuous variables. As Pearson Chi-Square tests
only for interactions among groups, any significance level less than 0.15 was then reanalyzed in binary groups - Theophylline vs. Montelukast,
Montelukast vs. Placebo and Theophylline vs. Placebo - to determine significant differences between groups.
a) Non-white patients have significantly higher FVC Bronchodilator reversibility than white patients at time 1.
b) Non-white patients are significantly less likely to report heartburn at time 1 than white patients.
c) Non-white patients have significantly lower pre-bronchodilator FEV1 than whites at times 2 and 3.
d) Non-whites are significantly more likely to report tremors at time 3 than white patients.
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1

p

0.53
0.31

Table 3.3. Number and rate of Episodes of Poor Asthma Control (EPACs), by Treatment Group and Race, 2002-20031

Theophylline
NonWhite
White

Treatment Groups
Montelukast
NonWhite
White

Placebo
NonWhite
White

Asthma EPACs
Events, n
Rate, events/person-year
95% CI
p-value

163
106
4.35
4.91
3.05-6.20 3.08-7.82
0.6852

106
130
2.66
5.75
1.86-3.81 3.97-8.32
0.0034*

183
110
4.59
4.50
3.39-6.21 2.95-6.85
0.9385

Episode Components
Peak flow, 30% drop
Events, n
Rate, events/person-year
95% CI
p-value

53
22
1.42
1.03
0.74-2.76 0.54-1.97
0.4946

25
18
0.63
0.80
0.37-1.07 0.41-1.58
0.5865

46
54
1.17
2.23
0.69-1.97 1.15-4.31
0.1312

Increased medication use
Events, n
Rate, events/person-year
95% CI
p-value

118
80
3.27
3.88
2.07-5.17 2.12-7.10
0.6569

83
96
2.15
4.60
1.37-3.36 2.88-7.34
0.0212*

140
60
3.69
2.59
2.53-5.37 1.44-4.67
0.3214

New use of oral
corticosteroids
Events, n
Rate, events/person-year
95% CI
p-value

16
14
0.43
0.65
0.26-0.71 0.39-1.07
0.2475

17
15
0.43
0.66
0.24-0.77 0.34-1.29
0.3313

23
11
0.58
0.45
0.31-1.06 0.24-0.86
0.5844

Unscheduled health care
Events, n
27
14
13
21
Rate, events/person-year
0.72
0.65
0.33
0.93
95% CI
0.44-1.18 0.36-1.17 0.20-0.54 0.52-1.65
p-value
0.7899
0.007*
CI= confidence interval
1 P values were obtained from Poisson regression with robust variance.
* Significant at the 0.05 level

32
9
0.8
0.37
0.40-1.61 0.15-0.93
0.1861
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Figure 3.2. Distribution Overlap of the Full Cohort Stabilized Inverse Probability Treatment Weights
(SWT) for all Treatments by Time Period and Race

-Stabilized Inverse Probability Weights (SWT) in each time period showed a mean (O) and median (─)
close to 1 indicating that the model was correctly specified.
-Overall, the mean and median of the SW was 0.98 and 0.99, respectively, and ranged from 0.9-10.4.
-Time Period 0: Baseline with 324 participants; Time Period 1: 1 month with 266 participants; Time
Period 2: 3 months with 265 participants; Time Period 3: 6 months with 249 participants
Figure 3.3a. Distribution of Stabilized Inverse Probability Weights in the Treated (Theophylline) and
Untreated (Montelukast) Groups

-Stabilized Inverse Probability Weights (SW) in the theophylline and montelukast groups followed a
similar distribution indicating balance between both groups.
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Figure 3.3b. Distribution of Stabilized Inverse Probability Weights in the Treated (Theophylline) and
Untreated (Placebo) Groups

-Stabilized Inverse Probability Weights (SW) in the theophylline and placebo groups followed a similar
distribution indicating balance between both groups.
Figure 3.3c. Distribution of Stabilized Inverse Probability Weights in the Treated (Montelukast) and
Untreated (Placebo) Groups

-Stabilized Inverse Probability Weights (SW) in the montelukast and placebo groups followed a similar
distribution indicating balance between both groups.
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Table 3.4. Effects of Treatment and Treatment Effect Modification by Race (white vs. non-white) on
Episodes of Poor Asthma Control(EPACS), Full Cohort MSM, 2002-20031

RR

T vs. M
95% CI

RR

T vs. P
95% CI

P

Asthma EPACs
Treatment
Treatment*Race

1.20
0.54

0.81-1.77
0.25-1.17

Episode Components
Peak flow, 30% drop
Treatment
Treatment*Race

1.77
0.63

Increased medication use
Treatment
Treatment*Race
New use of oral
corticosteroids
Treatment
Treatment*Race

RR

M v. P
95% CI

P

P

0.36
0.12

1.01
1.14

0.69-1.49
0.53-2.47

0.96
0.73

0.84
2.13

0.58-1.22
1.08-4.46

0.36
0.04*

0.95-3.28
0.18-2.19

0.07
0.47

0.70
0.41

0.38-1.30
0.12-1.40

0.26
0.15

0.40
0.64

0.22-0.72
0.20-2.12

0.00*
0.47

1.14
0.56

0.70-1.88
0.21-1.52

0.60
0.26

1.19
1.61

0.72-1.97
0.59-4.41

0.50
0.36

1.04
2.86

0.65-1.68
1.10-7.42

0.87
0.03*

1.01
1.04

0.58-1.76
0.34-3.20

0.98
0.94

1.16
1.88

0.67-2.01
0.63-5.64

0.59
0.26

1.16
1.80

0.64-2.10
0.544-5.95

0.63
0.34

Unscheduled health care
Treatment
1.23 0.71-2.12 0.46
1.47
0.75-2.86 0.26 1.19
0.62-2.31
0.60
Treatment*Race
0.34 0.11-1.01 0.05* 1.72
0.45-6.54 0.42 5.01 1.36-18.97 0.02*
1. p values for treatment effects on rates of episodes of poor asthma control are based on Poisson regression with
robust variance
T=Theophylline; M=Montelukast; P=Placebo; RR=Relative Risk Ratio
* Significant at the 0.05 level

97

Table 3.5. Effects of Treatment by Stratum for Those Outcomes in Which Effect Modification by Race
Was Found in the Full Cohort MSM1
T vs. M
M vs. P
Rate
95% CI
P
Rate
95% CI
P
Asthma EPACs
White
Non-White
Episode Components
Increased medication use
White
Non-White
Unscheduled health care
White
Non-White

1.64
0.88

0.97-2.75
0.49-1.58

0.06
0.67

0.58
1.23

0.36-0.92
0.70-2.17

0.02
0.48

0.62
1.76

0.34-1.11
0.83-3.73

0.11
0.14

0.53
2.69

0.26-1.09
0.89-8.11

0.09
0.08
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Chapter 4: Comparing Two Adherence Metrics Using Marginal Structural
Models to Determine Treatment Effectiveness on Asthma Control

Background: Poor adherence to treatment assignments will almost always lead to biased effect
measures. Adherence can be considered a time-dependent confounder as it is associated with the
outcome and is also influenced by past and current treatment. Marginal Structural Models (MSMs) have
been used to estimate causal effects of time-varying treatment selection in the presence of timedependent confounding and censoring in longitudinal studies. However, there is no gold standard for
measuring adherence and it is not clear as to what constitutes an unacceptable level of adherence. The
purpose of this paper is to demonstrate whether the use of different adherence metrics has any effect
on the direction and magnitude of the causal effect of asthma treatments on the rate of episodes of
poor asthma control (EPACs) in a 6 month randomized controlled trial (RCT) that experienced nonadherence and loss to follow up.

Methods: MSMs with inverse probability weighting were implemented. Pooled logistic regression
models were fitted to compare the probability of staying on assigned treatment (adherence) and of
remaining uncensored for subjects at each visit for two treatment arms (theophylline and montelukast)
using self-reported and blood assay adherence metrics. Final pooled logistic regression models were
fitted for the annual rate of acute asthma exacerbations comparing treatment arms and the weighted
sample using a Poisson generalized estimating equation (GEE) with an independent correlation matrix.

Results: There were significant differences in the proportion of patients that were non-adherent
between the self-report and blood assay adherence metrics. These differences were similar for the two
treatments. Still, the adjusted rate ratio, and corresponding 95% confidence intervals, comparing the
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two treatments for specific outcomes using both MSMs were nearly identical, indicating that adherence
and censoring was not a significant problem in these data and that exchangeability held throughout the
trial.

Conclusions: In theory MSMs hold much potential for further analyses of randomized clinical trials as it
allows adjustment for time-varying confounding and selection bias, issues more traditional regression
based methods cannot account for. However, it remains unclear as to what constitutes a substantial
level of non-adherence or censorship for MSMs to show differing results from the traditional Intent to
Treat (ITT) approach. At the very least, MSMs should be conducted as a sensitivity analysis to the ITT
approach in RCTs where there is preliminary evidence suggesting the presence of time-varying
confounders or selection bias.

Keywords: clinical trials, adherence, marginal structure models, inverse probability weighting, causal
inference, asthma control
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Introduction
Marginal structural models (MSM) have been theorized to be less biased than Intention to Treat
methods (ITT) in the estimation of causal effects of time-varying treatments in clinical trials that
experience non-adherence and attrition.1–6 This is due to the fact that unlike ITT, MSM measure all post
randomization prognostic factors (confounders and/or mediators) that may affect either treatment
selection or loss to follow up in an attempt to eliminate all back door pathways that may bias the
association between the treatment and the outcome, making the baseline randomization in the clinical
trials once again valid.

Parameters of a MSM are estimated using inverse probability weighting (IPW) which calculates weights
based on the inverse of the predicted joint probabilities (i.e. propensity score values) of an individual’s
treatment and censoring history conditional on their observed set of covariates. This ensures that the
reweighted data are balanced on the covariates at each point in time during the follow-up, making
baseline randomization once again valid. A final weighted model is then fitted using these weights with
only a function of exposure history predicting the outcome of interest, together with a robust ‘sandwich’
variance estimator.

As the direction and magnitude of the effect of “assigned” treatment depends on the adherence
pattern, accurate measurement of patient adherence is fundamental in estimating the casual effect of a
treatment on a disease using MSM. However, there are many problems with this assumption. First,
there is not a standard definition of what constitutes adherence.7–11 Adherence can be thought of as an
all or nothing response – always vs. never taking the assigned therapy – or as a continuum in which
patients can be adherent or non-adherent only part of the time, i.e. discontinuing therapy prematurely,
deviating from instructions but still taking the medication etc. Second, there is no standard method of
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assessing adherence in clinical trials. Despite a wide range of options, each method has advantages and
disadvantages and no single adherence intervention has been determined to be useful in all
situations.7,8,11–13

In this paper, I will assess whether the use of different adherence metrics (self-report vs. blood assay) in
a MSM changes the direction and magnitude of the causal effect of asthma treatments on the rate of
episodes of poor asthma control in a 6 month RCT that experienced non-adherence and loss to follow
up. This is a secondary data analysis of the American Lung Association Asthma Clinical Research Centers
(ACRC) Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial conducted in
2002-2003.14 The original ITT analysis published by the ACRC found no difference between treatment
groups when assessing EPACs, despite initial assumptions and/or previous research studies indicating
otherwise, possibly suggesting that results under the ITT approach may have been biased towards the
null. While the ACRC is known for having better average compliance than other clinical trial networks15,
average adherence rates in LODO trial was 85% for self-reported diary cards versus 60% for plasma drug
concentrations.

Marginal Structural Models
Marginal structural models (MSM) have been theorized to be less biased than Intention to Treat
methods (ITT) in the estimation of causal effects of time-varying treatments in clinical trials that
experience non-adherence and attrition.1–6 A concern with estimating treatment effects that span
more than one time point is that a subjects’ behavior and subsequently the distribution of risk factors
will assumedly change with time. For example, if participants who do not comply with treatment or
who are censored differ from those who comply or are still being followed, then imbalances with
respect to the risk factors by treatment group (confounding) can occur and this imbalance can fluctuate
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over time. Furthermore, in the presence of time-dependent confounding, a confounder may
simultaneously be a mediator between the current exposure and outcome. If reasons for nonadherence
or censorship are due to covariates that have been affected by prior treatment, selection bias will occur
and estimates from traditional regression models will be biased as they cannot adjust for intermediate
variables. Unlike conditional regression approaches used in ITTs, MSMs account for both the joint
effects of baseline and subsequent treatments and for the presence of time-dependent confounding
influenced by prior treatment, by modeling exposures at each follow up and the final outcome.1,3,5,6

Formally, MSM is a regression model for longitudinal data that relates any possible exposure and
censoring history, up to time t, to the corresponding counterfactual outcome at time t.2,16–19 In other
words, these models allow for the estimation of all potential outcome-treatment combinations for each
study visit, despite the fact that only one response for a given treatment level per visit will be observed
in the data, with the rest “counter to the facts”. This is possible because it is assumed that the average
causal effect of treatment is dependent on whether the choice of a treatment option at a particular time
point is affected by the presence of time-dependent confounding. If all time-dependent confounders
are eliminated then it can be assumed that all subjects had adhered to their assigned treatment and
therefore, the exposure is said to have a causal effect on the outcome, i.e. there is a difference in the
counterfactual outcomes under two or more treatment regimes.1,6,19,20 As MSMs describes the marginal
causal expectation of a potential outcome as a function of a specified treatment regimen, the
observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) will once again equal the unknown counterfactual
risk ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).

MSM parameters are estimated using inverse probability weighting (IPW). IPW adjusts for postrandomization confounding and selection bias due to 1) non-adherence, 2) mediators and 3) loss to
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follow up by creating a pseudo-population where the time-varying treatment is independent of stable
and time-varying covariates that preceded it, at every time point allowing for causal treatment
comparisons using standard repeated measure models.1,2,4–6,18,21–23 Instead of modeling the relationship
between a covariate and the outcome as is done in traditional regression, IPW models the relationship
between covariates and missingness with that of the putative cause.

Conducting an MSM-IPW analysis is a two-step process. The first step is to estimate each subject’s
probability of 1) having their own treatment history and 2) having their own censoring history at each
time-point and then use these to derive Inverse Probability Treatment (IPT-) and Inverse Probability
Censoring (IPC-) weights. The second step is to estimate the treatment-outcome association in
a conventional regression model for repeated measures that is weighted by the product of IPT- and IPCweights.

Weights can be either non-stabilized or stabilized. The former is estimated by taking the reciprocal of
the probabilities of receiving treatment given the covariates (1/p for those treated and 1-1/p for those
untreated), while the latter adds a numerator representing the overall probability of being treated for
those who were treated and of not being treated for those who were not treated using baseline
covariates only. As the numerator and denominator in stabilized weighting will share common factors,
the weights will be less variable, the sample size will be close to that of the original population and there
will be less chance of Type 1 errors.1,22,23 Therefore, stabilized weights increase statistical efficiency
attains better coverage of confidence intervals and is recommended when using IPW to fit a marginal
structural model. For the purposes of the following analysis, I will be referring to stabilized inverse
probability weights.
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Treatment Weights
Confounding due to non-adherence in RCTs is eliminated through the application of an inverseprobability-of-treatment weighting (IPTW).17,24,25 IPTWs adjust for imbalances in the characteristics of
the treated and untreated participants. It is fit by building a predictive model for receiving the
treatment of interest given past treatment and prognostic factor history at each time point and then
obtaining a single weight per subject by multiplying the current treatment weight with that of the
treatment weights from the previous time points. Most researchers do this in one step by fitting pooled
logistic regression treatment models with time as a class variable to allow a separate intercept for each
time. The resulting predicted probabilities (i.e. propensity scores) are used to construct the stabilized
weights for each subject at each time point during follow-up. The treatment weights are defined as:

𝑆𝑆𝑆𝑆(𝑡𝑡) = ∏𝑡𝑡𝑘𝑘=0

𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝑉𝑉]
𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝐿𝐿(𝑘𝑘),𝑉𝑉]

Equation 1

The denominator of the model represents the probability that the subject received their own treatment
history (ƒA k ), given all prior treatments (A k-1 ) and covariate histories (L) until the last visit (k) for all
possible treatments (R). The numerator acts as a stabilizing factor to reduce the variance of the
estimates and represents the overall probability of being treated for those who were treated and of not
being treated for those who were not treated. When analyzing RCTs with baseline randomization, the
value of A at time 0 will be each participant’s assigned treatment and since there is no confounding the
stabilized weight will be 1.6,16,18

Censoring Weights
To account for attrition bias due to loss to follow up, one may also calculate inverse-probability-ofcensoring weights (IPCW) following the same steps above.17,26 The only difference is that each study
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subject is assigned a weight that is the inverse probability of remaining in the trial for the entire duration
i.e. uncensored. The censoring weights are defined as:

𝑆𝑆𝑊𝑊(𝑐𝑐) = ∏𝑡𝑡𝑘𝑘=0

𝑓𝑓[𝐶𝐶(𝑘𝑘+1)=0|𝐶𝐶(𝑘𝑘)=0,𝐴𝐴(𝑘𝑘) ]
𝑓𝑓[𝐶𝐶(𝑘𝑘+1)=0|𝐶𝐶(𝑘𝑘)=0,𝐴𝐴(𝑘𝑘),𝐿𝐿(𝑘𝑘)]

Equation 2

where the denominator depicts the probability that the subject remained in the trial given their
treatment (A k ) and covariate histories (L) until the last visit (k) in each treatment group (R) and the
numerator, the overall probablity of remaining uncensored per treatment. The stabilized weights do
not eliminate censoring in the pseudo-population, they make censoring occur at random with respect to
the measured covariates. Complete cases with similar characteristics to those of censored cases are
weighted to represent those who were lost. Just as with treatment, when analyzing RCTs with baseline
randomization, the value of C at time 0 will be 0 as there is no loss to follow up.6,16,18

Treatment-Outcome Model
When both non-adherence and loss to follow-up are present, the weights from both models (treatment
and censoring) are multiplied together to form one stabilized weight per participant. The simulated
pseudo-population now represents a sample from the actual randomized study population in which
each participant completed follow up, all measured covariates are balanced across exposure groups, and
all mediators are removed from the causal pathway. It is the balance across exposure groups, i.e.
exchangeability, which allows for unbiased estimates of treatment effects in RCTs without
nonadherence and censoring. Once balance is established, the average causal effect of treatment on
the outcome can be unbiasedly estimated in a conventional regression model that does not include the
measured confounders as covariates.
Assumptions
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There are several assumptions that must be met when fitting a MSM. First is the assumption of no
unmeasured confounders, i.e. conditional exchangeability or sequential randomization. This assumption
requires that all covariates which are associated with treatment assignment, outcomes or censorship
are adjusted for at each visit, enabling treatment selection to once again be random as it was at
baseline.6,20,23 If unobserved confounders are present, then treatment groups will no longer be
exchangeable and residual bias in the treatment-outcome association can remain. Therefore, it is
important, although not empirically verifiable, to ensure that all possible confounders which affect
treatment selection and outcome are added to the models.

The second assumption of positivity assumes that the conditional probability of receiving either
treatment and of remaining under complete follow-up will be greater than zero. Positivity is guaranteed
in randomized control trials because, by design, there will be individuals assigned to each level of the
studied treatment and therefore, there is no possibility of a structural violation of positivity.17,20,23
However, depending on the sample size and the number of confounders, there can be instances where,
at one or more levels of the confounders, no one happens to be observed at one or more levels of the
exposure (zero cells). These random violations of probability occur by chance and can be corrected by
using parametric models or combining adjacent subgroups with cells greater than zero.17,23

The third is the unverifiable assumption that one is using the correct weighting and analysis models.
Any parametric model may be mis-specified by the omission of unmeasured confounders, non-linear
terms or interactive relationships. If misspecification occurs, residual bias in the treatment-outcome
association can remain or, in some cases, even increase.20,21 Sensitivity analyses to test the listed
structural model specifications above must be done to determine whether the stabilized weights have a
mean of 1.0 and a minimum and maximum that is not very extreme.
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Lastly, it is assumed that all missing data will be missing at random (MAR). The MAR assumption states
that conditional on some set of variables that are fully observed, the probability of missing outcome or
exposure is independent of all variables in the model.4,18,27

Measuring Adherence
Adherence has been defined by the World Health Organization as “the extent to which the person’s
behavior corresponds with agreed recommendations from a healthcare provider”.28 In most clinical
trials, this refers to the patient taking medications as prescribed by study personnel for the entire
duration of the trial. Unfortunately, it has been well documented that most clinical trials suffer from
some level of non-adherence, with adherence rates ranging from 50% to 80%.7,11,28,29

Poor adherence to treatment assignments will almost always lead to biased effect measures. First,
adherence to therapy is always a correlate of clinical outcomes; plenty of studies have shown that trial
participants who do not follow prescribed regimens have a poorer prognosis than subjects in the
respective groups who do.7,11–13,25 Furthermore, in longitudinal studies with time-varying treatments,
selection bias may occur if adherence is predicted by past treatment history.18,22,24,30,31 As such, the true
benefit of many effective medications, including optimal dosage, may be under- or overestimated in
studies with non-adherence.

Measuring adherence in clinical trials is, therefore, important as results cannot be realistically
interpreted without such information. Numerous methods are available for measuring patient
adherence to medication regimens and all are generally categorized as being subjective vs. objective or
direct vs. indirect.7,11,12,28 All direct metrics are considered objective as they not only provide proof that
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the drug was taken by the patient but are measured the same way regardless of situation. Direct
metrics include the detection of the drug or a metabolite in a biologic fluid; the detection of a biologic
marker that is given with the drug; or with direct observation of the patient receiving the medication.
Tests to detect the presence of the drug or drug marker can be conducted at specified intervals or
randomly, when feasible.

The majority of tools used to measure adherence in clinical trials are of the indirect type and can be
categorized as either subjective or objective, based on whether the assessment of medication-taking
behavior comes directly from the provider/patient or not. These include self-reporting by the patient;
medication measurement; use of prescription or electronic medical record review; and/or the use of
electronic monitoring devices.

Unfortunately, no one single metric has been considered the standard for measuring adherence in
clinical trials as all have their own advantages and disadvantages. 7,11,12,32,33 The strength of all the direct
metrics is that they provide a qualitative confirmation that the patient received a dose of medication at
some point. However, these metrics do not reveal patterns of adherence and are further susceptible to
differences in patient-specific metabolic variations. In addition, these metrics are expensive, difficult to
perform, may be invasive for patients, and can be impractical for routine use.

Of the indirect metrics, self-report methods (e.g. diaries, questionnaires, interviews) are by far the most
widely used adherence metric in clinical trials due to its generally low cost and simplicity of
administration. Self-reporting tools are useful for identifying patients who are candid non-adherers, as
well as, assessing the patient’s beliefs, attitudes and barriers to adherence. However, due to its
subjective nature, these metrics are susceptible to a number of reporting biases and have been deemed
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to be unreliable for assessing adherence patterns. For example, studies have shown that the majority of
information collected from diaries is either completed retrospectively, which increases the risk of
patient recall bias, or are fabricated as patients tend to over-report and/or exaggerate medication
adherence especially in the weeks before and after a clinical visit.31,34

Medical measurement, including dose counting, pill counting and canister weighing, is another common
indirect adherence metric used in clinical trials. These metrics are also relatively simple and low cost to
implement but provides a more objective and valid measure of adherence than self-report.7,12 However,
these metrics are not without their issues as patients can deliberately switch medications between
bottles, discard pills/medicines before visits, and/or “forget” to return medications at study visits to hide
true adherence. One study found that up to 20% of participants in a clinical trial were guilty of
medication dumping.31 Furthermore, medical measurement does not provide information on
medication-taking patterns or the reasons for the non-adherence as self-reported measurement does.

Pharmacy databases have been used to provide objective information on the rates of refilling
prescriptions during the trial. This indirect metric can be used to assess adherence patterns including
premature discontinuation of therapy. Pharmacy databases can also substantiate patient responses to
self-report measures or drug levels in the body through direct metrics. However for this metric to be
valid, the entire prescription refill history for a patient must be housed in a centralized pharmacy
system. Unfortunately, issues with insurance refill limits or formularies may cause patients to seek
study medications from more than one pharmacy.7 Another problem with using pharmacy databases is
the unverifiable assumption that prescription refill patterns correlate to patient-medication-taking
behavior.
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Lastly, electronic monitoring devices provide an objective measure of adherence by recording the times
and dates when a bottle is opened, drops are dispensed and canisters are activated.
Electronic monitoring has significant advantages over most of the other adherence metrics. First, it
provides continuous, reliable and precise measure of a patient’s adherence to the prescribed regimen
unlike that of direct, self-reporting or pharmacy refill measures. An electronic monitor can detect an
abnormal medication taking pattern and can verify the number of daily doses missed in partial
adherence situations. Furthermore, electronic monitors require that patients open containers, dispense
drops or activate canisters at the same time each day to guarantee same patterns of adherence, and
therefore, discarding medication is not as simple as it is with medical measurements. As a result,
electronic monitors are commonly used as a reference standard for validating other adherence
metrics.7,12 However, as with all indirect metrics, electronic monitors cannot prove that the patient
actually took their assigned treatment or its correct dose. Patients may falsify adherence measurement
by purposely activating the monitor but not taking the medication or invalidating the data by placing the
medication into another container. Furthermore, studies have shown that using an electronic monitor
to assess medication adherence is stressful to some patients who do not like the thought of being under
constant surveillance. Lastly, electronic monitors are costly; they are not typically covered by insurance
and require additional training of study staff and patients to appropriately use and care for the machine.
Thus, these devices are not in routine use.

Even with all the options available, measuring adherence remains no easy task. There is no one metric
that has been determined to be the gold standard for all settings. Selection of an adherence metric
should therefore be based on the goals of, and the resources available for, the study.

111

The Case for Precise Measurement of Adherence Data In the LODO trial
This is a secondary data analysis of the American Lung Association Asthma Clinical Research Centers
(ACRC) Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial.14 The LODO
trial aimed to evaluate the effectiveness of low dose theophylline, a drug known for its narrow
therapeutic window and severe interactions with various drugs, in maintaining asthma control in mild to
moderately severe asthmatics compared to the widely used anti-leukotriene antagonist montelukast
(Singulair) and placebo, respectively.

Due to the scientific evidence on theophylline’s significant anti-inflammatory properties at the time
LODO was being proposed (circa 2000), it was hypothesized by ACRC investigators that adding low dose
theophylline to the treatment of persistently symptomatic participants would decrease the rate of
asthma exacerbations when compared with placebo and would be equally effective as the more popular
and expensive drug, montelukast. However, results of the ITT approach found no difference in asthma
control between theophylline and montelukast (1.22; 95% CI=0.82-1.86; p=.35) as well as theophylline
and placebo (0.99; 95% CI=0.67-1.50); p=1.00) using an ITT approach.14

Like with most chronic diseases, non-adherence to asthma medications is extremely common in clinical
trials. One study found that patients tried to deceive investigators regarding their adherence to asthma
study drugs by continuously activating inhalers.29 Other studies, found that almost all diary information
was completed mostly retrospectively, increasing the risk of patient recall bias and/or fabricated
treatment adherence.31,35
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Suboptimal adherence has been found to not only have a direct influence on asthma outcomes but has
been proven to be a fundamental mediator in the association between treatment and outcomes.13,31,34,36
For example, non-adherence with study treatments cause an increase in the severity of asthma
symptoms, increased asthma attacks, reduced quality of life and the likelihood of both hospitalizations
and respiratory failure.31,35,36 These negative outcomes have also been shown to affect whether a
participant stays on their assigned treatment.37 In addition, since clinical trials are longitudinal studies,
current adherence metrics are in part a result of previous treatment, mediating the association between
treatment and asthma control.

Therefore, it is of upmost importance to distinguish poor asthma control related to nonadherence from
that of treatment-resistant asthma when interpreting the results of a clinical trial measuring the effects
of various asthma treatments.31,36 Unfortunately, the ITT analysis effectively ignores these factors,
attenuating treatment effect towards the null causing a Type II error in which investigators will claim no
difference in treatment when there might actually be an important difference.1,25,38 As the decision to
terminate, switch or augment treatments or drop out of the study is a nonrandomized event, influenced
by both subject attributes and previous treatment, it was assumed that time dependent confounding
may have existed in the LODO trial and as such, it would be of benefit to reanalyze the data using a
marginal structural model to allow for a participant’s propensity to adhere to change as circumstances
are perceived over the course of the study.

Unfortunately, there is no gold standard for adherence metrics and the use of multiple metrics in the
same study may indicate different levels of non-adherence. In the LODO trial, self-report adherence by
patient diaries found adherence rates to be between 85%-90% while blood assay adherence rates were
in the low to mid 60%. Due to the significant differences in the proportion of adherence between these
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two metrics, it was assumed that the causal effect of theophylline and montelukast on the annual rate
of asthma exacerbations may differ depending on the adherence measurement used.

As such, this paper assesses whether the use of different adherence metrics (self-report vs. blood assay)
in a MSM changes the direction and magnitude of the causal effect of asthma treatments on the rate of
episodes of poor asthma control in a 6 month RCT that experienced non-adherence and loss to follow
up. Figure 4.1 shows a possible directed acyclic graph39 that represents the relationships between the
time-varying treatments (generally a time-varying variable as each day you may take it or not take it)
and the above covariates with the outcome, assuming no unmeasured confounding. L(0) denotes
baseline demographic characteristics along with baseline FEV 1 . It was assumed that there was no effect
of L(0) on A(0), because of randomization and full initial compliance. Therefore, confounding is assumed
to occur only after A(0) (baseline). A(1), A(2) and A(3) represents treatments actually received,
irrespective of randomization, at follow up times 1, 2, and 3. L(1), L(2) and L(3) denotes the current
levels of the time varying covariates – adherence, pulmonary function measures, asthma symptoms,
medications and adverse effects at follow-up visits 1, 2, and 3. C(1), C(2), and C(3) accounts for lost to
follow-up which occurred due to past treatment history and confounder levels. Lastly, Y denotes the
annual rate of asthma exacerbations indicating poor asthma control.

Overall, there are 10 possible outcomes (arrows into Y) for each subject, representing all possible
combinations of treatments for the four time periods, of which only one is observed. However, once all
confounding paths are blocked, only the causal paths (green arrows into Y) remain.
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Methods
Study population
The American Lung Association Airway Clinical Research Centers (ACRC) is a network of clinical centers
throughout the country dedicated to improving asthma outcomes in diverse populations. Between 1999
and 2015, the network completed over ten trials that had a direct impact on the lives of asthma
participants and the cost of their care.15 As a multicenter network, the ACRC is well poised to conduct
comparative effectiveness research due to its ability to enroll large numbers of participants from diverse
populations from different regions of the USA to ensure that the research findings has external
generalizability and are relevant to large groups of participants.15 All data collected from the clinical
sites is managed and analyzed by a Data Coordinating Center at Johns Hopkins University. An overview
of ACRC studies is reported elsewhere.40 Since 2015, the ACRC was renamed as the Airways Clinical
Research Centers and its mission was expanded to include other obstructive lung disease such as COPD.
This change in focus is not relevant to this paper and when discussing the ACRC, it will refer to the
network as it was between 1999 and 2015.

Study Design
The Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial was the ACRCs
second trial that began in 2002 and ran throughout 2003. It was a multicenter, randomized, doubleblind, parallel design, placebo-controlled trial evaluating whether low-dose theophylline was as effective
as an add-on therapy in treating asthmatics compared to 1) montelukast and 2) placebo in 488
participants with poor asthma control.

To be eligible for the study, participants had to be over the age of 15 years, have physician-diagnosed
asthma, been prescribed daily asthma medication for at least a year, had an FEV 1 of 50% or more of
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predicted values and had a score of 1.5 or greater on the Asthma Control Questionnaire. Potential
participants who smoked or used oral corticosteroids, leukotriene antagonists or theophylline with four
weeks preceding enrollment or had other significant illness were ineligible to participate.

After a one to two week run-in, eligible participants were randomized in a stratified permuted block
method in a 1:1:1 allocation ratio to 300mg/day theophylline (n=160) or 10mg/day montelukast (n=164)
or placebo (n=164) – in addition to their existing asthma therapy. Participants were followed for six
months (24 weeks), attended three follow-up visits (one, three and six months after randomization) and
were contacted by phone periodically in between visits to ensure the participant was not experiencing
any problems associated with study participation (figure 4.2).

For the purposes of this paper, analyses will be restrict to only the theophylline and montelukast groups
as the placebo group did not have plasma assays taken. This reduces the number of study participants
to 324.

Treatment Groups
Participants were randomized in equal allocation ratio to one of the following treatment groups:

•

Theophylline (Theo-Dur®) 300 mg/capsule (n=160)

•

Montelukast (Singulair®) 10 mg/capsule (n=164)

Subjects were instructed to ingest 1 capsule daily following their evening meal. All treatments were
masked by opaque capsules.
After randomization, the remainder of the study was observation in the sense that participants could
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discontinue study medication. As such, for the IPW analysis treatment groups consisted of all those who
were compliant with their respective assigned treatments at each visit compared to those who were not
compliant for each arm of the original randomization. This allowed for a participant’s propensity for
adherence to vary as circumstances changed over the course of the study.

Primary Outcome
The outcome of interest was the annual rate of acute asthma exacerbations (events/person/time)
defined as having at least one of the following episodes of poor asthma control (EPACs):

•

30% drop in peak flow for 2 consecutive days; or

•

Increase of 2 or more used of rescue medication (4 puffs MDI, 2 nebulizer uses); or

•

New course of oral steroids for asthma; or

•

Unscheduled health care for asthma symptoms

This composite outcome measure was used to reflect the several dimensions of good asthma control,
including physiology, symptoms and health care use. It should be noted that EPACs is not a standardized
composite measure of asthma control and this definition was created by the ACRC for this and other
trials. This measure has been used as an outcome for many of their trials in order to achieve its mission
to provided evidence to support optimal standards of care into clinical or public health practice for
persons with asthma.
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Adherence
ACRC investigators collected data on treatment adherence two different ways – direct measurement of
venous blood plasma at the 1 and 6 month clinical visit (i.e. blood assay group) and self-report through
patient diaries over the entire duration of the trial (i.e. self-report group).

Plasma concentrations for theophylline were collected by particle-enhanced turbidimetric inhibition
immunoassay while montelukast concentrations were collected through reversed-phase liquid
chromatography. The detection levels for theophylline and montelukast were 2mg/L and 5ng/ml,
respectively. Persons with plasma concentrations lower than these levels were considered to be nonadherent.

Self-reported adherence was calculated as the proportion of days an individual reported taking
medication over the total number of days that the medicine should have been taken, within the
respective time period. A person was considered to be adherent to assigned treatment in a time period,
if they were at least 80% adherent to study medication. All other cases were considered to be nonadherent.

Potential Time-Dependent Confounders
A number of covariates were considered as potential time-dependent confounders. It was assumed that
these variables were measured prior to deciding whether or not to continue with their assigned
treatment or the study in general.

Variables that were collected only at baseline and remained static throughout the trial included age
(defined as a continuous variable), sex (male, female) and race (white, black or other).
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Covariates considered potential time-vary confounders included:

•

FEV 1 , FVC and PEF volumes - interpreted as percentages of predicted values based on Hankinson
et al. well-established reference equations for healthy subjects of similar demographic
characteristics (height, age, sex, race and weight). A detailed description on how percent
predicted values based on normal lung function are calculated has been previously
published.34,41

•

Average Asthma Symptom Utility Index (ASUI) was scored from 0 to 1, with 0 indicating severe
symptoms for at least one week to 1 signifying no symptoms in the two week period.42 The
items are then weighted according to participant preferences and scored based on a multiattribute utility function of ASUI= 1.200 x (S1 Cough * S2 Wheeze * S3 Shortness of Breath * S4
Awake At Night * S5 Medical Side Effects) - 0.200.

•

Medication use was defined as a binary measure. Participants were asked if they had used any
of the following medications since their last visit: inhaled corticosteroids, inhaled long-acting
beta-agonists, inhaled short-acting beta-agonists, inhaled anticholinergic, combination drugs
such as Advair.

•

Adverse effects were also defined as a binary measure. Participants were asked if they had any
of the following adverse effects since their last visit – nausea, vomiting, poor appetite,
heartburn, headache, insomnia, anxiety, tremor, heart palpitations and skin rash.
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•

Use of health care services was also defined since their last visit. Starting with the 1 month visit,
participants were asked if they visited with their doctor or were hospitalized since their last
study visit.

All potential time-varying confounders came from participant diary cards except for FEV 1 and FVC
measures which were collected through spirometry at each visit. It was assumed that these covariates
fully encompass the loosely associated four domains of asthma, as well as, both the clinician’s and
participant’s perspective and therefore, was considered good predictors of the outcome (asthma
exacerbation), treatment adherence and censorship.

Missing Data
Twenty visits in the plasma group (2.4% of 828 visits) and 28 visits in the self-report group (2.5% of 1,104
visits) had missing covariate estimates for one or more confounders despite attending visits and
providing exposure and outcome data. Missing covariate data were imputed using the mean value for
current treatment at each time point. These cases were retained for all analyses.

Data were censored at the time of the first missed visit (i.e. exposure), first missed blood draw (for the
blood assay group) or in cases where the outcome was missing. Research has indicated that censored at
first missed visit is generally the least biased across all missingness mechanisms.3,4,43 Censored data was
higher in the plasma concentration group with 91 participants missing data compared to 75 in the selfreport group.

Out of the 91 participants in the plasma group, 53 were lost to follow-up after the baseline visit – 26
from theophylline and 27 from montelukast – leaving 271 cases in the plasma group with complete data
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at the six week visit. Another 38 patients were lost to follow-up after the six-week visit – 18 from
theophylline and 20 from montelukast – leaving 233 cases in the plasma group with complete data at
the six month and final visit.

Out of the 75 participants in the self-report group, 58 cases were lost to follow-up after the baseline visit
– 33 from the theophylline group and 25 from montelukast - leaving 266 cases with complete data at
the six week visit. One case was lost to follow up between six weeks and three months and at the six
month visit, another 16 were censored – 9 from the theophylline and 7 from montelukast – leaving 249
cases with complete data at the six month and final visit.

Statistical Analysis
Inverse Probability Weighting Models
Pooled logistic regression models were fitted separately for the probability of staying on assigned
treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment
arm for both adherence metrics. The dataset for these models was discretized into one observation per
subject per visit so that 1) time could be fit as a class variable to allow a separate intercept for each time
and 2) lagged variables for previous treatment and confounder histories would be comparable between
subjects.

Stabilized treatment weights were created by dividing the baseline probability of selecting a treatment
(numerator in equation 1) by the probability of selecting treatment given prior treatment history and
potential confounders up to time t (denominator in equation 1). The calculation of censored
probabilities mimicked that of treatment adherence weights but was offset by one visit as censoring
looked forward i.e. ‘did the subject return for a following visit?’ compared to ‘what was the treatment at
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the previous visit?’ (equation 2). Each covariate was entered in the pooled logistic models as a main
effect only.

Resulting predicted probabilities were then used to construct the final stabilized treatment and
censoring weights for each subject at each visit. For the Inverse Probability Treatment Weights, the
pooled logistic regression models provided the estimated probability of remaining on assigned
treatment, so the next step was to subtract the propensity score by 1 to get the probability of not
staying on assigned treatment for those who were non-adherent. Once all subjects had a stabilized
weight for each visit, a final stabilized weight per participant was obtained by multiplying the estimated
probability of their observed treatment at each visit cumulatively over time, i.e. the first score was left
as is, and for all others, the scores at the current visit was multiplied by the score of the previous visit.
For the Inverse Probability Censoring Weights, the estimated probabilities of being uncensored for each
visit were multiplied cumulatively over time. The final Inverse Probability Weight for each subject was
the product of the treatment selection weights and the censoring weights.

To determine whether the final stabilized weights resulted in balanced data, distribution plots were
created to assess central tendency and skewness between the original and weighted data sets.

Outcome Models
Poisson regression models using PROC GENMOD were fitted for the annual rate of acute asthma
exacerbations (outcome) as a function of the assigned treatment (theophylline vs. montelukast) using
the weighted sample and a generalized estimating equation (GEE) with an independent correlation
matrix for both the blood assay and self-reported groups. GEE accounts for the correlation within-
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subjects typically seen when estimating regression parameters to make valid statistical inferences from
longitudinal data.44–46 Final models were fit to all uncensored cases with complete data.

All data management procedures were conducted with SAS 9.4 (SAS Institute, Cary, NC).47

Results
Participant Characteristics
Baseline characteristics of the 324 subjects randomized to the LODO study is shown in Table 4.1.
Assigned treatment groups were balanced with respect to demographics and baseline asthma
characteristics. Participants tended to be of middle-aged, predominantly female and white.

On average, participants pre-bronchodilator FEV 1 was slightly below that of a normal population
indicating mild asthma severity. Post-bronchodilator lung function continued to be mildly reduced on
average compared to a normal population. Around 9% of participants were prescribed daily asthma
medication, but did not use it. The majority of subjects either took short acting beta-agonists, inhaled
corticosteroids or a combination of medications.

Adherence over Time
Table 4.2 provides information on adherence rates over time for both study treatments and methods.
Adherence was significantly greater in the self-reported group compared with the blood assay group for
both theophylline and montelukast treatments throughout the trial. Theophylline adherence ranged
from 84% in the self-reported group to 79% in the blood assay group (p=<.0001) at 1 month and 86% vs.
61% (p=<.0001) at six months. Montelukast adherence ranged from 87% in the self-reported group to
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70% in the blood assay group at month 1 (p=0.0002). At six months, adherence to montelukast was 89%
in the self-reported group vs. 61% in the blood assay group (p=0.015).

According to plasma assays, a total of 125 participants (38.6%) did not adhere to their assigned study
treatment at some point in the study – 58 in the theophylline and 67 in the montelukast groups,
respectively. Thirty-four subjects never seemed to comply after baseline. At 1 month, 68 participants
were non-adherent with assigned medication – 27 and 41 in the theophylline and montelukast groups,
respectively. At 6 months, an addition 57 patients were non-adherent – 31 in the theophylline and 26 in
the montelukast groups.

According to patient diaries, 71 participants (21.9%) did not adhere to their assigned study treatment at
some point in the study – 56 in the theophylline and 51 in the montelukast groups, respectively. Eleven
participants were completely non-adherent to study medications. Thirty nine participants were nonadherent with assigned medication at 1 month – 21 and 18 in the theophylline and montelukast groups,
respectively. Twenty additional subjects were non-adherent at three months – 10 and 10 in the
theophylline and montelukast groups, respectively. At the six month visit, an additional 12 participants
did not adhere to the study medication – 4 in the theophylline group and 8 in the montelukast group.

Inverse Probability Weights
The model for the denominator of the weights is the most important component for determining the
predicted probabilities. Covariates with negative coefficients predict those individuals who would be
more likely to be non-adherent and be censored, while those with positive coefficients should be more
likely to be adherent and remain in the study.23
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For the inverse probability treatment weights, previous treatment was strongest predictor of present
treatment in all treatment groups regardless of adherence metric used. However, the coefficients were
much more pronounced in the self-report analysis than that of the blood assay (-2.58 in the theophylline
group vs. -1.85 in the montelukast group for self-report and -1.24 vs. -1.36 for blood assay, respectively).
None of the other time-varying covariates were strong predictors of treatment changes in the blood
assay group, but being male was significantly associated with the probability of staying on present
treatment in the self-report group (1.19, p=0.04). Despite this, it does not seem that bias in treatment
selection over time was particularly strong in these data. Information on the inverse probability
treatment weights for both self-report and blood assay can be found in Appendix 4.A and 4.B).

For the inverse probability censoring weights, most of the covariates in the MSM model were not
associated with censoring. The exceptions were current treatment with theophylline (1.17; p=0.02) and
ASUI score (2.23, p=0.005) for the blood assay group and being in the study at time 1 (-1.50, p=<.0001)
and time 2 (2.74, p=0.009), being black (-0.63, p=0.04) and age (0.03, p=0.006) for the self-report group.
Similarly to the treatment weights, this indicates that selection bias may not be particularly strong in this
data (see Appendix 4.C).

The mean of the final stabilized weights (treatment x censoring) was 0.98 (range 0.09-10.4) and 0.99
(range 0.16-4.43) for the self-reported and blood assay groups, respectively, indicating that both models
were correctly specified. Furthermore, the sum of the weights in both the self-reported and blood assay
pseudo populations matched the number of visits with complete data in the original sample (1104 and
828, respectively). Figure 4.3 shows the distribution overlap of the stabilized weights for all groups over
time in both the self-reported and blood assay groups.
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The distribution of theophylline vs. montelukast was examined through plotting the stabilized weights in
the treated and untreated groups over time both in the original and in the weighted data sets for both
the self-reported and blood assay groups. The central tendency of the covariate values coincided
between groups indicating that balance was achieved. The distribution plots for the weighted data sets
are shown in figure 4.4.

Outcome Models
Table 4.3 summarizes the outcome using Poisson regression models, looking at asthma control rates
using EPAC composite events as well as each component individually due to treatment effects.

The results of the MSM self-reported analysis found no significant treatment effect on overall asthma
exacerbation rates between theophylline and montelukast (RR=1.28, 95% CI: 0.85-1.94, p=0.24)
However, theophylline was significantly more likely to cause drops in peak flow than in the montelukast
group (RR = 2.25 p-value= 0.02) in the self-reported group. No further significant findings were found
for any of the individual components of asthma control.

The results of the MSM blood assay analysis were nearly identical to that of the MSM self-reported
analysis, although estimates were closer to the null and to the original results from the ITT results (table
4.3). The theophylline group was 24% more likely to have an asthma exacerbation than those in the
montelukast group, but this was not significant (95% CI: 0.84-1.84, p=0.28). There were no significant
findings of treatment effect for any of the individual components of asthma control in the blood assay
group.
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Discussion
Marginal structural models for repeated measures were used to estimate the causal effect of treatment
on asthma control in the LODO trial of the ALA-ACRC. This method was used as it was assumed that,
due to non-adherence and censoring over time, there may have been time-varying covariates that were
simultaneously confounders and intermediates that could not have been appropriately adjusted for by
using standard statistical methods.

Despite a significant difference in adherence rates between the self-reported group and the blood assay
group over time, the adjusted rate ratio, and corresponding 95% confidence intervals, obtained from
both MSMs were nearly identical. Using a measure of self-reported adherence, the theophylline group
had a 28% increased risk of having EPACs compared with the montelukast group. This was in
comparison to a 24% increased risk of EPACs in the blood assay group. None of these findings were
significant and were nearly identical to the original ITT estimates (table 4.3).

This is the first study to directly compare the effects of different adherence measures using MSMs. As
the direction and magnitude of the effect of “assigned” treatment depends on the adherence pattern, it
was assumed that different levels of adherence would have led to changes in the causal effects of
treatment on asthma control. As this was not the case, it indicates that 1) adherence and censoring was
not a significant problem in this data, 2) adherence levels as low as 60% may not be low enough to
severely compromise a study’s validity.

These results should be considered in the context of the following limitations. First, has been shown that
variations in adherence levels distorts the response rate and alter the number of patients required to
detect a significant difference between treatments.7 As this was a secondary analysis of a clinical trial,
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power was not calculated and as such, the sample size may not have been large enough to reach
definite conclusions.

Second, MSMs requires the untestable assumption of no unmeasured confounding; i.e. that subjects are
exchangeable, conditional on the measured variables.17,20,48,49 It was assumed that all the most
important confounders were identified using the expert knowledge of the ALA-ACRC investigators and
were then appropriately measured and included in the analysis. However, it can never be verified that
all joint predictors of exposure and outcome were added to the models.

Third, due to the small sample size and the number of potential confounders added to the MSM models,
finite-sample bias occurred leading to the presence of random zeros in a few of the exposure-covariate
groups. Therefore, one can assume that the positivity assumption was not met in this study. However,
random zeros are essentially guaranteed because of the infinite number of possible values and a more
valid assessment of positivity includes looking at extreme values, mean of weights and values of
exposure-covariate groups adjacent to those with zero.20 Overall, the mean stabilized weights in this
study were 0.98 in the self-report group and 0.99 in the blood assay and the sample did not have very
extreme values. Also, as seen in figure 4.5, many if not all of the exposure-covariate groupings with zero
were surrounded by non-zero groups.

Fourth, it was also assumed that the models used in this analysis were correctly specified. To explore the
robustness of the models, linear and quadratic terms of continuous variables were tested to restrict the
possible values of the propensity scores such that on a logit scale the conditional relation between the
continuous covariates and the risk of treatment can be represented by a parabolic curve, and each
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covariates contributions to the risk is independent of that of the other covariates.18 No significant
changes to the outcome were noted.

Additionally models were fitted with different groupings of covariates. For example, models were fitted
for individual side effects and medications alone, for composite measures of side effects and
medications and for both composite and individual grouping. Again, there were no significant changes
to the outcome. Finally, the fact that the mean of the final stabilized weights were close to 1 and that
each of the MSMs and the original ITT results were near identical, gives strength to the assumption that
the MSM was not mis-specified. Unfortunately, the assumption of a correctly specified model can never
be proven.

Lastly, it is impossible to predict the nature of the relationship between adherence and an outcome
without taking into account the pharmacokinetics and pharmacodynamics of the drug.7,11,12
Unfortunately, this is beyond the scope of this paper but cannot be ruled out as a reason that results
were not different between the two adherent groups.

Based on my research, I recommend that if there is a high likelihood or preliminary evidence suggesting
the presence of time-varying confounders or selection bias in a RCT then the MSMs approach should be
used, regardless of the length of the study or levels of non-adherence or censorship. Unfortunately,
there is no definitive guidance as to the type of adherence metric to use for such an analysis or at what
level of non-adherence or loss to follow up will lead to bias that severely compromises a study’s validity.
Therefore, conducting a MSM as a sensitivity analysis of the ITT can only bolster one’s confidence of the
estimated effects of treatment on an outcome.
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Conclusion
Despite the complexity of these models, MSMs hold much potential for further analyses of randomized
clinical trials as it allows adjustment for time-varying confounding and selection bias due to censoring,
issues more traditional regression based methods cannot account for.

In my analysis, fitting MSMs using two significantly different adherence metrics did not cause the null
outcomes to change. This may not have been the case if the LODO trial was longer than six months and
if the sample size was larger. However, it seems that despite the present of non-adherence and
censorship in the LODO trial, theophylline was no more effective than montelukast in preventing EPACs.

In any event, it is my recommendation that MSMs be used, at a minimum, as a sensitivity analysis to the
ITT approach in RCTs where there is preliminary evidence suggesting the presence of time-varying
confounders or selection bias.
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Figure 4.1. Structural relationships over time between treatments and asthma control in the Low Dose
Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial (ACRC, 2002-2003)1

1

Created through Daggity software: Johannes Testor, Juliane Hardt, and Sven Knuppel. Daggitty: A
graphical tool for analyzing causal diagrams. Epidemiology, 22(5): 745, 2011
-A0, A1, A2, A3 represent observed cumulative treatment exposure to either Theophylline, Montelukast
or Placebo from baseline randomization (A0), 1 month (A1), 3 months (A2) and 6 months (A3).
-L1, L2, L3 denote measured confounders (pulmonary function measures, asthma symptoms,
medications and adverse effects) that may be associated with A(k),respectively. L(0) denotes baseline
demographic characteristics along with baseline FEV 1 . It was assumed that there was no effect of L(0)
on A(0), because of randomization and full initial compliance.
-C1, C2, C3 reflects loss to follow up at 1 month (C1), 3 months (C2) and 6 months (C3).
Y indicates the outcome of annual rate of asthma exacerbations indicating poor asthma control. If all
possible confounding paths are blocked, the green arrows into Y represent the remaining causal paths.
Figure 4.2. A Schema of the Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma
(LODO) trial (ACRC, 2002-2003)

V1/Run-In: Potentially eligible patients were followed for a 1-2 week run-in period
V2/M0: Patients who successfully completed the run-in and agreed to be randomized were assigned to
one of the three treatments shown
V3: 1 month follow up visit
V4: 3 month follow up visit
V5: 6 month follow up visit
P1-P4: Telephone calls between visits to assess diary card completion and adverse/side effects
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Table 4.1. Baseline Characteristics of the 324 LODO Participants by Treatment Assignment
Theophylline
160

Montelukast
164

p-value 1
---

41.5 ± 14.7
25.0

39.8 ± 15.0
28.1

60.0
31.3
8.8

62.2
25.6
12.2

0.56
0.80
0.88
0.48
0.57

Asthma Symptoms, mean ± SD
ASUI Average Score

0.66 ± 0.15

0.68 ± 0.15

0.16

Pulmonary Function, mean ± SD
Pre-BD FEV1, % predicted*
Pre-BD FVC, % predicted*
Post-BD FEV1, % predicted*
Post-BD FVC, % predicted*
Peak Flow, % predicted*
FEV1 Bronchodilator % change
FVC Bronchodilator % change

78.3 ± 16.5
87.2 ± 14.8
84.4 ± 15.6
91.8 ± 15.7
83.4 ± 20.3
9.2 ± 12.6
5.9 ± 10.3

77.5 ± 17.5
87.1 ± 16.9
83.7 ± 17.1
91.6 ± 16.0
83.0 ± 20.3
9.3 ± 11.7
6.6 ± 13.8

0.32
0.65
0.18
1.00
0.39
0.94
0.06

Number of patients
Demographics
Age, mean ± SD
Male, %
White, %
Black, %
Other Race, %

Daily Asthma Treatments, %
90.0
92.7
Using asthma medication daily
0.51
2.5
4.9
Inhaled anticholinergic
0.52
22.5
22.6
Inhaled long-acting -agonist
0.56
58.1
60.4
Inhaled short-acting -agonist
0.79
37.5
40.2
Combination drugs
0.78
39.4
34.8
Inhaled Corticosteroids
0.63
*Predicted values of Hankinson and colleagues.
1) P values for categorical variables from Pearson Chi-Square test compared to ANOVA test for
continuous categories
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Table 4.2. Participant Adherence to Assigned Drug by Types of Adherence Metrics at Each Time Period1
Theophylline
Time
Period

Self-Report

Montelukast

Blood Assay

2

Self-Report

Blood Assay

2

N

n (%)

N

n (%)

p-value

N

n (%)

N

n (%)

p-value

Baseline

160

160 (100%)

160

160 (100%)

1.00

164

164 (100%)

164

164 (100%)

1.00

1 Month

127

106 (83.5%)

134

107 (79.9%)

<.0001

139

121 (87.1%)

137

96 (70.1%)

0.0002

3 Months

126

106 (84.1%)

NA

NA

NA

139

121 (87.1%)

NA

NA

NA

6 Months

117

101 (86.3%)

116

71 (61.2%)

<.0001

132

117 (88.6%)

117

71 (60.7%)

0.015

1 P values from Pearson Chi-Square tests
2 Blood assays were only collected at 1 and 6 months
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Figure 4.3a. Distribution Overlap of the Stabilized Inverse Probability Weights for all Treatments Over
Time, Self-Reported Group

-Stabilized Inverse Probability Weights (SW) in each time period showed a mean (◊)and median (─) close
to 1 indicating that the model was correctly specified.
-Overall, the mean and median of the SW was 0.98 and 0.99, respectively, and ranged from 0.9-10.4.
-Time Period 0: Baseline with 324 participants; Time Period 1: 1 month with 266 participants; Time
Period 2: 3 months with 265 participants; Time Period 3: 6 months with 249 participants
Figure 4.3b. Distribution Overlap of the Stabilized Inverse Probability Weights for all Treatments Over
Time, Blood Assay Group

-Stabilized Inverse Probability Weights (SW) in each time period showed a mean (◊) and median (─) close
to 1 indicating that the model was correctly specified.
-Overall, the mean and median of the SW was 0.99 and 1.0, respectively, and ranged from 0.16-4.43.
-Time Period 0: Baseline with 324 participants; Time Period 1: 1 month with 271 participants; Time
Period 3: 6 months with 233 participants
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Figure 4.4a. Distribution of Self-Reported Stabilized Inverse Probability Weights in the Treated
(Theophylline) and Untreated (Montelukast) Groups

Stabilized Inverse Probability Weights (SW) in the theophylline and montelukast groups had means of 1
and followed a similar distribution indicating balance between both groups.
Figure 4.4b. Distribution of Blood Assay Stabilized Inverse Probability Weights in the Treated
(Theophylline) and Untreated (Montelukast) Groups

Stabilized Inverse Probability Weights (SW) in the theophylline and placebo groups had means of 1 and
followed a similar distribution indicating balance between both groups.
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Table 4.3. Estimated Effects of Treatment on Episodes of Poor Asthma Control (EPACs) in the LODO Trial,
2002-2003 by Adherence Metric1

Treatment Groups
Number of patients
Asthma EPACs
Events, n
Rate, events/person-year
95% Confidence Interval
p-value

Intention to
Treat RR

Inverse
Probability
Weighting RR
- Self Report

Inverse
Probability
Weighting RR
- Blood Assay

1.22
0.82-1.86
0.35

1.28
0.85-1.94
0.24

1.24
0.83-1.85
0.29

Theophylline Montelukast
150
160

269
4.9
3.6-6.7
--

236
4.0
3.0-5.4
--

Episode Components
Peak flow, 30% drop
Events, n
75
43
Rate, events/person-year
1.3
0.7
1.85
2.25
95% Confidence Interval
0.8-2.2
0.5-1.1
0.96-3.54
1.12-4.54
p-value
--0.07
0.02*
Increased medication use
Events, n
198
179
Rate, events/person-year
3.5
3.0
1.16
1.26
95% Confidence Interval
2.4-5.0
2.2-4.2
0.71-1.90
0.75-2.11
p-value
--0.55
0.39
New use of oral
corticosteroids
Events, n
30
32
Rate, events/person-year
0.5
0.5
0.99
1.22
95% Confidence Interval
0.4-0.7
0.3-0.8
0.56-1.75
0.67-2.22
p-value
--0.97
0.51
Unscheduled health care
Events, n
41
34
Rate, events/person-year
0.7
0.5
1.27
1.32
95% Confidence Interval
0.5-1.0
0.4-0.8
0.72-2.24
0.71-2.47
0.40
p-value
--0.38
1
p values for treatment effects on rates of episodes of poor asthma control are based on Poisson
regression with robust variance and are significant at the 0.05 level (*)

1.78
0.90-3.52
0.10

1.19
0.71-1.99
0.51

1.19
0.67-2.12
0.56

1.40
0.76-2.56
0.28
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Chapter 5. Discussion
The overall goal of this dissertation was to demonstrate the advantages and disadvantages of using
Marginal Structural Models (MSMs) to 1) control for time-dependent confounding and 2) detect effect
modification in a RCT with a time-varying exposure, non-adherence and missing data.

Unlike the traditional regression used in the ITT approach, MSMs account for both the joint effects of
baseline and subsequent treatments as well as the presence of time-dependent confounding influenced
by prior treatment and selection bias due to censoring.1–4 By modeling exposures at each follow up and
the final outcome, MSMs are able to measure confounders and/or mediators that may affect either
adherence to an exposure or loss to follow up (attrition) in an attempt to eliminate all back door
pathways that may bias the association between the exposure and the outcome.1,3,5–8 In theory this will
lead to less biased estimates than ITT analyses. Furthermore, MSMs can detect effect modification by
the simple addition of a treatment covariate product term to the final logistic model weighted by the
inverse probability weights.1,9,10 In theory, this enables investigators to assess effect modification
without having to ensure that sample sizes are large enough for stratified analyses at the conclusion of a
study when effect modification was not considered a priori.

Despite the theoretical advantages of MSMs, my research found that the approach failed to invalidate
previous ITT analyses, regardless of adherence level. This indicates that either 1) MSMs do not
invalidate ITT analyses; 2) that the LODO trial just didn’t have a significant problem with adherence and
censoring; or 3) that the study was too short in duration with a sample size too small for timedependent confounding to occur and for a difference between MSM and ITT to exist. There are a
limited number of studies in the literature that have compared ITT to MSM but those that have, have all
found similar interpretations to my results.11,12,13
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In the case of effect modification, the MSM analysis was able to detect effect modification by race in
only one of the treatment groups (montelukast) but there were many limitations that precluded
confidence in the results. Most importantly, more research is needed to determine the most
appropriate way to calculate inverse probability treatment weights propensity scores as there is no
consensus in the literature on how best to calculate the propensity scores required for weighting and
achieve accurate subgroup results.

Summary of Findings
Chapter 2 - Aim 1
In aim 1 I used MSMs to check the validity of an ITT analysis in the LODO trial of the ALA-ACRC, a RCT with a
time-varying exposure, non-adherence and missing data assessing treatment effectiveness on asthma
control. MSMs were used as it was assumed that, due to non-adherence and censoring over time, there may
have been time-varying covariates that were simultaneously confounders and intermediates that could not
have been appropriately adjusted for by using standard statistical methods.

Although non-adherence and censoring occurred over time in the LODO trial, the effect estimates
obtained from the MSM, using no further adjustments other than the stabilized weights, were nearly
identical to that of the ITT analysis. Each method found no significant treatment effect on overall
episodes of poor asthma control (EPACs) among all three groups. The results of the ITT analysis found a
22% increased risk of EPACs for theophylline compared with montelukast (RR=1.22, 95% CI: 0.82-1.86,
p=0.35), no increased risk between theophylline and placebo (RR=0.99, 95% CI: 0.67-1.50, p=1.00), and
an 18% decreased risk of EPACs between montelukast and placebo (RR=0.82; 95% CI: 0.55-1.21, p=0.31).
This is in comparison to a 24% increased risk of EPACs for theophylline compared with montelukast
(RR=1.24, 95% CI: 0.83-1.84, p=0.28), no increased risk between theophylline and placebo (RR=1.01, 95%
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CI: 0.70-1.48, p=0.95), and a 17% decreased risk of EPACs between montelukast and placebo (RR=0.83;
95% CI: 0.57-1.19, p=0.27).

These findings are most likely the result of the short time frame of the study (6 months) and the
relatively level of overall adherence (84% for theophylline and 88% for both montelukast and placebo)
and censoring (6%) rather than the use of a mis-specified model. First, the mean of the final stabilized
weights (treatment x censoring) was 0.995 and ranged from 0.4 to 4.3, indicating that the model was
correctly specified. Furthermore, the sum of the weights in the pseudo population was 1785 which was
identical to the number of visits with complete data in the original sample. Second, the inverse
probability treatment weights indicated that previous treatment was the only strong predictor of being
non-adherent to treatment assignment for all treatment groups (-5.70 for theophylline, -4.96 for
montelukast and -18.17 for placebo). Similarly, inverse probability censoring weights found none of the
covariates to be strongly associated with censoring indicating that time-depending confounding and
selection bias over time were not particularly strong in these data.

Chapter 3 – Aim 2
In Aim 2, I used MSMs to detect effect modification by race in the LODO trial of the ALA-ACRC, a
RCT with a time-varying exposure, non-adherence and missing data assessing treatment effectiveness
on asthma control. Race was chosen as a potential effect modifier for two reasons. First, research has
indicated that certain racial and ethnic groups fare significantly worse than whites when assessing
asthma control14–21 and that certain first-line asthma treatments were not as effective in improving
asthma control in African Americans and Puerto Ricans in comparison with other racial and ethnic
subgroups.22–26 Second, this was a secondary data analysis of a trial that had larger than usual minority
representation.27,28
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Inverse probability treatment weights (IPTW) were initially computed for the full cohort and by racial
strata as a lack of consensus exists as to whether the propensity scores used to calculate the IPTWs
should be estimated on the full cohort or by strata.29–32 The mean stabilized weight in the full cohort
was 0.998 and ranged from 0.04 to 4.0, indicating that the model was correctly specified. In
comparison, the stratum-specific mean stabilized weights were similar to the full cohort for whites but
ranged from 0.02 to 10 in the non-white group. Furthermore, the non-white group had abnormally
large standard errors and violated the positivity assumption as many exposure-covariate groupings had
zero cases. This led to the conclusion that the non-white group was not of sufficient size to obtain
meaningful estimates. While it is assumed that strata-propensity scores would lead to better balance
between treatment groups and therefore, less bias in the treatment-outcome relationship, research has
indicated that weighting according to the distribution of effect modifiers observed in the full cohort is
the ideal method when estimating a casual contrast from RCTs.29 As such, the full cohort was used for
all subsequent analyses.

As hypothesized, qualitative effect modification on the multiplicative scale existed for a number of
treatment-outcome associations. However, race differences only seemed to exist for patients on
montelukast. In the unadjusted analysis, non-whites were twice as likely to have an EPAC on
montelukast as their white counterparts (5.75 vs. 2.66 episodes per person year, p=0.0034). Similar
findings were seen for increased medication use and health care visits. Results of the MSM also
indicated the presence of effect modification for overall EPACs, medication use and unscheduled health
care when treated with montelukast instead of placebo. Compared with whites, non-whites were more
than twice as likely to suffer from an EPAC on montelukast as on placebo (RR=2.13, 95% CI: 1.08-4.46, p=
0.04) and almost 3 times as likely to increase medication use (RR=2.86, 95% CI: 1.10-7.42, p=0.03). Nonwhites were over 5 times more likely to have unscheduled health care visits than whites while on
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montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02). Lastly, while only
borderline significant, it should be noted that compared with whites, non-whites on theophylline were
66% less likely to have unscheduled health care visits than those on montelukast (RR=0.34, 95% CI: 0.111.01, p=0.05).

These finding may be indicative of potential information bias in adherence levels, which was determined
in this study by self-report. Research has shown that minority groups are more likely to be over reliant
on symptom-driven management rather than daily use of controller medications.33–35 One study found
that at least a third of black patients claimed to not take their controller medications, with many
managing symptoms of asthma with short-term beta-agonists alone.35 However, since the significant
findings only applied to montelukast and not to theophylline, it may be more plausible that the
difference is due to pharmacogenetics reasons. Prior research has found that African Americans do not
respond as well as whites to inhaled corticosteroids and albuterol.23,24 Unfortunately, there have been
no studies to date that have examined racial differences in pharmacokinetics for montelukast.

Chapter 4 – Aim 3
In aim 3, I used MSMs to demonstrated whether the use of different adherence metrics had any effect
on the direction and magnitude of the causal effect of asthma treatments on the rate of episodes of
poor asthma control in the LODO trial of the ALA-ACRC, a RCT with a time-varying exposure, nonadherence and missing data assessing treatment effectiveness on asthma control. As the direction and
magnitude of the effect of “assigned” treatment depends on the adherence pattern, it was assumed
that conducting MSMs using two significantly different adherence proportions would result in different
effect estimates. In the LODO trial, adherence was measured by both self-report patient diaries and by
the collection of blood plasma. Adherence was significantly greater in the self-reported group
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compared with the blood assay group for both theophylline and montelukast treatments throughout the
trial. Theophylline adherence ranged from 84% in the self-reported group to 79% in the blood assay
group (p=<.0001) at 1 month and 86% vs. 61% (p=<.0001) at six months. Montelukast adherence ranged
from 87% in the self-reported group to 70% in the blood assay group at month 1 (p=0.0002). At six
months, adherence to montelukast was 89% in the self-reported group vs. 61% in the blood assay group
(p=0.015).

Despite a significant difference in adherence rates between the self-reported group and the blood assay
group over time, the adjusted rate ratio, and corresponding 95% confidence intervals, obtained from
both MSMs were nearly identical. The results of the MSM self-reported analysis found no significant
treatment effect on overall asthma exacerbation rates between theophylline and montelukast (RR=1.28,
95% CI: 0.85-1.94, p=0.24). However, theophylline was significantly more likely to cause drops in peak
flow than in the montelukast group (RR = 2.25 p-value= 0.02) in the self-reported group. No further
significant findings were found for any of the individual components of asthma control. The results of
the MSM blood assay analysis were nearly identical to that of the MSM self-reported analysis, although
estimates were closer to the null and to the original results from the ITT results. The theophylline group
was 24% more likely to have an asthma exacerbation than those in the montelukast group, but this was
not significant (95% CI: 0.84-1.84, p=0.28). There were no significant findings of treatment effect for any
of the individual components of asthma control in the blood assay group.

As seen in Aim 1, previous treatment was the strongest predictor of remaining on treatment assigned in
all treatment groups, regardless of adherence metric used. However, the coefficients were much more
pronounced in the self-report analysis than that of the blood assay (-2.58 in the theophylline group vs. 1.85 in the montelukast group for self-report and -1.24 vs. -1.36 for blood assay, respectively). None of
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the other time-varying covariates were strong predictors of treatment changes in the blood assay group,
but being male was significantly associated with the probability of staying on present treatment in the
self-report group (1.19, p=0.04).

For the inverse probability censoring weights, most of the covariates in the MSM model were not
associated with censoring. The exceptions were current treatment with theophylline (1.17; p=0.02) and
ASUI score (2.23, p=0.005) for the blood assay group and being in the study at time 1 (-1.50, p=<.0001)
and time 2 (2.74, p=0.009), being black (-0.63, p=0.04) and age (0.03, p=0.006) for the self-report group.
Similarly to the treatment weights, this indicates that selection bias may not be particularly strong in this
data.

Lastly, the mean of the final stabilized weights (treatment x censoring) was 0.98 (range 0.09-10.4) and
0.99 (range 0.16-4.43) for the self-reported and blood assay groups, respectively, indicating that both
models were correctly specified. Furthermore, the sum of the weights in both the self-reported and
blood assay pseudo populations matched the number of visits with complete data in the original sample
(1104 and 828, respectively).

As such, it can be assumed that adherence and censoring was not a significant problem in this data and
that adherence levels as low as 60% may not be low enough to severely compromise a study’s validity.

Limitations
For all aims, the following limitations should be considered. First, MSMs requires the untestable
assumption of no unmeasured confounding; i.e. that subjects are exchangeable, conditional on the
measured variables.5,9,36,37 It is assumed that all the most important confounders were identified using
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the expert knowledge of the ALA-ACRC investigators and were then appropriately measured and
included in the analysis. However, it can never be verified that all joint predictors of exposure and
outcome were added to the models.

Second, due to the small sample size and the number of potential confounders added to the MSM
models ran for all aims, finite-sample bias occurred leading to the presence of random zeros in a few of
the exposure-covariate groups. Therefore, one can assume that the positivity assumption was not met
in any of the aims. However, random zeros are essentially guaranteed because of the infinite number of
possible values and a more valid assessment of positivity includes looking at extreme values, mean of
weights and values of exposure-covariate groups adjacent to those with zero.5 Overall, the mean
stabilized weight in each study was close to 1 and samples did not have very extreme values.

Third, it was assumed that the models used in all aims are correctly specified. To explore the robustness
of the models, linear and quadratic terms of continuous variables were tested to restrict the possible
values of the propensity scores such that on a logit scale the conditional relation between the
continuous covariates and the risk of treatment can be represented by a parabolic curve, and each
covariates contributions to the risk is independent of that of the other covariates.38 No significant
changes to the outcome were noted. Additionally models were fitted with different groupings of
covariates. For example, models were fitted for individual side effects and medications alone, for
composite measures of side effects and medications and for both composite and individual grouping.
Again, there were no significant changes to the outcome. Finally, the fact that the mean of the final
stabilized weight was close to 1 and that the MSM and ITT results were near identical, gives strength to
the assumption that the MSM was not mis-specified. Unfortunately, the assumption of a correctly
specified model can never be proven.
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Aim 2 had two additional limitations. First, there is lack of consensus as to whether the IPTWs should be
estimated on the full cohort or by strata when using MSMs to detect effect modification.29–32 It is
assumed that strata-propensity scores would lead to better balance between treatment groups and
therefore, less bias in the treatment-outcome relationship when dealing with studies like this with rare
outcome events. However, the same research indicates that weighting according to the distribution of
effect modifiers observed in the full cohort is the ideal method when estimating a casual contrast from
randomized clinical trials (or any trial where there is well defined inclusion and exclusion criteria and
everyone has the indication under study). Unfortunately, there is no guideline as to what constitutes a
sufficient size for strata-specific IPTWs.29 Due to the small sample size in the non-white group, a full
cohort was used for aim 2.

Second, while there has been plenty of research published regarding racial disparities on asthma
morbidity and burden, it is important to note that race may not be the true causal factor but instead
serves as a proxy or marker for one or more of the complex, multilevel and intertwined environmental
and cultural factors thought to be associated with asthma control disparities.17,20,39–42 Related to this last
point, the original LODO study results found that the use of inhaled corticosteroids modified the effect
of treatment on asthma control. Comparatively, the only significant difference in baseline characteristics
in this study was the fact that whites were significantly more likely to be taking inhaled corticosteroids
than their non-white counterparts (p-value= 0.02). Adding credence to the argument that race is an
effect modifier by proxy and not a direct effect modifier in this study is the fact that while there was
significance for effect modification in some treatment-outcome relationships, there was no significant
relationship found between race and any of the asthma control outcomes. Having an association with
the outcome is a prerequisite of being an effect modifier.9,43–45 Unfortunately, effect modification by
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inhaled corticosteroids was not examined in this paper and it is unknown if it would have impacted the
results of the MSM analysis.

Aim 3 also had two additional limitations. First, it has been shown that variations in adherence levels
distorts the response rate and alter the number of patients required to detect a significant difference
between treatments.46 As this was a secondary analysis of a clinical trial, power was not calculated and
as such, the sample size may not have been large enough to reach definite conclusions. Second, it is
impossible to predict the nature of the relationship between adherence and an outcome without taking
into account the pharmacokinetics and pharmacodynamics of the drug.46–48 Unfortunately, this is
beyond the scope of this paper but cannot be ruled out as a reason that results were not different
between the two adherent groups.

Strengths and Public Health Significance
The biggest strength of my dissertation is that it adds to the limited research on using MSMs to analyze
RCTs with incomplete adherence and/or censorship. As far as I know, aim 2 and aim 3 are the first
studies of its kind to use MSMs to detect effect modification and to directly compare the effects of
different adherence measures in a RCT. While there is no other studies to compare results of aim 2 and
aim 3 to, I have confidence that the research was conducted appropriately as my findings from aim 1
mirror that of other trials conducted with similar proportions of noncompliance and censorship.

Despite my original hypotheses that the use of MSMs would lead to less biased estimates compared to
ITT due to its ability to account for time-varying exposures, non-adherence and censorship, the results of
all three aims indicate that in practice, MSMs may not invalidate ITT effect measures. More research is
warranted however, as patients and clinicians usually prefer to know what are the benefits and risk of
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receiving a treatment rather than being assigned to one and my research may have used too small of a
sample and too short of a trial to see a real difference.

Policy Recommendations and Future Research Directions
Theoretically, MSMs hold much potential for the analyses of RCTs as it allows adjustment for timevarying exposures, time-dependent confounding and selection bias due to censoring, issues more
traditional regression based methods cannot account for. However, this may not be the case in practice
as my research in aim 1 mirrors the findings of previously conducted RCT studies which found that
MSMs do not invalidate effect estimates from ITT analyses.

While some may conclude that concordance between the effect estimates from ITT and MSM indicates
that the former is still superior for RCT analyses, I caution that more practical guidance on the benefits
and limitations of MSMs is required before coming to that conclusion. It would be beneficial to known if
there are any specific conditions in which MSMs would produce meaningful differences in estimates
compared to ITT. This kind of research is extremely limited even for non-experimental study designs.49,50

There is also no definitive guidance as to what level of non-adherence or loss to follow up will lead to
bias that severely compromises a study’s validity. In my aim 3, a non-adherence level of 60% was still
not enough to see a change in effect estimates from that of a non-adherence level of close to 90%.
However, this study was the first of its kind and more studies simulating different levels of adherence
are needed.

Lastly, while MSMs have been commonly used to adjust for confounding in longitudinal studies with
time-varying exposures and time-dependent covariates, they have been rarely used for detecting effect
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modification. Unfortunately, there is very little information on the appropriate way to accurately assess
effect modification using MSMs despite the obvious need for ways to combine moderation analysis with
advanced causal methods. While I attempted to add to the literature with my aim 2, my results are
limited due to the inability to calculate strata-specific IPTWs using my sample. As such, more simulated
research is needed to determine the best way to calculate IPTWs when assessing effect modification
using MSMs and what is the minimum strata specific sample size that is required.

Based on my research, I recommend that MSMs be used for sensitivity analyses in RCTs where there is
preliminary evidence suggesting the presence of time-varying exposures, time-dependent confounding
and/or selection bias and where MSM’s limitations can be reasonably ignored.

Conclusion
In theory MSMs hold much potential for further analyses of randomized clinical trials as it allows
adjustment for time-varying exposures, time-dependent confounding and selection bias, issues more
traditional regression based methods cannot account for. However, it remains unclear as to whether
this is the case in practice. At the very least, MSMs should be conducted as a sensitivity analysis to the
ITT approach in RCTs where there is preliminary evidence suggesting the presence of time-varying
exposures, time-dependent confounding and/or selection bias and when MSM’s limitations can be
reasonably ignored. Conducting a MSM as a sensitivity analysis of the ITT can only bolster one’s
confidence of the estimated effects of treatment on an outcome. In terms of effect modification, more
research is needed to determine the most appropriate way to calculate inverse probability treatment
weights propensity scores as there is no consensus in the literature on how best to calculate the
propensity scores required for weighting and achieve accurate subgroup results.
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Appendix 2.A: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Theophylline1
Parameter

Estimate

Std. Error

Chi-Square

Pr > ChiSq

Intercept
-1.0050
2.7907
0.1297
0.7187
Time At One Month
2.1844
0.4316
25.6155
<.0001
Time At Three Months
2.6348
0.4881
29.1382
<.0001
Previous treatment with theophylline
-5.6501
1.3644
17.1494
<.0001
Age
-0.00728
0.0118
0.3810
0.5370
Male
0.2494
0.4133
0.3642
0.5462
Black Race
0.1599
0.3752
0.1817
0.6700
Other Race
0.6954
0.6928
1.0075
0.3155
Previous ASUI score
-0.7728
1.2098
0.4081
0.5230
Previous Pre-BD FEV1, % predicted
0.00626
0.0330
0.0360
0.8496
Previous Pre-BD FVC, % predicted
-0.0481
0.0356
1.8281
0.1764
Previous Post-BD FEV1, % predicted
-0.0152
0.0334
0.2077
0.6486
Previous Post-BD FVC, % predicted
0.0480
0.0341
1.9851
0.1589
Previous Peak Flow, % predicted
0.0227
0.0122
3.4386
0.0637
Previous use of anticholinergics
0.8856
0.8551
1.0726
0.3004
Previous use of long-acting beta agonists
-0.1052
0.4603
0.0523
0.8192
Previous use of short-acting beta agonists
0.2742
0.3389
0.6549
0.4184
Previous use of combination drugs
0.0186
0.3904
0.0023
0.9621
Previous use of inhaled corticosteroids
0.0303
0.4056
0.0056
0.9405
Previous complaint of nausea
-0.6625
1.1931
0.3083
0.5787
Previous complaint of vomiting
2.0315
1.5873
1.6379
0.2006
Previous complaint of poor appetite
0.3431
0.7953
0.1861
0.6662
Previous complaint of heartburn
-0.6842
0.6526
1.0994
0.2944
Previous complaint of headaches
-0.0391
0.4545
0.0074
0.9314
Previous complaint of insomnia
0.3158
0.4608
0.4696
0.4932
Previous complaint of anxiety
0.8114
0.5663
2.0527
0.1519
Previous complaint of tremors
-0.4519
1.2770
0.1252
0.7234
Previous complaint of heart palpitations
-1.0438
1.0718
0.9485
0.3301
Previous complaint of skin rash
-0.3170
1.1658
0.0740
0.7857
Previous visit to the hospital
-0.3782
0.9440
0.1605
0.6887
Previous visit to a doctor
0.1166
0.4186
0.0775
0.7806
1) Positive coefficients represent factors that increased the probability of receiving theophylline while negative coefficients denote factors that
decreased the probability of receiving theophylline, i.e. previous treatment

157

Appendix 2.B: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Montelukast1
Parameter

Estimate

Std. Error

Chi-Square

Pr > ChiSq

Intercept
1.1615
3.1357
0.1372
0.7111
Time At One Month
2.8209
0.4745
35.3434
<.0001
Time At Three Months
3.1624
0.5661
31.2123
<.0001
Previous treatment with montelukast
-4.9230
1.3204
13.9014
0.0002
Age
-0.00656z
0.0136
0.2322
0.6299
Male
0.3919
0.4113
0.9079
0.3407
Black Race
-0.5415
0.4179
1.6789
0.1951
Other Race
0.2028
0.5720
0.1258
0.7229
Previous ASUI score
1.8411
1.1225
2.6898
0.1010
Previous Pre-BD FEV1, % predicted
-0.0245
0.0305
0.6429
0.4226
Previous Pre-BD FVC, % predicted
0.0121
0.0263
0.2122
0.6450
Previous Post-BD FEV1, % predicted
0.0206
0.0325
0.4012
0.5265
Previous Post-BD FVC, % predicted
-0.0246
0.0250
0.9698
0.3247
Previous Peak Flow, % predicted
-0.0201
0.0112
3.2289
0.0723
Previous use of anticholinergics
0.4357
0.9027
0.2330
0.6293
Previous use of long-acting beta agonists
-0.2981
0.5019
0.3527
0.5526
Previous use of short-acting beta agonists
-0.2553
0.3835
0.4432
0.5056
Previous use of combination drugs
-0.5382
0.4367
1.5193
0.2177
Previous use of inhaled corticosteroids
-0.6370
0.4333
2.1618
0.1415
Previous complaint of nausea
-0.1704
1.2911
0.0174
0.8950
Previous complaint of vomiting
0.3640
1.5882
0.0525
0.8187
Previous complaint of poor appetite
1.3875
1.2115
1.3118
0.2521
Previous complaint of heartburn
-0.6652
0.7724
0.7417
0.3891
Previous complaint of headaches
0.5969
0.4298
1.9291
0.1649
Previous complaint of insomnia
-0.4719
0.5463
0.7459
0.3878
Previous complaint of anxiety
0.6391
0.6528
0.9585
0.3276
Previous complaint of tremors
-1.4015
2.1850
0.4114
0.5213
Previous complaint of heart palpitations
0.2659
1.2046
0.0487
0.8253
Previous complaint of skin rash
1.7337
1.0743
2.6043
0.1066
Previous visit to the hospital
-0.3368
1.0004
0.1133
0.7364
Previous visit to a doctor
0.2892
0.4202
0.4737
0.4913
1) Positive coefficients represent factors that increased the probability of receiving montelukast while negative coefficients denote factors that
decreased the probability of receiving montelukast, i.e. previous treatment
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Appendix 2.C: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Placebo1
Parameter

Estimate

Std. Error

Chi-Square

Pr > ChiSq

Intercept
-7.9301
3.5402
5.0177
0.0251
Time At One Month
4.9187
0.8473
33.7029
<.0001
Time At Three Months
4.5387
0.8561
28.1041
<.0001
Previous treatment with placebo
-18.3575
750.7
0.0006
0.9805
Age
0.00191
0.0154
0.0155
0.9010
Male
-0.3968
0.4991
0.6320
0.4266
Black Race
0.1006
0.4766
0.0446
0.8328
Other Race
0.7361
0.8404
0.7672
0.3811
Previous ASUI score
3.8638
1.5649
6.0957
0.0136
Previous Pre-BD FEV1, % predicted
-0.0186
0.0472
0.1557
0.6931
Previous Pre-BD FVC, % predicted
0.0677
0.0413
2.6836
0.1014
Previous Post-BD FEV1, % predicted
0.00449
0.0477
0.0089
0.9249
Previous Post-BD FVC, % predicted
-0.0577
0.0391
2.1769
0.1401
Previous Peak Flow, % predicted
-0.0118
0.0138
0.7300
0.3929
Previous use of anticholinergics
-0.1018
1.4251
0.0051
0.9430
Previous use of long-acting beta agonists
-0.1683
0.6246
0.0726
0.7876
Previous use of short-acting beta agonists
-0.0264
0.4037
0.0043
0.9479
Previous use of combination drugs
1.0359
0.5637
3.3765
0.0661
Previous use of inhaled corticosteroids
1.2569
0.5719
4.8295
0.0280
Previous complaint of nausea
0.8391
0.8205
1.0459
0.3064
Previous complaint of vomiting
0.9931
1.1198
0.7865
0.3752
Previous complaint of poor appetite
0.3595
1.3219
0.0740
0.7856
Previous complaint of heartburn
0.8371
0.7812
1.1481
0.2840
Previous complaint of headaches
0.2046
0.5879
0.1211
0.7278
Previous complaint of insomnia
0.2979
0.5498
0.2937
0.5879
Previous complaint of anxiety
1.1212
0.7537
2.2130
0.1369
Previous complaint of tremors
1.2217
1.1341
1.1605
0.2814
Previous complaint of heart palpitations
-0.4847
1.6485
0.0864
0.7687
Previous complaint of skin rash
-0.5512
1.3232
0.1735
0.6770
Previous visit to the hospital
0.4389
1.0379
0.1789
0.6723
Previous visit to a doctor
0.9318
0.5077
3.3689
0.0664
1) Positive coefficients represent factors that increased the probability of receiving placebo while negative coefficients denote factors that
decreased the probability of receiving placebo, i.e. previous treatment
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Appendix 2.D: Coefficients Obtained from the Denominator of the Pooled Logistic Censoring Model1
Parameter

Estimate

Std. Error

Chi-Square

Pr > ChiSq

Intercept
23.8525
334.3
0.0051
0.9431
Time At Baseline
12.5669
73.9229
0.0289
0.8650
Time At One Month
0.3140
0.3190
0.9686
0.3250
Time At Three Months
-0.0355
0.2995
0.0141
0.9056
Assigned to theophylline
-12.2756
216.2
0.0032
0.9547
Assigned to montelukast
-11.4687
216.2
0.0028
0.9577
Currently on theophylline
0.1481
0.5447
0.0739
0.7857
Currently on montelukast
0.6640
0.6715
0.9776
0.3228
Currently on placebo
12.4110
216.2
0.0033
0.9542
Age
0.0284
0.00954
8.8338
0.0030
Male
-0.2037
0.2726
0.5583
0.4550
Black
-0.5365
0.2590
4.2892
0.0384
Other Race
-0.6405
0.3676
3.0355
0.0815
ASUI score
1.6982
0.8028
4.4746
0.0344
Pre-BD FEV1, % predicted
-0.0451
0.0205
4.8521
0.0276
Pre-BD FVC, % predicted
0.0469
0.0203
5.3440
0.0208
Post-BD FEV1, % predicted
0.0312
0.0213
2.1511
0.1425
Post-BD FVC, % predicted
-0.0316
0.0162
3.8178
0.0507
Peak Flow, % predicted
-0.0125
0.00793
2.4877
0.1147
Use of anticholinergics
-11.1890
203.8
0.0030
0.9562
Use of long-acting beta agonists
-0.3967
0.4010
0.9785
0.3226
Use of short-acting beta agonists
0.1123
0.2451
0.2100
0.6467
Use of combination drugs
-0.1834
0.2848
0.4147
0.5196
Use of inhaled corticosteroids
0.0224
0.3117
0.0052
0.9427
Complaint of nausea
-0.3521
0.6622
0.2826
0.5950
Complaint of vomiting
-11.9122
265.0
0.0020
0.9641
Complaint of poor appetite
0.0164
0.6767
0.0006
0.9807
Complaint of heartburn
0.4928
0.3831
1.6545
0.1983
Complaint of headaches
0.0977
0.3111
0.0986
0.7535
Complaint of insomnia
-0.2728
0.3555
0.5890
0.4428
Complaint of anxiety
0.5425
0.4169
1.6938
0.1931
Complaint of tremors
-0.3890
0.7971
0.2381
0.6256
Complaint of heart palpitations
-0.6081
0.6950
0.7653
0.3817
Complaint of skin rash
0.9618
0.4706
4.1768
0.0410
Visit to the hospital
-0.5784
0.8912
0.4213
0.5163
Visit to a doctor
0.1741
0.3041
0.3278
0.5670
1) Positive coefficients represent factors that increased the probability of remaining in the study while negative coefficients denote factors that
decreased the probability of remaining in the study
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Appendix 3.A: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Theophylline1
Full-Cohort Propensity Score

Subgroup-Specific Propensity Scores

Overall

White

Non-White

Parameter

Estimate

Std.
Error

p

Estimate

Std.
Error

p

Estimate

Std.
Error

p

Intercept

-0.72

2.75

0.79

-1.43

3.74

0.70

51.48

997.40

0.96

Non-White

0.27

0.35

0.44

Time At One Month

2.18

0.43

<.0001

-2.11

-0.53

-<.0001

-3.56

-1.19

-0.00

Time At Three Months

2.63

0.49

<.0001

3.64

0.82

<.0001

2.42

0.81

0.00

Previous treatment with

-5.72

1.38

<.0001

-5.72

1.53

0.00

-30.27

400.90

0.94

Age

-0.01

0.01

0.51

-0.03

0.02

0.03

0.05

0.03

0.07

Male

0.26

0.41

0.52

0.16

0.55

0.76

-0.70

0.92

0.45

Previous ASUI score

-0.75

1.21

0.53

-0.36

1.72

0.84

-2.25

2.81

0.42

Previous Pre-BD FEV1, % predicted

0.01

0.03

0.86

0.06

0.05

0.26

-0.10

0.07

0.13

Previous Pre-BD FVC, % predicted

-0.05

0.04

0.17

-0.10

0.06

0.08

-0.01

0.06

0.86

Previous Post-BD FEV1, % predicted

-0.02

0.03

0.63

-0.06

0.05

0.23

0.08

0.08

0.27

Previous Post-BD FVC, % predicted

0.05

0.03

0.15

0.10

0.06

0.08

0.01

0.05

0.87

Previous Peak Flow, % predicted

0.02

0.01

0.05

0.01

0.02

0.71

0.04

0.03

0.11

Previous use of anticholinergics

0.92

0.86

0.28

0.85

1.14

0.46

2.52

1.82

0.17

Previous use of long-acting beta agonists

-0.12

0.46

0.80

0.23

0.58

0.69

-1.06

1.10

0.34

Previous use of short-acting beta agonists

0.24

0.33

0.48

0.18

0.45

0.68

0.86

0.77

0.26

Previous use of combination drugs

0.00

0.39

1.00

0.58

0.52

0.26

-0.68

0.89

0.45

Previous use of inhaled corticosteroids

0.05

0.41

0.89

-0.22

0.53

0.68

0.75

0.76

0.32

Previous complaint of nausea

-0.72

1.19

0.55

0.38

1.33

0.78

-9.14

151.70

0.95

Previous complaint of vomiting

2.08

1.59

0.19

1.29

1.93

0.50

2.05

926.70

1.00

Previous complaint of poor appetite

0.34

0.79

0.66

0.89

1.06

0.40

-10.47

168.40

0.95

Previous complaint of heartburn

-0.67

0.65

0.30

-0.53

0.81

0.51

-10.25

177.80

0.95

Previous complaint of headaches

-0.08

0.45

0.86

0.14

0.59

0.81

-0.75

1.14

0.51

Previous complaint of insomnia

0.32

0.46

0.48

-0.06

0.59

0.91

1.44

1.14

0.21

Previous complaint of anxiety

0.79

0.56

0.16

0.98

0.71

0.17

0.41

1.36

0.76

Previous complaint of tremors

-0.53

1.24

0.67

0.11

1.76

0.95

-10.36

156.20

0.95

Previous complaint of heart palpitations

-1.08

1.06

0.31

-0.83

1.41

0.56

-10.65

156.00

0.95

Previous complaint of skin rash

-0.40

1.16

0.73

0.24

1.41

0.87

-10.41

224.20

0.96

Previous visit to the hospital

-0.39

0.94

0.68

-0.93

1.22

0.45

2.15

1.60

0.18

Previous visit to a doctor

0.11

0.42

0.80

0.30

0.57

0.59

-0.03

0.96

0.97

1) Positive coefficients represent factors that increased the probability of receiving theophylline while negative coefficients denote factors that
decreased the probability of receiving theophylline, i.e. previous treatment
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Appendix 3.B: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Montelukast1
Full-Cohort Propensity Score

Subgroup-Specific Propensity Scores

Overall

White

Non-White

Parameter

Estimate

Std.
Error

p

Estimate

Std.
Error

p

Estimate

Std.
Error

p

Intercept

0.80

3.14

0.80

6.08

1201.6

1.00

19.93

1488.0

0.99

Non-White

-0.28

0.36

0.43

--

--

--

--

--

--

Time At One Month

2.78

0.47

<.0001

3.52

0.73

<.0001

2.98

0.89

0.00

Time At Three Months

3.16

0.57

<.0001

3.25

0.72

<.0001

4.13

1.21

0.00

Previous treatment with

-4.97

1.31

0.00

-4.26

1.52

0.01

-25.08

423.1

0.95

Age

0.00

0.01

0.77

-0.01

0.02

0.51

0.03

0.03

0.31

Male

0.32

0.40

0.42

0.32

0.59

0.59

1.23

0.85

0.15

Previous ASUI score

1.72

1.11

0.12

2.30

1.50

0.13

1.48

2.18

0.50

Previous Pre-BD FEV1, % predicted

-0.03

0.03

0.39

-0.03

0.04

0.49

-0.03

0.07

0.62

Previous Pre-BD FVC, % predicted

0.01

0.03

0.59

0.01

0.04

0.83

0.03

0.05

0.59

Previous Post-BD FEV1, % predicted

0.02

0.03

0.47

0.04

0.05

0.45

0.05

0.06

0.39

Previous Post-BD FVC, % predicted

-0.03

0.02

0.28

-0.04

0.05

0.45

-0.05

0.04

0.24

Previous Peak Flow, % predicted

-0.02

0.01

0.08

-0.02

0.02

0.30

-0.04

0.02

0.11

Previous use of anticholinergics

0.62

0.88

0.48

0.43

1.28

0.74

0.87

1.67

0.60

Previous use of long-acting beta agonists

-0.27

0.50

0.59

-0.97

0.70

0.17

0.75

1.13

0.51

Previous use of short-acting beta agonists

-0.30

0.38

0.43

0.10

0.51

0.85

-0.63

0.78

0.42

Previous use of combination drugs

-0.56

0.44

0.20

-0.89

0.60

0.13

-0.33

0.85

0.69

Previous use of inhaled corticosteroids

-0.66

0.43

0.12

-0.85

0.62

0.17

-1.03

0.90

0.26

Previous complaint of nausea

-0.10

1.28

0.94

-0.29

1.60

0.86

-7.32

323.7

0.98

Previous complaint of vomiting

0.39

1.57

0.80

-0.93

1.97

0.64

32.11

1485.3

0.98

Previous complaint of poor appetite

1.35

1.19

0.26

1.70

1.55

0.27

-9.33

351.5

0.98

Previous complaint of heartburn

-0.85

0.76

0.26

-1.06

1.16

0.36

-0.53

1.42

0.71

Previous complaint of headaches

0.57

0.43

0.18

1.00

0.61

0.10

1.65

0.92

0.07

Previous complaint of insomnia

-0.49

0.55

0.38

-0.71

0.80

0.37

-0.18

1.06

0.87

Previous complaint of anxiety

0.60

0.65

0.36

0.18

0.91

0.84

0.89

1.36

0.51

Previous complaint of tremors

-1.05

2.21

0.64

-9.99

1201.6

0.99

0.43

388.9

1.00

Previous complaint of heart palpitations

0.25

1.19

0.83

4.59

2.08

0.03

-12.55

175.5

0.94

Previous complaint of skin rash

1.81

1.04

0.08

1.70

1.59

0.28

-12.14

295.0

0.97

Previous visit to the hospital

-0.45

1.01

0.66

1.53

1.46

0.29

-12.89

183.1

0.94

Previous visit to a doctor
0.32
0.42
0.44
0.10
0.55
0.85
0.61
0.87
0.48
1) Positive coefficients represent factors that increased the probability of receiving montelukast while negative coefficients denote factors that
decreased the probability of receiving montelukast, i.e. previous treatment
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Appendix 3.C: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Placebo1
Full-Cohort Propensity Score
Overall

Subgroup-Specific Propensity Scores
White
Non-White

Parameter

Estimate

Std.
Error

p

Estimate

Std.
Error

p

Estimate

Std.
Error

p

Intercept

-8.04

3.52

0.02

-13.14

5.18

0.01

13.84

271.1

0.96

Non-White

0.24

0.44

0.58

--

--

--

--

--

--

Time At One Month

4.88

0.84

<.0001

5.38

1.16

<.0001

8.76

2.95

0.00

Time At Three Months

4.50

0.85

<.0001

4.12

1.00

<.0001

15.82

24.06

0.51

-18.43

736.1

0.98

-15.21

665.4

0.98

-23.31

1068.3

0.98

Age

0.00

0.02

0.90

-0.01

0.02

0.67

0.06

0.04

0.14

Male

-0.31

0.48

0.52

-0.81

0.68

0.24

1.97

1.61

0.22

Previous ASUI score

3.88

1.56

0.01

3.47

2.21

0.12

5.65

5.06

0.26

Previous Pre-BD FEV1, % predicted

-0.02

0.05

0.74

-0.05

0.07

0.46

0.04

0.13

0.74

Previous Pre-BD FVC, % predicted

0.07

0.04

0.11

0.09

0.05

0.10

0.00

0.15

0.98

Previous Post-BD FEV1, % predicted

0.00

0.05

0.98

0.03

0.06

0.67

-0.09

0.14

0.53

Previous Post-BD FVC, % predicted

-0.06

0.04

0.15

-0.07

0.05

0.15

-0.01

0.13

0.94

Previous Peak Flow, % predicted

-0.01

0.01

0.42

0.02

0.02

0.44

-0.09

0.04

0.03

Previous use of anticholinergics

-0.02

1.42

0.99

-0.29

2.31

0.90

-10.73

56.44

0.85

Previous use of long-acting beta agonists

-0.16

0.62

0.80

0.22

0.79

0.78

-2.19

2.26

0.33

Previous use of short-acting beta agonists

-0.03

0.40

0.93

-0.65

0.54

0.23

1.51

1.15

0.19

Previous use of combination drugs

0.99

0.56

0.08

1.93

0.83

0.02

0.55

1.40

0.69

Previous use of inhaled corticosteroids

1.25

0.57

0.03

1.83

0.86

0.03

1.35

1.49

0.36

Previous complaint of nausea

0.81

0.82

0.32

1.68

1.09

0.12

1.41

10.09

0.89

Previous complaint of vomiting

0.99

1.11

0.38

1.14

1.30

0.38

2.32

168.30

0.99

Previous complaint of poor appetite

0.47

1.30

0.72

-0.70

1.91

0.71

2.19

3.80

0.57

Previous complaint of heartburn

0.77

0.77

0.32

0.27

0.93

0.77

2.40

2.52

0.34

Previous complaint of headaches

0.11

0.57

0.85

-0.09

0.75

0.91

1.51

1.71

0.38

Previous complaint of insomnia
Previous complaint of anxiety

0.25
1.11

0.54
0.75

0.64
0.14

0.11
0.98

0.74
0.98

0.88
0.31

2.02
0.70

1.77
2.49

0.25
0.78

Previous complaint of tremors

1.18

1.11

0.29

3.00

1.80

0.10

1.61

3.97

0.69

Previous complaint of heart palpitations

-0.33

1.63

0.84

2.02

2.69

0.45

-8.74

106.4

0.93

Previous complaint of skin rash

-0.58

1.33

0.66

-0.72

1.32

0.59

-1.91

175.3

0.99

Previous visit to the hospital

0.46

1.04

0.66

0.12

1.34

0.93

-2.53

3.39

0.46

Previous treatment with

Previous visit to a doctor
0.97
0.50
0.05
1.58
0.69
0.02
2.29
1.70
0.18
1) Positive coefficients represent factors that increased the probability of receiving placebo while negative coefficients denote factors that
decreased the probability of receiving placebo, i.e. previous treatment
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Appendix 4.A: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Models Using SelfReported Adherence1

Parameter

Estimate

Analysis of Maximum Likelihood Estimates
Theophylline
Montelukast
Std.
ChiPr >
Std.
ChiError
Square ChiSq Estimate
Error
Square

Pr >
ChiSq

Intercept

2.604

3.052

0.728

0.394

14.405

925.4

0.000

0.988

Time At One Month

-0.595

0.484

1.515

0.218

-0.460

0.465

0.977

0.323

Time At Three Months

0.321

0.473

0.459

0.498

-0.365

0.448

0.664

0.415

Previous treatment with

-2.580

0.483

28.581

<.0001

-1.854

0.505

13.501

0.000

Age

-0.015

0.013

1.403

0.236

-0.024

0.014

2.943

0.086

Male

1.186

0.574

4.275

0.039

0.439

0.467

0.882

0.348

Black Race

0.217

0.414

0.273

0.601

-0.001

0.495

0.000

0.998

Other Race

1.328

0.872

2.320

0.128

-0.462

0.467

0.978

0.323

Previous ASUI score

1.493

1.146

1.699

0.193

0.978

1.132

0.746

0.388

Previous Pre-BD FEV1, % predicted

-0.037

0.034

1.179

0.278

-0.045

0.038

1.384

0.239

Previous Pre-BD FVC, % predicted

0.037

0.031

1.412

0.235

0.032

0.031

1.098

0.295

Previous Post-BD FEV1, % predicted

0.024

0.033

0.509

0.476

0.065

0.038

2.861

0.091

Previous Post-BD FVC, % predicted

-0.051

0.027

3.493

0.062

-0.060

0.028

4.663

0.031

Previous Peak Flow, % predicted

0.017

0.012

1.931

0.165

-0.003

0.011

0.069

0.793

Previous use of anticholinergics

-1.030

1.192

0.747

0.388

0.574

0.689

0.695

0.405

Previous use of long-acting beta agonists

0.441

0.507

0.756

0.385

-0.190

0.486

0.153

0.696

Previous use of short-acting beta agonists

0.313

0.370

0.715

0.398

0.124

0.386

0.103

0.748

Previous use of combination drugs

-0.026

0.425

0.004

0.952

-0.296

0.452

0.429

0.512

Previous use of inhaled corticosteroids

-0.380

0.439

0.749

0.387

-0.153

0.439

0.121

0.728

Previous complaint of nausea

1.317

0.671

3.854

0.050

-0.663

1.049

0.400

0.527

Previous complaint of vomiting

-0.172

1.331

0.017

0.897

0.592

1.475

0.161

0.688

Previous complaint of poor appetite

-0.567

0.906

0.392

0.531

0.526

1.164

0.204

0.651

Previous complaint of heartburn

0.149

0.620

0.058

0.810

-0.071

0.566

0.016

0.901

Previous complaint of headaches

-0.114

0.450

0.064

0.800

0.465

0.424

1.200

0.273

Previous complaint of insomnia

0.246

0.452

0.295

0.587

-0.789

0.576

1.874

0.171

Previous complaint of anxiety

0.728

0.553

1.733

0.188

1.147

0.626

3.361

0.067

Previous complaint of tremors

1.278

1.140

1.257

0.262

-13.590

925.4

0.000

0.988

Previous complaint of heart palpitations

-0.910

1.126

0.654

0.419

0.651

0.940

0.480

0.489

Previous complaint of skin rash

0.352

1.443

0.060

0.807

0.249

1.025

0.059

0.808

Previous visit to the hospital

-1.278

0.954

1.793

0.181

0.715

0.811

0.777

0.378

Previous visit to a doctor
-0.160
0.419
0.146
0.703
0.256
0.418
0.374
0.541
1) Positive coefficients represent factors that increased the probability of receiving their assigned treatment while negative coefficients denote
factors that decreased the probability of receiving their assigned treatment, i.e. previous treatment
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Appendix 4.B: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Models Using Blood
Assay Adherence1
Analysis of Maximum Likelihood Estimates

Parameter

Estimate

Theophylline
Std.
ChiError Square

Pr >
ChiSq

Estimate

Montelukast
Std.
ChiError
Square

Pr >
ChiSq

Intercept

-6.011

3.075

3.823

0.051

13.696

526.4

0.001

0.979

Time At One Month

1.031

0.378

7.424

0.006

0.062

0.366

0.029

0.866

Previous treatment with

-1.238

0.585

4.475

0.034

-1.355

0.512

7.013

0.008

Age

0.026

0.012

4.543

0.033

0.002

0.012

0.023

0.881

Male

0.054

0.407

0.017

0.895

0.537

0.375

2.054

0.152

Black Race

0.220

0.377

0.341

0.559

-0.189

0.391

0.235

0.628

Other Race

1.051

0.726

2.092

0.148

0.078

0.470

0.028

0.868

Previous ASUI score

2.019

1.064

3.597

0.058

0.412

1.118

0.136

0.712

Previous Pre-BD FEV1, % predicted

0.057

0.031

3.349

0.067

-0.038

0.023

2.758

0.097

Previous Pre-BD FVC, % predicted

-0.018

0.032

0.310

0.578

0.026

0.022

1.390

0.238

Previous Post-BD FEV1, % predicted

-0.059

0.033

3.091

0.079

0.005

0.026

0.031

0.859

Previous Post-BD FVC, % predicted

0.017

0.030

0.305

0.581

-0.010

0.022

0.209

0.648

Previous Peak Flow, % predicted

0.002

0.012

0.036

0.849

0.007

0.010

0.598

0.440

Previous use of anticholinergics

0.540

0.879

0.378

0.539

-0.655

0.882

0.552

0.458

Previous use of long-acting beta agonists

0.739

0.470

2.475

0.116

-0.234

0.425

0.303

0.582

Previous use of short-acting beta agonists

0.178

0.350

0.259

0.611

-0.020

0.349

0.003

0.954

Previous use of combination drugs

-0.046

0.399

0.013

0.909

-0.294

0.368

0.638

0.424

Previous use of inhaled corticosteroids

-0.676

0.412

2.693

0.101

-0.445

0.389

1.312

0.252

Previous complaint of nausea

0.354

0.661

0.286

0.593

0.446

1.190

0.141

0.708

Previous complaint of vomiting

-0.512

1.475

0.121

0.728

0.455

1.848

0.061

0.805

Previous complaint of poor appetite

-0.505

1.084

0.217

0.642

-0.607

1.452

0.175

0.676

Previous complaint of heartburn

-0.496

0.657

0.570

0.450

-0.481

0.562

0.732

0.392

Previous complaint of headaches

0.561

0.409

1.879

0.171

0.243

0.393

0.381

0.537

Previous complaint of insomnia

-0.246

0.468

0.276

0.600

-1.192

0.481

6.141

0.013

Previous complaint of anxiety

0.590

0.619

0.910

0.340

0.380

0.701

0.294

0.588

Previous complaint of tremors

2.086

1.498

1.940

0.164

-0.188

1.890

0.010

0.921

Previous complaint of heart palpitations

0.299

1.076

0.077

0.781

0.485

1.307

0.138

0.711

Previous complaint of skin rash

1.197

1.107

1.169

0.280

2.524

1.462

2.981

0.084

Previous visit to the hospital

0.512

0.843

0.369

0.544

-13.712

526.4

0.001

0.979

Previous visit to a doctor
0.024
0.396
0.004
0.952
0.107
0.379
0.080
0.778
1) Positive coefficients represent factors that increased the probability of receiving assigned treatment while negative coefficients denote factors
that decreased the probability of receiving assigned treatment, i.e. previous treatment
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Appendix 4.C: Coefficients Obtained from the Denominator of the Pooled Logistic Censoring Models1
Analysis of Maximum Likelihood Estimates – Censoring for All Groups

Parameter

Estimate

Self-Report
Std.
ChiError
Square

Pr >
ChiSq

Estimate

Blood Assay
Std.
ChiError
Square

Pr >
ChiSq

Intercept

12.192

730.3

0.000

0.987

-2.142

2.433

0.776

0.379

Time At Baseline

14.187

203.4

0.005

0.944

15.132

185.4

0.007

0.935

Time At One Month

-1.502

0.348

18.626

<.0001

0.052

0.255

0.042

0.839

Time At Three Months

2.743

1.052

6.803

0.009

---

---

---

---

Assigned to theophylline

-0.537

1.020

0.277

0.599

0.552

0.565

0.954

0.329

Currently on theophylline

0.507

0.642

0.625

0.429

1.175

0.502

5.487

0.019

Currently on montelukast

0.619

0.861

0.516

0.473

0.760

0.401

3.589

0.058

Age

0.033

0.012

7.530

0.006

0.016

0.010

2.821

0.093

Male

-0.086

0.341

0.064

0.801

0.085

0.290

0.085

0.771

Black

-0.628

0.318

3.889

0.049

-0.396

0.279

2.014

0.156

Other Race

-0.255

0.480

0.281

0.596

0.003

0.424

0

0.995

ASUI score

0.472

0.952

0.245

0.620

2.226

0.797

7.797

0.005

Pre-BD FEV1, % predicted

-0.016

0.022

0.530

0.467

-0.027

0.025

1.128

0.288

Pre-BD FVC, % predicted

0.035

0.024

2.207

0.137

0.022

0.024

0.832

0.362

Post-BD FEV1, % predicted

0.002

0.025

0.004

0.951

0.016

0.026

0.398

0.528

Post-BD FVC, % predicted

-0.011

0.023

0.241

0.623

-0.004

0.023

0.023

0.879

Peak Flow, % predicted

-0.013

0.009

1.993

0.158

-0.006

0.008

0.536

0.464

Use of anticholinergics

-0.544

1.104

0.243

0.622

-1.367

1.085

1.587

0.208

Use of long-acting beta agonists

-0.127

0.422

0.090

0.764

-0.335

0.386

0.754

0.385

Use of short-acting beta agonists

0.138

0.309

0.199

0.656

0.322

0.260

1.537

0.215

Use of combination drugs

0.198

0.346

0.326

0.568

0.061

0.302

0.041

0.839

Use of inhaled corticosteroids

0.210

0.378

0.308

0.579

0.361

0.315

1.319

0.251

Complaint of nausea

-1.630

1.072

2.312

0.128

0.107

0.555

0.037

0.848

Complaint of vomiting

-12.346

730.3

0.000

0.987

-0.686

1.267

0.293

0.588

Complaint of poor appetite

0.796

0.733

1.179

0.278

0.487

0.692

0.495

0.482

Complaint of heartburn

0.469

0.499

0.886

0.347

0.031

0.427

0.005

0.942

Complaint of headaches

-0.125

0.386

0.105

0.746

0.235

0.302

0.607

0.436

Complaint of insomnia

-0.256

0.386

0.437

0.508

-0.424

0.341

1.547

0.214

Complaint of anxiety

-0.074

0.551

0.018

0.894

0.323

0.484

0.446

0.504

Complaint of tremors

-0.662

1.163

0.324

0.569

-0.378

0.764

0.244

0.621

Complaint of heart palpitations

1.161

0.876

1.760

0.185

0.093

0.758

0.015

0.903

Complaint of skin rash

1.202

0.645

3.473

0.062

0.927

0.583

2.531

0.112

Visit to the hospital

0.197

0.862

0.052

0.819

0.256

0.736

0.121

0.728

Visit to a doctor
1.367
0.317
18.552
<.0001
0.162
0.304
0.285
0.594
1) Positive coefficients represent factors that increased the probability of being censored while negative coefficients denote factors that decreased
the probability of being censored
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